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In vitro cell culture, ex vivo brain slice culture, and in vivo model systems of 
Parkinson’s disease (PD), as well as postmortem brains from PD patients, have 
implicated microglial hyperactivation, mediated by inflammatory ligands, in the loss of 
dopaminergic neurons in the substantia nigra region of the brain. The signaling 
pathways leading to this chronic, sustained microglial activation in response to 
environmental stressors or disease-associated molecular patterns (DAMPs) are not 
clearly understood. We show herein the role of mitochondrial dysfunction in mediating 
pro-inflammatory signaling cascades in microglial cells in response to environmental 
factors such as pesticides and metals. Exposure to the pesticides rotenone and 
tebufenpyrad as well as the neurotoxic divalent metal manganese (Mn) leads to the 
activation of the NLRP3 pro-inflammatory signaling cascade in microglial cells. 
Mitochondrial superoxide generation plays a key role in activation of the NLRP3 
inflammasome. Furthermore, activation of NLRP3 produces neurotoxic factors, like IL-
1β and IL-18, that lead to neurodegeneration. The novel mitochondria-targeted 
antioxidant mito-apocynin was able to reduce mitochondrial superoxide generation 
and NLRP3 inflammasome activation. We also demonstrated that Mn leads to 
mitochondrial dysfunction by downregulation of mitochondrial fusion protein (Mfn2). 
Lastly, we show that Mn exposure leads to the propagation of the NLRP3 
inflammasome through the mechanism of exosomal release of ASC, an 
inflammasome component. This finding has high translational relevance since 
exosomes isolated from welder cohorts known to have been exposed to Mn fumes 
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carry a higher exosomal load of ASC. Collectively, we demonstrated the gene-
environment crosstalk which modulates neuroinflammation and neurodegeneration.  
Alpha-synuclein aggregates are a major component of Lewy bodies and 
neurites, which are pathological hallmarks of PD. Classical activation of microglial 
cells has been shown to be mediated by pre-formed fibrillar α-synuclein (αSynAgg), but 
the signaling mechanism is not well understood. We sought to identify the role of 
microglial potassium channels in regulating αSynAgg-induced neuroinflammation. We 
show conclusively, in both cell culture and animal models of PD, that αSynAgg-induced 
neuroinflammation is associated with upregulation of the voltage-gated potassium 
channel Kv1.3. Remarkably, Kv1.3 was also highly induced in post-mortem PD patient 
tissues, as well as in peripheral blood mononuclear cells (PBMC) isolated from PD 
patients. We show that Fyn kinase, a src family kinase, regulates Kv1.3 
transcriptionally through the p38 MAPK and NFκB pathways. Fyn was also observed 
to directly bind to Kv1.3, phosphorylating tyrosine 139 to modulate the channel’s 
activity.  Lastly, we demonstrate that Kv1.3 inhibition reduces neuroinflammation and 
neurodegeneration in vitro and in preclinical setups. Overall, we identify key 
mechanistic pathways in response to both environmental stressors and DAMPs which 
strongly contribute to the chronic microglial pro-inflammatory responses that 





Thesis Layout & Organization 
The alternative format was chosen for this thesis and consists of manuscripts 
that have been formatted for submission to peer-reviewed journals. The dissertation 
contains a general introduction, three research papers, general conclusions, future 
directions charting out where the research story will be taken next, and two 
appendices which have also been prepared for publication. Because of the 
Dissertation’s journal format, each manuscript chapter includes a list of references 
cited. However, references pertaining to the background and literature review, as well 
as those used in the general conclusions are listed separately at the end of the 
dissertation. The Introduction in Chapter 1 provides a background and overview of 
Parkinson’s disease (PD). Chapter 2 covers current evidence implicating a pathogenic 
role for reactive microgliosis in mediating progressive dopaminergic neuron loss in 
PD, and concentrates on the effect of environmental stressors in activating glial cells 
that leads to neuroinflammation. This provides an overview of the research objectives 
pertaining to Chapters 4 and 5.  Chapter 3 pertains to Chapter 6 and gives a brief 
introduction of the different microglial ion channels with respect to their role in 
inflammation and their potential as drug targets. The manuscript from Chapter 2 was 
recently published in Npj Parkinson’s Disease. It elucidates the role of mitochondrial 
complex-I inhibitors in activating the NLRP3 inflammasome signaling pathway in cell 
culture and animal models of PD.  Chapter 3 explores how neurotoxic manganese 
(Mn2+) can induce and propagate the NLRP3 inflammasome. This manuscript is 
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currently under preparation for submission in Science Signaling. Chapter 4 studies 
how the voltage-gated potassium channel Kv1.3 contributes to microgliosis and 
inflammasome activation in cell culture and animal models of PD as well as in human 
post-mortem PD brain tissues. Chapter 4 is being prepared for submitting for 
publication. Chapter 5 is a general conclusion of the findings and provides future 
directions.  
Apart from the five chapters, this thesis consists of two appendices. Appendix 
1 is on developing a faster method for isolating primary microglial cells used for most 
of the studies in Chapter 2. This method was published in the Journal of Visualized 
Experiments. Appendix 2, is under revision in Neurotoxicology, is a comparative 
analysis and characterization of a recently developed microglial cell line that was used 
for conducting the studies in Chapters 3 and 4. 
All of the research described by the author in this thesis was performed during 
the course of his doctoral studies at Iowa State University under the guidance of his 






Parkinson's names a disease whose symptomology has been known about 
since ancient times. The ancient Indian medical system of Ayurveda refers to it as 
“Kampavata.” In Western medical literature, it was described in AD 175 by the Greek 
physician Galen as the "shaking palsy". However, it was not until 1817 that a detailed 
medical article, "An Essay on the Shaking Palsy", was published by the London doctor 
James Parkinson, thereby “paralysis agitans” as a recognized medical condition. 
Parkinson’s essay arose from the examination or interview of six people who 
manifested the symptoms. In 1872, after an even more detailed study of its full clinical 
spectrum, the French neurologist Jean Martin Charcot renamed it Parkinson's disease 
since there was much more to the disease than just paralysis and tremor. 
Symptoms of the disease are progressive and degenerative and it tends to 
more often afflict older individuals. Although a dopamine deficiency in the brain is what 
triggers the most recognizable motor symptoms, why this initially occurs is less clear. 
Though PD has been known for more than a century there is no cure for PD. L-dopa 
is a dopamine replacement therapy which is the gold standard for PD treatment till 
date. In Ayurvedic literature, and a current study showed that Mucuna pruriens extract 
can reduce PD like symptoms in a rodent model of PD and contains L-dopa and other 




Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder affecting around 2% of the population over the age of 60, and its incidence is 
expected to rise dramatically with the advancing median age of the population, 
worsening the substantial socioeconomic burden on patients, their families, and 
society. The main pathological hallmark of this disease is the degeneration of 
dopaminergic (DAergic) neurons within the nigrostriatal tract that project from the 
substantia nigra (SN) to the striatum, resulting in a severe depletion of striatal DA that 
clinically manifests as a range of debilitating motor symptoms (Lotharius and Brundin, 
2002; Wolters, 2009). The underlying mechanism of the neuronal degeneration is not 
well understood but mitochondrial dysfunction, chronic inflammation, and oxidative 
stress have been implicated in different animal models of PD (Goldman, 2014; Mullin 
and Schapira, 2015). The role of inflammation in PD was first suggested in 1988 when 
major histocompatibility complex molecules were shown to be upregulated in PD 
patients (Whitton, 2007). Various pro-inflammatory factors like tumor necrosis factor 
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α (TNF-α) and IL-1β have been shown to be 
upregulated in cerebrospinal fluid (CSF) and 
different regions of the brain in PD patients 
(Nagatsu et al., 2000). Moreover, in animal 
models of PD, such as the 6-OHDA, MPTP, and 
rotenone models, selective loss of dopaminergic 
neurons is accompanied by chronic 
inflammation (Ghosh et al., 2016; Kosloski et al., 
2013; Panicker et al., 2015). Treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs), 
like ibuprofen, can be effective against PD-
related inflammation (Rees et al., 2011).  
Microglia are resident immune cells of the 
brain that primarily mediate brain inflammation 
(Gammon, 2013; Liu and Hong, 2003). Depending on the stimuli, microglia secrete 
both anti-inflammatory and pro-inflammatory factors, as well as growth factors, 
thereby tightly controlling neuronal survival  (Mosley et al., 2012). Glial activation 
leading to inflammation have been well documented both in peripheral and central 
nervous system in PD (Table 1). Though microglia have been identified as key 
modulators of chronic neuroinflammation, the underlying mechanisms remain 
equivocal. Hence, understanding the mechanisms driving this chronic inflammation in 
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Table 2: List of genes associated with Parkinsonian Syndrome 
Symbol Gene 
Name 
Inheritance  Disease 
PARK 1 SNCA Autosomal Dominant Early Onset PD 
PARK 2 Parkin Autosomal Recessive Early Onset PD 
PARK 3 Unknown Autosomal Dominant Classical PD 
PARK 4 SNCA Autosomal Dominant Early Onset PD 
PARK 5 UCHL1 Autosomal Dominant Classical PD 
PARK 6 PINK1 Autosomal Recessive Early Onset PD 
PARK 7 DJ1 Autosomal Recessive Early Onset PD 
PARK 8 LRRK2 Autosomal Dominant Classical PD 
PARK 9 ATP13A2 Autosomal Recessive Atypical PD  
PARK 10 Unknown Risk Factor Classical PD 
PARK 11 Unknown Autosomal Dominant Late Onset PD 
PARK 12 Unknown Risk Factor Classical PD 
PARK 13 HTRA1 Autosomal Dominant Classical PD 
PARK 14 PLA2G6 Autosomal Recessive Early-onset dystonia-
parkinsonism 
PARK 15 FBXO7 Autosomal Recessive Early-onset parkinsonian-
pyramidal syndrome 
PARK 16 Unknown Risk Factor Classical PD 





Table 2. (continued) 
 
PARK 18 EIF4G1 Autosomal Dominant Classical PD 
PARK 19 DNAJC6 Autosomal Recessive Early Onset PD 
PARK 20 SYNJ1 Autosomal Recessive Early Onset PD 
PARK 21 DNAJC13 Autosomal Dominant Classical PD 
PARK 22 CHCD2 Autosomal Dominant Late Onset PD 
PARK 23 VPS13C Autosomal Recessive Early Onset PD 
   
  
PD is a multifactorial disease with several associated genes as mentioned in 
Table 1.  having diverse roles with regards to the neuroinflammation contributing to 
PD pathology. Microglial cells can be classically activated by αSynAgg, leading to the 
production of proinflammatory factoras like TNFα, IL-1β, nitrites, and others (Kim, C. 
et al., 2013; Lee et al., 2010; Su et al., 2008).  LRRK2, a gene associated with 
autosomal dominant disease, activates microglial pro-inflammatory signaling 
pathways (Moehle et al., 2012). Loss of function in PINK1 and DJ1 induces microglial 
activation through activation of the NF-B pathway (Kim, J. et al., 2013) and  the 
hyperactivation of STAT1, respectively (Kim, J.H. et al., 2013). More than 90% of PD 
cases are sporadic and the effect of environment in PD pathogenesis cannot be 
overlooked. Exposure to environmental toxicants, such as pesticides and metals, have 
been linked to a higher risk of developing PD. These environmental stressors have 
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been shown to induce microglial activation and neuroinflammation. Rotenone, a 
classical PD toxicant, activates microglial cells leading to the production of 
proinflammatory neurotoxic factors (Sarkar et al., 2017). Overexposure to the divalent 
metal manganese (Mn) activates the proinflammatory signaling cascade in microglial 
and astroglial cells (Dodd and Filipov, 2011; Filipov et al., 2005; Kirkley et al., 2017). 
Recently, diesel exhaust particles (DEP) have also been implicated in microglial 
activation (Levesque et al., 2013). The cellular events triggered by environmental 
stressors suggest a crosstalk between genes and the environment. Thus, mapping 
out the novel signaling pathways underlying the hyperactivation of microglia would 
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Abstract 
Parkinson’s disease is the most prevalent motor disorder and is characterized 
by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region 
of the brain. Though the pathology of PD is well established the cause of this cell 
death is not well understood. 90% of PD is sporadic and environment plays a major 
role in disease pathogenesis. The etiology of PD is complex. Neuroinflammation is 
one of the key factors that have been implicated in neuronal loss. Non-steroidal anti-
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inflammatory drugs (NSAID’s) have been shown to reduce risk of developing PD. But 
the signaling mechanism underlying neuroinflammation is equivocal. Astroglia and 
microglia are the two key immune cells which play an important role in maintain the 
neurons. Recently, astroglial and microglial activation have been linked to PD. 
Exposure to environmental stressors from various sources have been shown to affect 
these glial cells. Exposure to complex I-inhibiting pesticides rotenone have been 
shown to induce inflammation and neurodegeneration in animal models. Further 
rotenone, can induce NLRP3 inflammasome activation, leading to chronic 
inflammation, in microglial cells. Paraquat, the most widely used herbicide, have been 
shown to directly induce microglial NOX2 leading to oxidative stress and inflammation. 
Moreover, overexposure to neurotoxic metals like Manganese (Mn) have been 
implicated in a PD-like disease manganism. Occupational exposure to Mn have been 
shown to induce microglial activation. Mn can cause mitochondrial dysfunction in 
astroglial cells leading to inflammation. Mn can further potentiate the effect of LPS on 
microglial cells. This neurotoxic metal has been shown to induce the pro-inflammatory 
pathway nuclear factor κB (Nfκb). Moreover, recent studies have shown that diesel 
fume exhaust leads to microglial activation in mouse model. In this review, we discuss 
the recent advances in our knowledge, the mechanism of microglial response and 




Glial hyper-activation and inflammation have been linked to multiple 
neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease 
(PD) among others (Block et al., 2007; Halle et al., 2008; Heneka et al., 2013).   But 
the mechanism underlying glial activation is still under active research. Multiple 
signaling proteins like NADPH oxidase (NOX), Nuclear factor kb (NFκb), and the 
inflammasomes have been linked to glial inflammation (Panicker et al., 2015; Langley 
et al., 2017a; Sarkar et al., 2017b).   
Environment plays a major role in pathogenesis of PD, with around 90% PD 
cases being sporadic. Exposure to metals, pesticides, traumatic brain injury among 
others have been linked to higher incidence of PD (Rokad et al., 2016; Harischandra 
et al., 2017; Sarkar et al., 2017a). These environmental factors play a key role in glial 
inflammation (Lawana et al., 2017). This review summarizes some of the key signaling 
pathways involved in glial inflammation and the crosstalk of environmental factors with 
these signaling proteins leading to sustained inflammation in a neurodegenerative 
environment.  
Signaling Pathways 
NOX enzyme complex 
NADPH oxidase is a membrane bound enzyme complex which are involved in 
generating superoxide. The cellular localization of NOX varies depending on the NOX 
catalytic subunit (Fig. 1). Till date, 7 NOX catalytic units, namely Nox1 (Banfi et al., 
2000), Nox2 (Cheng et al., 2001; Segal, 2005) , NOX3 (Cheng et al., 2001), NOX4 
(Geiszt et al., 2000), NOX5 (Banfi et al., 2001), Duox1 (Edens et al., 2001), and Duox2 
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(Edens et al., 2001) have been identified. In microglia NOX2 plays an important role 
in regulating inflammation. Phosphorylation of a subunit of NOX2, p47phox, leads to 
activation of this enzyme complex in glial cells (Roepstorff et al., 2008). Multiple 
kinases including MAPK, PKC isoforms and others have been shown to phosphorylate 
NOX2 in glial cells (Belarbi et al., 2017).  LPS treatment induced NOX2 activation in 
microglial cells leading to inflammation. Reduction of NOX2 activation has been 
shown to reduce inflammation in glial cells (Langley et al., 2017a). NOX2 have been 
shown to play a critical role in PD pathogenesis. NOX2 deficient mice fail to induce 
dopaminergic neuronal loss and inflammation in MPTP mouse model of PD (Wu et 
al., 2003). Furthermore, inhibition of NOX2 using a derivative of Apocynin, mito-
apocynin was shown to protect neuronal loss in MPTP and Mitopark mouse model of 
PD (Ghosh et al., 2016; Langley et al., 2017a). Recently, NOX4 have been shown to 
be upregulated in PD patients suggesting a probable role of NOX4 activation in PD 
pathogenesis (Zawada et al., 2015). Given the mitochondrial localization of NOX4, the 
activation of this catalytic unit may drive the glial inflammation as recent studies have 
linked mitochondrial superoxide generation in regulating glial inflammation (Sarkar et 
al., 2017b). Further studies looking into the possible mechanism of NOX4 induced 
inflammation may lead to identification of key anti-inflammatory targets.  
Nfκb pro-inflammatory pathways 
 Nuclear factor kb (NFκb) activation in microglia cells have been termed as the 
“holy grail” for anti-inflammatory drug targets (Lawrence, 2009). The NFκb 
transcription factor consist of various subunits like p50, p65 and others. Inhibitor of 
Nfκb (Iκb) binds to the subunits of NFκb and inhibits its translocation into the nucleus. 
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Under inflammagen stress, Iκb gets phosphorylated by Iκb kinase (IKK) and marked 
for degradation, which leads to the translocation of p50-p65 heterodimer into the 
nucleus and transcription of pro-inflammatory factors like IL-1β, TNFα and NOS2 
(Panicker et al., 2015). This activation of NFκb is termed as the classical activation or 
the canonical pathway of NFκb. Alternative activation of NFκb leads to translocation 
of RelB-p52 to nucleus. Though the role of this type of NFκb activation is not clear in 
inflammation, alternative activation plays a role in B-lymphocyte function (Bonizzi et 
al., 2004). Recently, another alternative activation of NFκb have been discovered 
which leads to nuclear translocation of p50-p50 homodimer leading to production of 
anti-inflammatory factors. P50 KO mice were more susceptible to endotoxemia. 
Further, p50 was shown to regulate anti-inflammatory factor IL-10 suggesting its role 
in antiinflammation (Cao et al., 2006). Activation of classical NFκb pathway have been 
linked to neuroinflammation in glial cells leading to secondary neurodegeneration in 
AD, PD and other neurodegenerative disease (Block et al., 2007; Shih et al., 2015).    
Inflammasomes 
Inflammasomes were first described by Tschopp in the early 2000s, as large, 
cytosolic multimeric assembly platforms, that effect the activation of pro-inflammatory 
caspases such as Caspase-1.  Recently, studies on microglial cells have shown that 
rotenone can induce NLRP3 inflammasome activation by regulating mitochondrial 
dysfunction and autophagy (Lawana et al., 2017; Martinez et al., 2017; Sarkar et al., 
2017b). In the last decade, inflammasome activation have been implicated as a key 
molecular mechanism regulating inflammation in immune cells. NLRP3 
inflammasome is one of the major functional inflammasome in microglial which has 
15 
 
been implicated in neurodegenerative disorders including AD (Halle et al., 2008; 
Heneka et al., 2013). Inflammasomes are tightly regulated processes in cells which 
require two signals for activation. Signal I generally activate the Nfκb activation leading 
to transcription of NLRP3, pro-IL-18 and pro-IL-1β. Signal II, which can be disease 
associated molecular patterns, and pathogen associated molecular patterns, through 
some unknown mechanism leads to the assembly of NLRP3 inflammasome complex 
and cleavage of pro-IL-18 and pro-IL-1β to its matured form and secreted. Potassium 
efflux have also been implicated in activation of inflammasomes.  The inflammasome 
complex consist of NLR3, the adapter protein ASC, and pro-Caspase 1. Upon 
activation caspase-1 is cleaved by autolytic cleavage (Freeman and Ting, 2016) which 




Rotenone is a classical PD toxicant and is a mitochondrial complex I inhibitor. 
Rotenone have been shown to cause dopaminergic neuronal loss in vitro and in vivo 
(Sherer et al., 2007; Cannon et al., 2009; Inden et al., 2011; Charli et al., 2016).  
Further analysis showed that microglia are activated by rotenone to produce 
superoxide, which is selectively toxic to dopaminergic neurons, and dependent on 
NOX2, as genetic deletion of NOX2 was neuroprotective against rotenone (Gao et al., 
2003). Rotenone exposure in rodent models have been shown to induce microglial 
activation (Sarkar et al., 2017b). Mount et al. , further demonstrated that microglia 
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isolated from IFNγ deficient microglia, did not induce  dopaminergic neuronal death in 
response to rotenone treatment (Mount et al., 2007).   
Our group along with others have recently shown the importance of 
mitochondrial dynamics in regulating glial inflammation (Zhou et al., 2011; Sarkar et 
al., 2017a; Sarkar et al., 2017b). A recent report suggested that rotenone induced 
neuroinflammation can be reduced by opening of ATP-dependent mitochondrial 
potassium channel, KATP. The opening of this channel reduced p38 MAPK activity 
thereby reducing inflammation in microglial cells (Zhou et al., 2008).   
Rotenone have been shown to induce microglial activation in BV2 microglial 
cell line leading to production of iNos, and other proinflammatory factors like TNFα 
and IL-1β. N-acetylcysteine, an ROS scavenger, was shown to reduce this rotenone-
induced inflammation by reducing Nfκb and p38 MAPK activation. This suggests the 
probable role of rotenone-induced ROS in activating the abovementioned 
inflammatory signaling cascade in microglial cells (Gao et al., 2013). Rotenone has 
further been shown to directly interact with membrane bound NOX2, the catalytic 
subunit of NOX2 enzyme complex, thereby playing an important role in superoxide 
and ROS generation. Diphenyleneiodonium, a NOX inhibitor, reduced the interaction 
of rotenone with this enzyme complex (Zhou et al., 2012).  
Recent studies by Zhao et al. showed that exposure to rotenone lead to 
induction of NLRP3 inflammasome in macrophage (Zhou et al., 2011). Our group have 
demonstrated that rotenone exposure leads to NLRP3 inflammasome activation in 
microglial cells in cell culture and animal models. We have further shown that 
mitochondrial superoxide formation plays an important role in rotenone induced 
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inflammasome activation. Treatment with mitochondrially targeted derivative of anti-
oxidant of apocynin, mito-apocynin, reduced NLRP3 inflammasome assembly and 
dopaminergic neuronal death by reducing rotenone-induced superoxide generation 
(Sarkar et al., 2017b). Lawana et al. further demonstrated that c-abl tyrosine kinase 
regulates rotenone-induced NLRP3 inflammasome activation by modulating the 
priming step of inflammasome and by reducing the dysregulation of mitochondrial 
dynamics (Lawana et al., 2017).  Rifampicin, an antibacterial drug used in 
tuberculosis, has been further shown to reduce microglial activation by reducing 
rotenone-induced NLRP3 inflammasome activation (Liang et al., 2015).  
Paraquat 
 Paraquat (N,N′ -dimethyl-4,4′-bipyridinium dichloride), one of the widely used 
herbicides, have been linked to higher PD risk (Hertzman et al., 1990; Cicchetti et al., 
2005; Costello et al., 2009), and selective loss of DA neurons in substantia nigra 
region in rodent models (Cicchetti et al., 2005). Apart from having direct neurotoxic 
activity, paraquat can activate microglial cells by activating NOX2 in culture (Bonneh-
Barkay et al., 2005). PHOX -/- mice , lacking the catalytic subunit of NOX2 have 
attenuated neurotoxicity and glial activation post paraquat exposure (Wu et al., 2005). 
NADPH oxidase inhibitor, apocynin, have been shown to reduce paraquat induced 
glial activation (Miller et al., 2007).  Furthermore, a novel isoform of PKC, PKCδ, have 
been shown to play a role in paraquat mediated toxicity. Treatment with PKCδ specific 
inhibitor, rottlerin, inhibited paraquat induced NOX2 activation and ROS generation 
(Miller et al., 2007). Recent studies by Castello et al. suggested that mitochondria are 
a key source of paraquat induced H2O2 production. This study further showed that 
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mitochondrial complex III, and mitochondrial transmembrane potential is a key player 
in the ROS generation and acts as a redox modulator (Castello et al., 2007). Our 
studies in microglia suggested that mitochondrial ROS drives inflammasome 
activation (Sarkar et al., 2017b). But further studies looking the role of redox 
modulation by paraquat leading to inflammasome activation is required.  These 
studies further show that paraquat leads to glial activation by interacting with NOX2 
and leading to ROS generation.  
Other Pesticides 
 Other than rotenone and paraquat, other pesticides like dieldrin, tebufenpyrad 
and organophosphates have been shown to modulate microglial inflammation and 
proliferation. Exposure to dieldrin, an organochloride, have been shown to cause 
dopaminergic neuronal loss (Song et al., 2010). Dieldrin was shown to induce 
generation of ROS in microglial cells (Mao and Liu, 2008) which have been shown to 
cause neuronal damage. NOX inhibitors reduced the microglia generated ROS post 
dieldrin exposure (Mao et al., 2007).  Tebufenpyrad, a complex 1 inhibitor have been 
shown to induce dopaminergic neuronal death in cell culture (Charli et al., 2016). Our 
group further showed that tebufenpyrad induced NLRP3 inflammasome activation in 
microglial cells leading to release of IL-1β (Sarkar et al., 2017b). Organophosphate 
pesticide diisopropylflurophosphate (DFP) have been shown to neurotoxic. A recent 
study showed that DFP can also activate microglial cells in the hippocampus leading 
to production of proinflammatory factors like IL-1β and TNFα (Li et al., 2015). These 
studies together suggest that pesticide exposure can lead to glial inflammation 




Prolonged exposure to heavy metals at occupational sites has revealed much 
about the environmental linkages to the etiology of neurodegenerative disorders such 
as Alzheimer’s (AD) and Parkinson’s (PD)(Rokad et al., 2016).  
Manganese 
Aerial overexposure to the transition metal manganese (Mn) was first noted in 
miners(Archibald and Tyree, 1987), and subsequently in industrial workers like 
welders (Kwakye et al., 2015). Although Mn has a multitude of physiological functions 
(e.g., enzyme cofactor for superoxide dismutase and arginase, immunity, bone 
development, and reproduction)(Karki et al., 2015), accruing toxic levels will 
predominately localize to the globus pallidus, but also to the striatum and substantia 
nigra, leading to manganism, which is phenotypically similar to PD(Milatovic et al., 
2007; Kwakye et al., 2015). Excluding occupation as a factor, diets including grains, 
legumes, and nuts represent the main source of Mn, of which less than 5% is 
intestinally absorbed(Karki et al., 2013; Kwakye et al., 2015). On the other hand, 30-
40% of inhaled Mn is absorbed into the bloodstream, where it travels primarily bound 
to albumin and β-globulin as Mn+2 (refer Mn as Mn+2 unless otherwise noted) (Karki et 
al., 2013). This oxidation state of Mn is facilitated into and within the central nervous 
system (CNS) by transporters such as divalent metal ion transporter 1 (DMT1) found 
on cell membranes (Sidoryk-Wegrzynowicz and Aschner, 2013; Karki et al., 2015). 
 
 As the most numerous constituent of the CNS, astrocytes are the glue whose 
physiological roles are indispensable for cellular homeostatic maintenance(Volterra 
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and Meldolesi, 2005). Astrocytes regulate extracellular glutamate amongst neurons in 
tripartite synapses(Popoli et al., 2011; Karki et al., 2013). Disruption of this regulation 
by Mn is possible by the induction of tumor necrosis factor-α (TNFα). This 
inflammatory response leads to increased yin yang-1 expression that can inhibit the 
production of excitatory amino acid transporter-2, which is necessary for glutamate 
reuptake(Karki et al., 2014; Karki et al., 2015). By way of this mechanism, it is 
observable that Mn neurotoxicity can be understood as a secondary dysfunction 
brought on by astrocytic inflammation. 
 
 Along with pericytes, the end-feet of astrocytes envelope blood vessels to 
regulate blood-brain barrier trafficking(Pekny and Pekna, 2014). Interestingly, 
astrocytes have been demonstrated to have an increased affinity for Mn, with 
concentrations up to 50-fold greater than in neurons(Aschner et al., 1992; Gonzalez 
et al., 2008). Once internalized, the Mn is sequestered by mitochondria via the calcium 
(Ca+2) uniporter(Gunter et al., 2006). Kinetical analyses reveal the influx of Mn over 
this mitochondrial uniporter is slower than Ca+2 itself, but Mn efflux is far slower(Gavin 
et al., 1990; Martinez-Finley et al., 2013). Although the atomic charge properties and 
size of Mn are quite analogous to Ca+2, which explains the sequestration of Mn by the 
Ca+2 uniporter, the two Ca+2 efflux mechanisms are poor exporters of Mn(Gunter et 
al., 1975; Gunter and Sheu, 2009; Martinez-Finley et al., 2013). Specifically, Na+-
independent Ca+2 efflux does transport Mn; however, Na+-dependent Ca+2 efflux, the 
predominant mechanism in CNS mitochondria, has not been reported to export 
Mn(Gavin et al., 1990; Gunter and Sheu, 2009; Martinez-Finley et al., 2013). This 
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extremely sluggish efflux of Mn both explains the prolonged CNS clearance and the 
source of toxicity(Martinez-Finley et al., 2013). Indeed, Mn can competitively inhibit 
both efflux pathways, raising the intramitochondrial Ca+2 concentration that can impair 
aerobic respiration and elicit reactive oxygen species(Gavin et al., 1990; Tjalkens et 
al., 2006; Martinez-Finley et al., 2013; Streifel et al., 2013).  
Mn toxicity has been well documented in neurodegeneration and glial biology 
(Hazell et al., 1999; Filipov et al., 2005a; Milatovic et al., 2007; Sidoryk-Wegrzynowicz 
et al., 2009; Dodd and Filipov, 2011; Sarkar et al., 2017a). More specifically, Mn 
induces TNF-α and inducible nitrogen synthase (iNOS) in astrocytes (Moreno et al., 
2008; Moreno et al., 2009), causes mitochondrial dysfunction by its accumulation in 
mitochondria (Yin et al., 2008), and it was shown to induce neurotoxicity in a rat model 
of manganism by modulating microgliosis (Zhao et al., 2009). Mn exposure has been 
shown to induce classical activation in microglial cells (Chang and Liu, 1999) as well 
as astrocytes(Sarkar et al., 2017a) in the central nervous system, leading to 
production of pro-inflammatory cytokines. The plethora of pro-inflammatory factors 
have been shown to cause neuronal damage (Filipov et al., 2005b). Furthermore, Mn 
has been shown to enhance, LPS-induced production of pro-inflammatory factors in 
microglial cells (Dodd and Filipov, 2011). Langley et al. recently illustrated that Mn 
potentiates the activation of microglial cells in MitoPark mouse model of PD, 
suggesting a probable crosstalk between gene and environment in regulating 
microglial homeostasis (Langley et al., 2017b).   
Though Mn has been shown to induce microglial activation, the mechanism 
underlying this inflammation has been equivocal. A recent study has shown that Mn 
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induces NLRP3 inflammasome activation in BV2 microglial cell line. This 
inflammasome activation was accompanied by modulation in autophagy dysfunction 
and lysosomal dysfunction (Wang et al., 2017). Lysosomal cathepsin B played a major 
role in activating Mn-induced inflammasome (Wang et al., 2017). Our study showed 
that Mn can lead to mitochondrial dysfunction in microglial cells which drives the 
inflammasome activation. Moreover, we showed that Mn leads to propagation of 
inflammasome by regulating the exosomal release of inflammasome component ASC.  
Other Metals 
 Other than Mn, other metals like Copper (Cu), Lead (Pb), Zinc (Zn), and Iorn 
(Fe) have been linked to glial activation. Modulation Cu homeostasis have been 
implicated in change in microglial phenotype in AD mouse models (Zheng et al., 
2010). Further, exposure to Cu has been shown to reduce amyloid β clearance in AD 
by microglia, as well as production of proinflammatory factors like TNFα and IL-6 
(Kitazawa et al., 2016). Moreover, Cu exposure have further been linked to S-
nitrosothiol signaling dysfunction and NO metabolism in microglial cells (Rossi-
George and Guo, 2016). 
 Pb exposure have been linked to astrogliosis and microgliosis in brain 
(Chibowska et al., 2016). Pb exposure increased the levels of IL-6 and TGF-β1 by 
modulation of MAPK (Kasten-Jolly et al., 2011). Pb further increases the level of pro-
inflammatory cytokine IL-18, IL-1β, and IL-1α by induction of p38 MAPK (Conti et al., 
1999; Wheeler et al., 2003; Cordova et al., 2004). Furthermore, Pb exposure reduces 
the level of anti-inflammatory factor IL-10 in rodent models (Kasten-Jolly et al., 2012). 
Pb further, induced the expression of Caspase 1 and Nos 2 in rodent model of lead 
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toxicity (Kasten-Jolly et al., 2012). Though the mechanism of Pb-induced activation of 
glia is still not clear, the potential of inflammasome activation by Pb is immense given 
the fact that Pb induces both the end products of inflammasome activation, IL-1β and 
IL-18, as well as cleavage of caspase 1. Zinc treatment have also been shown to 
potentiate LPS-induced microglial inflammation and production of inflammatory 
factors like IL-1β and IL-6. Further, this potentiation was blocked using a cell 
permeable Zinc chelator. P2X7 receptor antagonist also reduced the effect of Zinc on 
microglial activation suggesting the role of this receptor in zinc-induced microglial 
activation (Higashi et al., 2017).  All these studies taken together confirms the role of 
environmental metals in regulating glial inflammation.  
Diesel Exhaust Particle 
Another environmental stressor affecting dopaminergic neurons are diesel 
particle extract. Block et al. demonstrated that diesel exhaust particle induced a dose-
dependent loss of dopaminergic neurons (Block et al., 2004). Interestingly, diesel 
exhaust particle did not elicit this neurotoxic effect in neuron rich culture lacking 
microglia, suggesting the probable role of microglia in diesel exhaust particle-induced 
neurotoxicity. These particles were shown to be taken up by the microglial cells, 
thereby generating superoxide, which were neurotoxic. Moreover, NADPH oxidase 
have been shown to play an important role in diesel particle-induced microglial 
activation. NADPH oxidase knockout mice failed to induce superoxide generation and 
neuronal loss post diesel exhaust particle exposure (Block et al., 2004). Rats exposed 
to diesel exhaust further had increased level of pro-inflammatory factor, IL-6, nitrated 
proteins, and IBA1. Midbrain region has been shown to be mostly affected by diesel 
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exhaust with increase in inflammatory factors, TNFα, IL-1β, IL-6, and MIP-1α 
(Levesque et al., 2011). Surprisingly, in HAPI microglial cell line diesel exhaust did not 
induce the production of these inflammatory cytokines, but potentiated the release of 
these factors on LPS treatment (Levesque et al., 2011). This diesel particle-induced 
microglial activation is regulated by MAC1. Pretreatment with MAC1 antibody have 
been shown to reduce microglial activation post diesel extract treatment. Moreover, 
MAC1 knockout neuron glia culture were protected from diesel exhaust induced 
neurotoxicity and H2O2 production (Levesque et al., 2013). Exposure to diesel exhaust 
particles leading to neuroinflammation and microglial activation leading to 
neurotoxicity is more pronounced in males compared to females(Cole et al., 2016). 
These studies in summary indicate the probable role of lung-brain axis in regulating 
microglial activation in neurodegenerative disorders. Further understanding 
underlying the mechanism of diesel exhaust particle induced microgliosis may unravel 
key insights in the role of air pollution in regulating brain functions.    
Conclusion and Future Directions 
 As discussed in this review glial activation leading to inflammation is regulated 
by multiple signaling proteins and cascade, including NOX2, NfκB, inflammasome and 
others. Environmental exposures to metals, pesticides and air pollution regulates the 
glial inflammation through crosstalk with the these signaling molecules. Pesticides like 
rotenone and tebufenpyrad, environmental metals like manganese leads to microglial 
activation by regulating inflammasome activation (Fig. 3). Paraquat induces oxidative 
stress and microglial ROS generation by modulating NOX activity. These gene-
environment cross talks have been linked to multiple neurodegenerative disorders like 
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AD and PD. Understanding the mechanism underlying this interrelationship between 
the signaling proteins and our environment will give us key insights into probable 
cause of these sporadic disease which are associated with neuroinflammation.   
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Fig. 1: Cellular localization of various NADPH oxidase (NOX) isoforms. NOX1 is 
localized on lysosomal and nuclear membrane. NOX2 is localized on plasma 
membrane. NOX4 is localized on plasma membrane, mitochondrial membrane, 






Fig. 2. Mechanism of NLRP3 inflammasome activation in glial cells (Adopted 




Fig. 3. Schematic representation of mechanism of pesticide and Metal induced 
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Neuroinflammation is one of the major key pathophysiological hallmark of 
neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and traumatic brain injury (TBI). Microglia, the first responders of the brain, are 
the drivers of this neuroinflammation. Microglial activation, leading to induction of pro-
inflammatory factors, like IL-1β, TNFα, nitrites and others, have been shown to induce 
neurodegeneration. Non-steroidal anti-inflammatory drugs (NSAID’s) have been 
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shown to reduce risk of developing PD. But the mechanism underlying the microglial 
activation is still under active research. Recently, microglial ion channels have come 
to the forefront as potential drug targets for in multiple neurodegenerative disorders 
including AD and PD. Microglia expresses a variety of ion channels including 
potassium channels, calcium channels, chloride channels, sodium channels, and 
proton channels. The diversity of channels present on microglia is responsible for the 
dynamic nature of these immune cells of the brain. These ion channels regulate 
microglial proliferation, chemotaxis, phagocytosis, antigen recognition and 
presentation, apoptosis, and cell signaling leading to inflammation, among other key 
critical functions. Understanding the role of these ion channels and the signaling 
mechanism these channels regulate under pathological conditions is an active area 
of research. This review will be focusing on the roles of different microglial ion 
channels, and their potential role in regulating microglial functions in 





Microglia, the first responders of the brain, are key players in shaping up the 
neural circuit during development, as well as maintaining the neuronal health 
(Paolicelli et al. 2011). Hyperactivation of microglial cells have been linked to multiple 
disease including epilepsy (Sharma et al. 2017), Parkinson’s disease (PD) (Panicker 
et al. 2015), Alzheimer’s disease (AD) (Halle et al. 2008), and Traumatic brain injury 
(TBI) (Turtzo et al. 2014). Microglia derived proinflammatory factors have been shown 
to be neurotoxic and can lead to neuronal loss (Sarkar et al. 2017). Hence, anti-
inflammatory drugs targeting microglial activation, and proliferation have gained 
importance in recent years. 
Microglial ion channels perform a diverse set of functions which leads to 
microglia-induced inflammation, proliferation and migration (Feske et al. 2015). In 
neurodegenerative disease conditions multiple of these ion channels have been 
shown to be upregulated, which make them lucrative drug targets. In this review, we 




Kv1.3 is one of the 40 voltage gated channel in human genome. Kv1.3 channel 
was identified in T cells following its cloning (DeCoursey et al. 1985; Grissmer et al. 
1990; Matteson and Deutsch 1984). It is composed of 4 α subunits and each of the 
subunits has 1 P loop and 6 transmembrane segments (S1-S6). 4 Arginine residues 
in S4 segment are responsible for the opening of this channel due to polarization. 
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Other than T cells, Kv1.3 channels have been identified in lymphocytes, RGC’s, 
microglia and various other cell types. Kv1.3 knock out mice have been shown to be 
resistant to diet induced obesity (Upadhyay et al. 2013; Xu et al. 2004), immune to 
experimental autoimmune encephalomyelitis (EAE)(Gocke et al. 2012) and also 
improved sense of smell(Fadool et al. 2004) showing the diverse function of this 
voltage gated channel. The role of this channel has been studied in mostly 
autoimmune disease and also ischemia and in development in RGC’s. The N-terminal 
end of this channel has a proline-rich sequence which has been shown to bind to src-
homology domain of src-family kinase (SFK).  
First sequenced and cloned by Chandy in 1991 (Chandy 1991), the transcript 
of Kv1.3 in microglial cells was first discovered in 1993 by Norenberg et al (Norenberg 
et al. 1993).  Since then the role of Kv1.3 in microglial function and activation have 
been implicated. A study by Schlichter et al. demonstrated that primary microglia in 
culture do express functional Kv1.3 outward rectifier channels but following prolonged 
culturing, these microglia loose the channel function (Schlichter et al. 1996). Kv1.3 
plays an important role in driving LPS-induced inflammation in microglial cells. 
Fordyce et al. demonstrated that Kv1.3 channel activity in microglial cells is necessary 
to kill hippocampal neurons using a co-culture system. This study further showed that 
Kv1.3 inhibitors reduced the respiratory burst and free radical production in microglial 
cells hence reducing the formation of peroxynitrite, a key inflammatory molecule 
(Fordyce et al. 2005). A recent study by Rangaraju et al. further elucidated the Kv1.3 
dependent pathways in microglial cells post LPS treatment (Rangaraju et al. 2017). 
This study used a Kv1.3 inhibitor, Shk, to inhibit the channel activity post LPS 
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treatment and performed whole cell proteomics to determine the Kv1.3 dependent 
pathways involved during in an inflammagen insult. Interestingly, blocking Kv1.3 
reduced phosphorylation of STAT1 which is an immediate downstream signaling of 
LPS-TLR signaling cascade. Blocking of Kv1.3 further reduced the microglial 
phagocytic activity, and also modulated microglial chemotaxis and migration. Kv1.3 
was further shown to be regulating MHC-1 antigen presentation pathways in microglia 
by regulating TAP1 and EHD1. Interestingly, Kv1.3 inhibition also altered one of the 
subunits of GA binding protein (GABP) which has been involved in mitochondrial DNA 
replication, and oxidative phosphorylation (Quiros et al. 2016). Interestingly, Kv1.3 is 
also present on the mitochondrial membrane, and has been linked to cytochrome c 
release and apoptosis in lymphocytes (Gulbins et al. 2010; Szabo et al. 2008). But till 
date, no studies have looked into the probable role of mitochondrial Kv1.3 in microglia 
and its role in microglial function. Recently, our group along with others have shown 
the importance of mitochondrial dynamics in driving inflammation in microglial cells 
(Lawana et al. 2017; Sarkar et al. 2017). Hence, studies on mitochondrial Kv1.3 and 
its role in regulating mitochondrial health in glial cells may provide key mechanistic 
insights.  
Microglial Kv1.3 have been shown to be induced in multiple disease models 
like stroke, AD, HIV induced dementia, radiation induced brain injury, and status 
epilepticus. Menteyne et al. showed that Kv1.3 is the predominant potassium channels 
in the kainate mouse model of epilepsy in microglial cells. In this study, post kainate 
treatment in CX3CR1(eGFP/+) mice, whole-cell-patch clamp was performed on GFP-
microglial cells, which demonstrated an increase of Kv1.3 current in the activated 
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microglia. Treatment with Kv1.3 inhibitor, agitoxin-2 and margatoxin inhibited this 
current (Menteyne et al. 2009). Microglial cells have been also shown to play a critical 
role in HIV induced neuropathology. HIV-1 regulatory protein, Tat, induced microglial 
inflammation, by induction of Kv1.3 and classical activation of Nfκb (Visentin et al. 
2001). siRNA knockdown of Kv1.3 in microglial cells reduced the neurotoxicity induced 
by Tat by reducing the release of pro-inflammatory factors in microglial cells. Also, 
Kv1.3 inhibition lead to a decrease in activation of ERK1/2 MAPK pathway induced by 
Tat (Liu et al. 2013). Also, the gp-120 subunit of HIV-1 virus have been shown to 
activate microglial cells. Gp-120 further induced Kv1.3 channel activity in the glial 
cells. Furthermore, inhibition of Kv1.3 reduced microglial activation by reduction of p38 
MAPK pathway (Liu et al. 2012). Methamphetamine drug abuse have been also linked 
to higher risk of HIV-1 induced neurotoxicity. Liu et al. further demonstrated that 
methamphetamine exacerbates gp-120-induced microglial Kv1.3 current activity, 
leading to hyperactivation of microglial cells and neurodegeneration (Liu et al. 2017).  
Kv1.3 was also increased in a mouse model of radiation induced brain injury. 
Further, Shk, a peptide inhibitor of Kv1.3, reduced microglial inflammation, and 
neurotoxicity, and promoted proliferation of neural stem cells and neurogenesis (Peng 
et al. 2014). Furthermore, Reeves et al. demonstrated that in a model of TBI, 
Clofazimine, a Kv1.3 inhibitor, treatment reduced microglial activation and 
microgliosis, hence reducing the white matter pathology of the disease (Reeves et al. 
2016).   
Microgliosis and neuroinflammation have been shown to be an important factor 
contributing to neuronal loss in AD (Halle et al. 2008). Kv1.3 is has been shown to be 
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highly expressed in microglial cells in AD brains. Moreover, the Kv1.3 positive glial 
cells were shown to be associated with amyloid β (Aβ) tangles in the frontal cortex of 
AD patients (Rangaraju et al. 2015). A recent study further demonstrated that Aβ 
induced microglial activation and Kv1.3 upregulation in microglial cells. Furthermore, 
Kv1.3 was also induced in the transgenic mouse model APP/PS1 of AD. 
Pharmacological inhibition of Kv1.3 channel in vivo in this mouse model of AD, 
resulted in reduced inflammation as well as rescue of disease phenotype. Also, Kv1.3 
inhibition resulted in higher uptake of Aβ and reduced cerebral amyloid load. PAP1, 
the Kv1.3 inhibitor further, improved hippocampal neuronal plasticity, behavioral and 
cognitive deficits in mouse model of AD (Maezawa et al. 2017). Though the 
importance of microglial Kv1.3 in AD has been elucidated, further studies looking into 
the downstream signaling mechanism of Kv1.3 in microglia may identify some novel 
pathways in regulating microglial function in disease pathology. Furthermore, the 
upstream signaling cascade leading to Kv1.3 activation in disease condition have not 
been studied.   
The role of Kv1.3 is not well known in PD. We demonstrated that Kv1.3 is highly 
induced by aggregated α-synuclein. Furthermore, post mortem PD patients had higher 
microglial Kv1.3. Inhibition of Kv1.3 reduced microglial activation and 
neurodegeneration in multiple PD models in vitro and in vivo. Kv1.3 is regulated by 
p38 MAPK pathway and Nfκb pathway. We also showed that Fyn, a src family kinase 
can modulate the function of this potassium channel by directly binding to Kv1.3 and 
phosphorylating it. The significant number of studies suggesting the role of this 
channel in disease pathology and inflammation and its diverse role in regulating 
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microglial signaling cascade in various disease models makes it an interesting target 
for a drug. But further studies, understanding the role of mitochondrial Kv1.3 in 
microglia, in disease condition, may give key insights in understanding the role of 
mitochondria in regulating microglial function.   
Kca3.1 
First identified by György Gárdos in 1958 (Gardos 1958), Kca3.1 is a voltage 
independent potassium channel activated by intracellular calcium. The activation of 
this channel leads to hyperpolarization of the membrane leading to calcium influx 
(Joiner et al. 1997; Wei et al. 2005). Kaushal et al. demonstrated that Kca3.1 inhibition 
reduced microglial activation and pro-inflammatory cytokine release by regulating p38 
MAPK pathway but not Nfκb signaling cascade. Moreover, TRAM-34, a Kca3.1 
blocker, reduced degeneration of retinal ganglion cells in an optic nerve transection 
mouse model (Kaushal et al. 2007). A study by Maezawa and colleagues, further 
demonstrated that oligomeric Aβ-induced microglial activation and proliferation in vitro 
and activated this voltage independent potassium channel. TRAM-34 treatment 
inhibited the activation of microglia and oligomeric Aβ-induced neurotoxicity further 
suggesting a role of Kca3.1 in regulating neuroinflammation and neurodegeneration 
(Maezawa et al. 2011). The expression of Kca3.1 was shown to be induced in 
microglial cells surrounding infarction areas in a stroke mouse model. Treatment with 
TRAM-34, further reduced the microglial activation and infarction area in this stroke 
model (Chen et al. 2011). Kca3.1 expression was highly induced in microglial cells in 
a spinal cord injury mouse model. Inhibition of this channel not only reduced 
production of inflammatory cytokines TNFα and IL-1β but also improved locomotor 
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deficits and tissue protection (Bouhy et al. 2011). Kca3.1 also plays an important role 
in regulating glioblastoma invasiveness, and activation and propagation of microglia 
(D'Alessandro et al. 2013). Surprisingly, LPS did not elicit Kca3.1 channel activity, but 
ATP and IFNγ elicited moderate amount of Kca3.1 channel activity (Nguyen et al. 
2017).  
KATP 
ATP sensitive-KATP channels were first identified in cardiac myocytes (Noma 
1983), and are composed of eight protein subunits, four subunits of inward rectifier, 
Kir6.1 or Kir6.2 and four subunits of sulfonylurea receptors (Inagaki et al. 1995). These 
channels act as metabolic sensors and have a variety of physiological functions, 
including insulin secretion, and inflammation (Quan et al. 2011).  Glial KATP channels 
have been implicated in various disorders including stroke, multiple sclerosis and PD. 
Iptakalim, a KATP channel opener, was able to reduce glial activation, production of 
proinflammatory factors like TNFα and p38 MAPK activation in MPP model of PD. 
Furthermore, these protective effects were reversed when a KATP channel blocker, 
hydroxydecanoate, was used (Yang et al. 2009). Moreover, opening of KATP channel 
reduced neuroinflammation induced by rotenone in BV2 microglial cell line by reducing 
p38/JNK MAPK pathway (Zhou et al. 2008). This ATP sensitive potassium channel is 
further involved in NOS2 production from microglial cells in response to LPS (Kurland 
et al. 2016). Taken together, most of the current literature suggest a prominent anti-
inflammatory role of KATP in regulating microglial activation in neurodegenerative 
disorders. Further studies, looking into the potential signaling cascades involved in 
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regulating KATP will give leads to potential anti-inflammatory strategies in disease 
condition.  
Other Potassium Channels 
 Various potassium channels including the ones discussed above play 
important roles in regulating microglial functions by modulating signaling cascades. 
Kir2.1, an inward rectifier channel, has been shown to be induced upon alternative 
activation of microglial cells (Lam et al. 2017). Furthermore, Kir2.1 inhibition reduced 
microglial proliferation upon anti-inflammatory stimulus (Lam et al. 2017). Kir2.1 
further modulates microglial chemotaxis, migration, and intracellular calcium signaling 
at resting and alternative activation states (Lam and Schlichter 2015).  Kv1.5 have 
also been shown to be induced in classically activated microglial cells (Jou et al. 1998). 
Furthermore, Kv1.5 knockout microglia have reduced production of NO and 
proliferation post inflammatory insult (Pannasch et al. 2006) suggesting the role of this 
outward potassium channel in multiple microglial functions. Further Kv1.5 channel 
expression was also highly induced in amyloid β treated microglial cells (Chung et al. 
2001).  Together, the role of potassium channels in microglia is diverse in 
physiological and disease condition (Fig. 1). Modulation of these ion channels may 
lead to discovery of key drug targets for neurodegenerative disorders but further 
mechanistic study to understand the downstream signaling of these channels are 
necessary.  
Sodium Channels 
First identified in jellyfish, sodium channels play a major role in diverse 
physiological functions including cognition, locomotion, and depolarization (Marban et 
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al. 1998). Sodium channels were the first voltage gated channels to be cloned in 1984 
(Noda et al. 1984), but the role of sodium channel in microglial channels is not well 
studied.  
Primary rat microglia isolated from prenatal pups expressed different isoform 
of sodium channels including Nav1.1, Nav1.5, and Nav1.6 (Black et al. 2009). These 
channels control a range of microglial functions. Sodium channel inhibition lead to 
reduced phagocytosis in LPS-activated microglial cells. Further, these channels play 
an important role in regulating the proinflammatory cytokine release from microglial 
cells. Phenytoin, a sodium channel inhibitor, reduced the production of IL-1α, IL-1β, 
and TNFα, induced by LPS but had minimal effect on the other secretory cytokines 
and chemokines. Furthermore, sodium channel inhibition, reduced ATP-induced 
microglial chemotaxis and migration (Black et al. 2009). 
Deng et al.  identified the key role of sodium channels in microglial cells in 
hypoxic environment. This study showed that activated microglia express higher level 
of sodium channels. Further, these activated microglial cells induced the production 
of proinflammatory factors including, TNFα and IL-1β, which resulted in the loss of 
neurons and also linked to periventricular white matter damage associated with 
hypoxic environment in brain (Deng et al. 2011).  
ATP release in extracellular space, leading to neuronal damage and 
inflammation have been linked to multiple neurodegenerative disorders (Gan et al. 
2015; Jun et al. 2007; Rodrigues et al. 2015; Shin et al. 2016). Persson et al. 
demonstrated that inhibition of Nav1.6 modulates the ERK1/2 MAPK pathway thereby 
regulating the accumulation of Rac1 in response to extracellular ATP in microglial 
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cells. This study further showed that Nv1.6 directly regulates the cellular polarization, 
spatial arrangement and microglial movement in response to ATP (Persson et al. 
2014).  
Microglial sodium channels have been shown to be upregulated in multiple 
disease models including spinal cord injury and multiple sclerosis. Sodium channel 
blockage lead to a decreased microglial activation and production of proinflammatory 
cytokines in spinal cord injury model. Inhibiting sodium channels lead to reduced 
activation of classical Nfκb, pro-inflammatory pathway, and p38 MAPK pathway but 
did not alter the activation of JNK pathway (Jung et al. 2013). In animal model of 
experimental autoimmune encephalopathy, Nav1.6 was found to be highly 
upregulated in activated microglial cells (Craner et al. 2005). But recent studies 
looking into specific inhibition of sodium channels have shown that Nv1.2, Na1.4, and 
Nav1.6 blockage exacerbates experimental autoimmune encephalomyelitis (Stevens 
et al. 2013). These studies suggest that sodium channel plays a complex role in 
regulating microglial function. Further studies, understanding the modulation of these 
diverse channels in disease condition and the signaling pathway is necessary.    
Other Channels 
Another key channel affecting microglial function in disease model is the unique 
voltage gated proton channel, Hv1. Microglia, but not astrocytes and neurons, have 
been shown to express Hv1 current. Interestingly, Hv1 knockout mice have reduced 
neuronal loss in an ischemic stroke mouse model.  Hv1 was shown to play an 
important role in NADPH oxidase mediated ROS generation in glial cells, which was 
shown to play an important role in neurodegeneration in stroke model (Wu et al. 2012).  
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This voltage-gated proton channel compensates cellular loss of electrons with protons 
hence activating NADPH oxidase (Wu 2014). Dextromethorphan which has an anti-
inflammatory activity have been shown to reduce proton channels in microglial cell 
line, BV2 (Song and Yeh 2012). Moreover Hv1 knockout microglia had lower NOX 
activation in a cell culture model of periventricular leukomalacia (Yu et al. 2017). Tian 
et al. demonstrated that this unique proton channel can be a potential target for 
modulating microglial activation profile in disease model. Hv1 deficient microglia was 
further shown to shift the microglial activation profile towards an alternative anti-
inflammatory M2-like phenotype in stroke model (Tian et al. 2016).  ROS generation 
and NADPH oxidase activation in microglial cells is one of the major inflammatory 
pathways in multiple neurodegenerative disorders including PD (Langley et al. 2017) 
and AD (Hernandes and Britto 2012; Zekry et al. 2003). NOX inhibition has been 
implicated as therapeutic targets in these neurodegenerative disorders (Cifuentes-
Pagano et al. 2015). But the potential role of Hv1 in AD or PD, the two most prevalent 
neurodegenerative disorders have not been elucidated.  
Other Channels 
Multiple calcium channels as well as purinergic receptors have been reported 
to modulate various physiological functions of microglia in disease conditions 
(Echeverry et al. 2016; Espinosa-Parrilla et al. 2015; Sperlagh and Illes 2014).  L-type 
voltage gated calcium channels have been implicated in microglial activation in AD 
and prion disease. Misfolded prion protein, a classical hallmark of prion associated 
disease, increased the expression of L-type calcium channels and induced microglial 
activation. Treatment with inhibitors of L-type voltage sensitive calcium channels 
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reduced the microglial activation suggesting the role of this type of channels in 
classical activation of glial cells (Silei et al. 1999). Cav1.2 subunit of voltage gated 
calcium channel was shown to be upregulated in glial cells in mouse model of AD and 
was related to increase in amyloid β load (Daschil et al. 2013). Moreover, Cav1.2 and 
Cav1.3 have been shown to be upregulated in microglial cells in a rodent model of N-
methyl-D-aspartate-induced hippocampal neurodegeneration (Espinosa-Parrilla et al. 
2015). Furthermore, blocking of these calcium channels reduced the production of 
proinflammatory factors, TNFα and NO, in BV2 microglial cell line post LPS treatment 
further elucidating the role if these channel in regulating microglial inflammation 
(Espinosa-Parrilla et al. 2015). 
Transient receptor potential (TRP) channels, which are non-selective cation 
channels, further regulation microglial functions under physiological and disease 
conditions (Echeverry et al. 2016). Out of the TRPV subfamily of channels TRPV1, 
TRPV2, and TRPV4 has been shown to regulate major microglial functions. TRPV1 
has been associated with microglial inflammation. Induction of TRPV1 lead to 
increased ROS production and NOX activity leading to inflammation (Schilling and 
Eder 2009). Induction of TRPV1 channels have been shown to produce other 
proinflammatory factors, like IL-6 and NO, and activation of pro-inflammatory signaling 
cascade Nfκb (Sappington and Calkins 2008; Talbot et al. 2012) and MAPK (Miyake 
et al. 2015). TRPV1 have also been linked to microglial chemotaxis. Induction of 
TRPV1 lead to increased microglial chemotaxis, while TRPV1-selective blockers 
reversed the effect (Miyake et al. 2015). TRPV2 is predominantly present in the 
endoplasmic reticulum and translocate to the plasma membrane post-stress. Though 
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the role of glial TRPV2 is not well established, this channel may be regulating 
intracellular calcium signaling leading to microglial activation (Hassan et al. 2014). 
TRPV4, a mechanosensitive channel, have been shown to play an important role in 
infrasound induced glial activation and production of proinflammatory factors (Shi et 
al. 2013). Further, TRPV4 blockage reduced LPS-induced TNFα release and 
microglial activation (Konno et al. 2012).    
TRPM family of non-selective calcium channels further play a role in regulating 
inflammation in microglial cells. TRPM2 have been shown to induce H2O2-induced 
microglial activation by modulating calcium influx. TRPM2 knockout mice have 
reduced inflammatory response in response to LPS/ IFN-γ and have reduction in 
activation of MAPK and JNK signaling cascade (Miyake et al. 2014). TRPM2 and 
TRPM4 channel activity have been shown to be induced under inflammatory insult 
and may play a critical role in monitoring microglial cytokine release (Beck et al. 2008; 
Haraguchi et al. 2012). TRPM7, a calcium permeable channel, have been shown to 
modulate microglial migration and invasion during alternative activation (Siddiqui et al. 
2014). Microglial ATP sensitive purinergic receptor P2X7, have been recently 
implicated to play an important role in activation of NLRP3 inflammasome (Burm et al. 
2016). NLRP3 inflammasome is one of the major functional inflammasome in 
microglial which has been implicated in neurodegenerative disorders including AD 
(Halle et al. 2008; Heneka et al. 2013). The microglial functions modulated by these 
channels are diverse. The mechanism underlying the channel dependent pathways is 




Conclusion and Future Directions 
As discussed in this review, the current literature has a wealth of information 
suggesting the probable role of microglial ion channels in regulating diverse 
physiological and disease associated microglial function (Table 1). The potential of 
microglial ion channels as drug target is immense keeping into consideration the 
diverse function of these channels. As mentioned in Fig. 2, these channels have been 
shown to regulate both classical and alternative microglial activation. Hence proper 
modulation of microglial ion channels may lead to reduced inflammation or anti-
inflammatory microglial phenotype in neurodegenerative conditions. These ion 
channels may regulate multiple key inflammatory or anti-inflammatory signaling 
cascade in glial cells and hence modulate neuroinflammation in disease condition. 
Using one or more of these ion channels as drug targets may be beneficial in case of 
neurodegenerative disorders, considering the role of inflammation in these diseases. 
Although we have a lot evidence regarding the probable role of these channels in glial 
cells, the signaling pathways involved is not clearly understood. Future studies, 
looking into the channel dependent pathways in these glial cells may open a new 
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Fig. 1: Signaling pathways regulated by potassium channels in microglial cells 
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The NLRP3 inflammasome signaling pathway is a major contributor to the 
neuroinflammatory process in the central nervous system.  Oxidative stress and 
mitochondrial dysfunction are key pathophysiological processes of many chronic 
neurodegenerative diseases, including Parkinson’s disease (PD). However, the inter-
relationship between mitochondrial defects and neuroinflammation is not well 
understood. In the present study, we show that impaired mitochondrial function can 
augment the NLRP3 inflammasome-driven proinflammatory cascade in microglia. 
Primary mouse microglia treated with the common inflammogen, LPS, increased 
NLRP3 and pro-IL-1 expression. Interestingly, exposure of LPS-primed microglial 
cells to the mitochondrial complex-I inhibitory pesticides, rotenone and tebufenpyrad, 
specifically potentiated the NLRP3 induction, ASC speck formation and pro-IL-1 
processing to IL-1 in a dose-dependent manner, indicating that mitochondrial 
impairment heightened the NLRP3 inflammasome-mediated proinflammatory 
response in microglia. The neurotoxic pesticide-induced NLRP3 inflammasome 
activation was accompanied by bioenergetic defects and lysosomal dysfunction in 
microglia.  Furthermore, the pesticides enhanced mitochondrial ROS generation in 
primary microglia, while amelioration of mitochondria-derived ROS by the 
mitochondria-targeted antioxidant mito-apocynin completely abolished IL-1 release, 
indicating mitochondrial ROS drives the potentiation of NLRP3 inflammasome in 
microglia.  Exposure to conditioned media obtained from mitochondrial inhibitor-
treated, LPS-primed microglial cells, but not unprimed cells, induced dopaminergic 
neurodegeneration in cultured primary mesencephalic and human dopaminergic 
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neuronal cells (LUHMES). Notably, our in vivo results with chronic rotenone rodent 
models of PD further support the activation of proinflammatory NLRP3 inflammasome 
signaling due to mitochondrial dysfunction. Collectively, our results demonstrate that 
mitochondrial impairment in microglia can amplify NLRP3 inflammasome signaling, 
which augments dopaminergic neurodegenerative process. 
Keywords:    Mitochondria, mitochondrial dysfunction, microglia, microglial activation, 





Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder affecting around 2% of the US population over age 60. Its incidence is 
expected to rise dramatically with the advancing median age of the population, 
worsening the substantial socioeconomic burden on patients, their families and 
society. The main pathological hallmark of this disease is degenerating dopaminergic 
(DAergic) neurons within the nigrostriatal tract that project from the substantia nigra 
(SN) to the striatum, resulting in severely depleted striatal DA that clinically manifests 
as a range of debilitating motor symptoms1,2. The underlying mechanisms of the 
neuronal degeneration are not well understood, but mitochondrial dysfunction, chronic 
inflammation, and oxidative stress have been implicated in different animal models of 
PD3-5. The role of inflammation in PD was first suggested in 1988 when major 
histocompatibility complex molecules were shown to be upregulated in PD patients6. 
Furthermore, various proinflammatory factors like tumor necrosis factor  (TNF-α) and 
IL-1 were found to be upregulated in cerebrospinal fluid (CSF) and different regions 
of the brain in PD patients7. In various animal models of PD, including nigrostriatal 
lesions with 6-OHDA, MPTP, and rotenone, a selective loss of DAergic neurons is 
accompanied by chronic neuroinflammation8-12, partly mediated by microglia, the 
resident immune cells in the brain5,13-15. Since, depending on stimuli, microglia secrete 
both anti-inflammatory and pro-inflammatory factors, as well as growth factors, they 
are critical for regulating neuronal survival16,17. Though various inflammogens have 
been shown to stimulate microglia-mediated neuroinflammatory processes, the 
precise mechanisms underlying neuroinflammation remain equivocal. Understanding 
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the mechanism driving chronic brain inflammation may lead to a better understanding 
of PD pathogenesis and progression. 
Mitochondrial dysfunction and perturbations in mitochondrial dynamics in 
DAergic neurons are well established causes of neuronal degeneration in PD18-24. 
Despite this, the link between mitochondrial impairment in microglia per se and 
neuroinflammation is not well characterized. Recent studies have implicated 
inflammasome activation in inflammatory neurodegenerative disorders25,26 like 
Alzheimer’s disease (AD), multiple sclerosis and traumatic brain injury (TBI)25,27. 
Inflammasomes are multiprotein oligomers mainly formed by ASC, caspase-1, and 
the inflammasome component (e.g., NLRP3, NLRP1, NLRC4, AIM2). Multiple 
inflammasomes have been identified in microglia, astrocytes and neurons. The major 
function of an inflammasome is to cleave pro-IL-1 to IL-1, or to produce IL-18 to 
enhance and sustain inflammation. Both NLRP3 and NLRP1 inflammasomes have 
been implicated in AD pathogenesis28,29. NLRP3 inflammasome activation normally 
requires two signals for its function. Signal 1 activates the NFB pathway facilitating 
pro-IL-1 and NLRP3 transcription and translation. Signal 2 forms the inflammasome 
complex comprising NLRP3, ASC, and caspase-1, which in turn cleaves pro-IL-1 to 
IL-1. Signal 2 can vary from pathogens to aggregated proteins to ATP. Mechanisms 
underlying inflammasome complex formation remain unresolved30. 
The current study addresses the putative link between mitochondrial 
impairment and inflammasome activation in microglial cells, which may help identify a 
mechanism behind chronic inflammation-driven neurodegeneration. Recently, we 
demonstrated in a DAergic neuronal cell culture model that mitochondria-impairing 
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pesticides compromise mitochondrial dynamics (structure and function) by inhibiting 
mitochondrial complex-I21. Here, we demonstrate that impairing mitochondrial function 
in primary microglial cells, which had been treated with the classical PD mitochondrial 
neurotoxicant rotenone and the acaricide tebufenpyrad, may play an important role in 
inducing the NLRP3 inflammasome. Furthermore, we demonstrate the activation of 
NLRP3 inflammasome in a chronic rotenone animal model of PD. We also 
demonstrate that mitochondrial derived ROS contributes to inflammasome activation 
by utilizing a mitochondrially targeted derivative of apocynin. 
Results 
Rotenone and tebufenpyrad activate NLRP3 inflammasome in primary microglia  
We utilized two mitochondrial complex-1 inhibitors, rotenone and tebufenpyrad, 
to confirm cross-talk between mitochondrial dysfunction and microglial NLRP3 
inflammasome signaling. Exposure of LPS-primed (1 µM for 3 h) or unprimed primary 
mouse microglia cells to a concentration (1 M for 24 h) of rotenone or tebufenpyrad 
sufficient to inhibit mitochondrial complex-131 did not induce cell death, as measured 
by MTS assay (Fig. 1a). Next, Luminex multiplex cytokine assays revealed a dramatic 
increase in the levels of IL-1, but not that of TNF-α, confirming that the rotenone and 
tebufenpyrad treatments of primed cells induced release of the pro-inflammatory 
cytokine that is mediated by inflammasome signaling (Fig. 1b). Pesticide treatments 
alone did not increase either IL-1 or TNF-α in unprimed primary microglia (Fig. 1b).  
Next, LPS-primed or unprimed primary microglia were exposed to rotenone and 
tebufenpyrad for 3 and 6 h. Western blotting (Fig. 1c) revealed a time-dependent 
increase in cleaved caspase-1 levels when compared to LPS-primed and unprimed 
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microglia, although cleaved caspase-1 did increase slightly in LPS-primed microglia. 
Both the enhanced release of IL-1 and cleavage of caspase-1, suggesting the 
induction and activation of inflammasome signaling following mitochondrial complex-
1 inhibition. Next, ICC analysis revealed that NLRP3 immunoreactivity is indeed 
induced in rotenone- and tebufenpyrad-treated, LPS-primed microglia, but not in 
control microglia (Supplementary Fig. 1). As expected, NLRP3 induction also occurred 
in the LPS-priming alone group. Exposure of LPS-primed microglia to a secondary 
stimulus like rotenone or tebufenpyrad after NLRP3 induction resulted in the 
association of NLPR3 with ASC32, as revealed by the proximal ligation Duolink assay 
(Fig. 1d). Furthermore, both rotenone- and tebufenpyrad-treated primed microglial 
exhibited inflammasome activation-linked ASC speck formation33 (Fig. 1e). These 
data collectively support the two-pronged approach of inflammasome activation as 
previously described27,32. Signal 1, which in our study is LPS, induces the expression 
of NLRP3 and pro-IL-1β, but not the cleavage of pro-IL-1β to its active form IL-1β. 
Signal 2, which in our study are the mitochondrial inhibitors, leads to formation of the 
inflammasome complex consisting of NLRP3, ASC and caspase-1. This complex 
formation leads to activation of caspase-1, which in-turn cleaves pro-IL-1β to IL-1β. 
That is why we observed increased IL-1β release only in the LPS+Rot and LPS+Tebu 
groups.  
Wilson et al.34 have shown that NLRP3 inflammasome activation also induces 
IL-18 release along with IL-1β. Thus, we treated LPS-primed mouse microglia with 
either tebufenpyrad or rotenone for 2 h and then measured pro-IL-18 by qRT-PCR 
mRNA analysis. In line with previous reports32,both pro-IL-1 mRNA levels, and pro-
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IL-18 levels, increased significantly in LPS-primed and pesticide treatment groups, 
(Supplementary Fig. 2A-B).  
A study by Sherer et al. 35 reported that the IC50 for complex I inhibition is in 
nano molar range for both rotenone and tebufenpyrad, the cell type used in their study 
is of neuronal lineage which is more susceptible to complex I inhibitors than 
macrophage-like cells, including microglial cells used in our study. A much higher dose 
of rotenone (10 µM) has been previously used in inflammasome studies32. High micro-
molar doses of rotenone are known to induce acetylation of tubulin 36. Microtubule 
acetylation has also recently been linked to NLRP3 inflammasome activation 37. 
Misawa et al. 37 reported that SIRT2 downregulation leads to acetylation of α-tubulin, 
which modulates NLRP3 inflammasome activation. Hence, to confirm if our micro-
molar dose of pesticides affects microtubule assembly and inflammasome activation, 
primary microglial cells were treated with 1 µM rotenone and tebufenpyrad for 3 h 
following LPS priming. ICC analysis revealed that SIRT2 and acetylated α-tubulin 
levels did not change significantly following pesticide exposure (Supplementary Fig 
3). These data suggest that pesticide-induced inflammasome activation is not 
dependent on microtubule assembly at early time points.   
Next, we utilized a neuron-microglia co-culture system to see if pesticide 
exposure alone can prime the microglial cells. Mouse MN9D dopaminergic neuronal 
cells were grown on inserts placed in wells growing microglial cells. The cells were 
treated with 1 µM rotenone for 6 h, after which q-RT-PCR analysis revealed that 
pesticide exposure induced NLRP3 (Supplementary Fig. 4A) and pro-IL-β 
(Supplementary Fig. 4B) in the co-cultured microglial cells. To further validate our in 
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vitro study in vivo, we made use of the rotenone mouse model of PD38. Mice were 
gavaged daily for 28 days with 30 mg/kg rotenone. Rotenone significantly increased 
NLRP3 gene expression as revealed by qPCR analysis of striatal lysates (Fig. 1f). 
Immunoblot analysis showed that rotenone also significantly increased inflammasome 
markers such as NLRP3, cleaved caspase 1 p20, pro-IL-1 and cleaved IL-1β (Fig. 
1g-l).  
 
Next, we also utilized the rat model of rotenone. Rats were injected with 2.8 mg 
of rotenone for 4 days, and sacrificed after 3 months11, q-RT-PCR analysis revealed 
that, like in the mouse model, rotenone induced NLRP3 expression in rats 
(Supplementary Fig. 5A). Moreover, immunohistochemical analysis revealed that 
rotenone exposure upregulated NLRP3 in the IBA1-positive microglial cells 
(Supplementary Fig. 5B). We wanted to clarify that the LPS priming used in the in vitro 
model acts as signal 1 to activate the NFκB pathway. However, in the in vivo models, 
LPS priming is not necessary since the rotenone-induced neuronal stress can itself 
act as signal 130. Furthermore, including LPS priming step in vivo will make the model 
more complex as LPS can induce inflammasome activation39. Also, unlike an LPS 
priming step for in vitro models, it is not possible to get rid of the LPS in vivo after a 
certain time. These results collectively showed that mitochondrial complex-1 inhibition 
can lead to NLRP3 inflammasome activation in an environmental pesticide toxicant-
driven mouse model of PD. Together, these findings indicate that rotenone and 
tebufenpyrad can activate the NLRP3 inflammasome in primary mouse microglia.  
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Mitochondrial complex-1 inhibition induces a dose-dependent release of IL-1 
in primed microglia through the NLRP3 inflammasome pathway 
To test if the effects of rotenone and tebufenpyrad on inflammasome activation 
are dose-dependent, we exposed LPS-primed primary mouse microglia to 10-1000 
nM of rotenone or 50-1000 nM of tebufenpyrad for 24 h and then the medium was 
used for determining the levels of extracellularly released IL-1.  Luminex assays 
revealed both rotenone (Fig. 2a) and tebufenpyrad (Fig. 2b) induced a dose-
dependent release of IL-1 from LPS-primed cells. Indeed, even doses as low as 50 
nM induced NLRP3 inflammasome-mediated IL-1 release. 
To further confirm whether the rotenone- and tebufenpyrad-induced IL-1β 
release is due to the activation of NLRP3 inflammasome, LPS-primed and unprimed 
primary microglial cells were pretreated with 100 nM MCC-950, a potent NLRP3 
inflammasome inhibitor  40, for 1 h followed by co-treatment with rotenone or 
tebufenpyrad for 6h. An MTS assay revealed that 100 nM MCC-950, tested alone or 
in combination with the pesticides, did not lead to cell death, confirming that the 
NLRP3 inhibitor’s effect was not due to cytotoxicity (Supplementary Fig. 6). Also, the 
MCC-950 pre-treatment almost completely blocked the rotenone-induced secretion of 
IL-1β (Fig. 2c) and tebufenpyrad (Fig. 2d).  As a negative control, MCC-950 does not 
block the rotenone- or tebufenpyrad-induced release of IL-12, which is not dependent 
on NLRP3 activation (Fig. c-d, right panels).  
The other NLRP family members AIM2 and NLRC4 can also mediate the 
release of IL-1β 41.  Thus, we treated LPS-primed mouse primary microglia with the 
mitochondrial inhibitors for 2 h and then measured various inflammasomes by qRT-
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PCR mRNA analysis. We observed a huge induction in NLRP3 mRNA levels only in 
LPS-primed microglia without changes in AIM2 or NLRC4 levels (Fig. 2e), again 
suggesting specificity towards NLRP3 induction in primary microglia. Together, these 
results strongly suggest that the complex-1 inhibitor-induced release of IL-1β is indeed 
mediated by NLRP3 activation.  
Mitochondrial complex-1 inhibitors induce structural and functional changes in 
microglia   
Next, we characterized the microglial structural and functional changes 
underlying   cross-talk between mitochondrial dysfunction and NLRP3 inflammasome 
activation. We first treated LPS-primed primary microglial cells with 1 µM rotenone or 
tebufenpyrad for 3 h. Exposure of LPS-primed cells to both complex-1 inhibitors 
impaired mitochondrial bioenergetics as indicated by compromised basal respiration, 
ATP-linked respiration, and spare respiratory capacity, which were measured using a 
Seahorse Bioscience XFe24 analyzer (Fig. 3a). Next, we treated LPS-primed primary 
microglia for 2 h with rotenone or tebufenpyrad and then stained them with TMRM, a 
dye which is readily sequestered into active mitochondria and stains them according 
to their potential. Pesticide-treated primed microglia exhibited reduced TMRM 
fluorescence (Fig. 3b) compared to unprimed cells, suggesting inflammasome-related 
mitochondrial dysfunction. Furthermore, an ATP assay (Fig. 3c) revealed that the 
pesticide-treated primed microglia produced less ATP when compared to unprimed 
cells, suggesting that their mitochondria were functionally damaged at an early stage 
of inflammasome activation. We tested for additional markers of pesticide-induced 
mitochondrial structural damage in primed primary microglial cells treated with 1 µM 
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rotenone or tebufenpyrad by staining them for 6 h with MitoTracker Red. Quantification 
of fluorescence revealed that mitochondria in pesticide-treated, LPS-primed microglial 
cells exhibited greater fission-related circularity and solidity than did non-treated cells 
(Fig. 3d-e).  
To identify if the mitochondrial dysfunction is an effect of inflammasome 
activation, we co-treated primary microglial cells with the NLRP3-specific inhibitor 
MCC-950 (100 nM) and 1 µM rotenone or tebufenpyrad for 3 h. The mitochondrial 
stress assay revealed that inhibiting the NLRP3 inflammasome did not reverse the 
mitochondrial defects (Supplementary Fig. 7a-b). These data indicate the probable 
role of mitochondria upstream of inflammasome activation. 
Together with inflammasome results, these findings indicate that complex-1 
inhibition-associated NLRP3 inflammasome activation is accompanied by 
mitochondrial structural and functional dysfunction in microglial cells.  
Mitochondrial superoxide generation plays a role in rotenone- and 
tebufenpyrad-induced NLRP3 inflammasome activation 
Damaged mitochondria release superoxide (O2-), which not only causes 
oxidative damage to cells 42, but also activates inflammasome signaling in peripheral 
immune cells 43,44. To decipher the role of superoxide in complex-1 inhibition-
associated NLRP3 inflammasome activation, we treated primed microglia with 
rotenone or tebufenpyrad for 3 h and then stained with MitoSox dye to detect 
mitochondrial superoxide generation. The pesticide-treated primed microglia exhibited 
intense MitoSox staining, but unprimed and primed-only cells did not (Fig. 4a). Next, 
real-time images taken every 1 h of primed wild-type microglial cells treated with 
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tebufenpyrad or rotenone revealed intense MitoSox fluorescence in the pesticide-
treated groups within 2 h (Supplementary Video. 1-3).  
Previous studies by Dr. Jorg Tschopp 32 and others45 have shown that blocking 
mitophagy increases superoxide generation, which leads to NLRP3 inflammasome 
activation. Furthermore, upon activation, NLRP3 redistributes and colocalizes with the 
mitochondria. Mitochondrial prion-like proteins called MAVS mediate this 
redistribution of NLRP3 to mitochondria 45. Since NLRP3 has been shown to 
translocate to mitochondria upon inflammasome activation 32, we next examined 
whether NLRP3 co-localizes with superoxide generated by damaged mitochondria. 
LPS-primed or unprimed primary mouse microglia treated with rotenone or 
tebufenpyrad for 3 and 6 h were stained for MitoSox and NLRP3. A marked increase 
in NLRP3 immunoreactivity overlapping with the increased MitoSox Red fluorescence 
was observed in pesticide-treated cells (Fig. 4b), suggesting that the NLRP3 
mitochondrial translocation depends on mitochondrial superoxide generated from 
damaged mitochondria. The degree of co-localization was further visualized as a shift 
in the 3D color plot (Fiji plugin), signifying that MitoSox and NLRP3 overlap, merging 
along the diagonal on the red and green channel axes. 
We also hypothesized that reducing mitochondrial superoxide levels would 
decrease inflammasome activation and in turn lower IL-1β release.  For this study, we 
pretreated primary microglia for 1 h with 40 µM of mito-apocynin (Mito-Apo), a 
mitochondria-targeted derivative of apocynin that was previously shown by our group 
to reduce oxidative stress and superoxide generation 9,46. This was followed by a 3 h 
rotenone or tebufenpyrad treatment of primed microglia. Mito-Apo pretreatment 
89 
 
significantly reduced superoxide generation as evidenced by reduced MitoSox 
staining (Fig. 4e). Furthermore, Luminex assays revealed that Mito-Apo significantly 
reduced rotenone- and tebufenpyrad-induced IL-1β release in primed cells (Fig. 4c-
d). Mito-Apo was more effective in reducing inflammasome activation than its 
precursor, apocynin.  
Interestingly, ICC analysis further revealed that Mito-Apo not only reduced the 
superoxide generation, but also reduced the NLRP3 colocalization, with the 
superoxide-generating mitochondria indicating the probable upstream role of 
mitochondria in NLRP3 inflammasome activation (Fig. 4b). These findings suggest 
that inhibition of mitochondrial superoxide generation can reduce NLRP3 
inflammasome activation and that the mitochondrial ROS plays a central role in the 
functional interaction between mitochondrial dysfunction and NLRP3 inflammasome 
activation.  
Lysosomal dysfunction enhances rotenone- and tebufenpyrad-induced NLRP3 
inflammasome activation in microglia 
Healthy cells degrade damaged mitochondria through a lysosomal mechanism 
called mitophagy47. Since blocking mitophagy has already been shown to induce 
inflammasome activation 32, we hypothesized that lysosomal dysfunction may add to 
the accumulation of damaged mitochondria and more superoxide. We treated primary 
microglia with rotenone or tebufenpyrad for 6 h following LPS priming. Staining with 
LysoTracker dye revealed markedly reduced LysoTracker fluorescence in pesticide-
treated primed cells relative to unprimed cells, indicating the occurrence of lysosomal 
dysfunction in pesticide-treated primed microglial cells (Fig. 5a). 
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Next, to determine the extent of lysosomal damage, we stained the primary 
cells with LAMP2, a lysosomal marker, and found a significant reduction of LAMP2 
immunoreactivity in rotenone- and tebufenpyrad-treated groups (Fig. 5b). High 
magnification imaging of primary microglia double-stained with LAMP2 and the 
autophagy marker LC3 revealed that LAMP2 forms large vesicle-like structures in 
response to tebufenpyrad and rotenone (Fig. 5c). Western blot analysis further 
revealed that 1 µM pesticides induced LC3-II in primed microglial cells after 3 h (Fig. 
5d). Lysosomal membrane rupture leads to cathepsin release and activation, which 
have been shown to further modulate NLRP3 inflammasome activation 48. Since our 
ICC analysis showed reduced LAMP2, we performed a Cathepsin D assay (Fig. 5e). 
This assay revealed that 1 µM rotenone or tebufenpyrad induced the activity of this 
lysosomal enzyme, further indicating lysosomal dysfunction in microglia. Collectively, 
these findings indicate that the loss of lysosomal activity may lead to the accumulation 
of damaged mitochondria which can result in the overproduction of superoxide leading 
to enhanced, persistent inflammasome activation. 
Conditioned medium from complex-1 inhibitor-treated primed microglia induce 
DAergic neurodegeneration in primary mesencephalic cultures and human 
DAergic cells 
To investigate the functional importance of complex-1 inhibition-induced 
microglial NLRP3 inflammasome activation, we used both mouse primary neuronal 
culture and differentiated LUHMES cells and conditioned medium from complex-1 
inhibitor-treated primary microglial cells. Media collected from primed and unprimed 
microglial cells treated with tebufenpyrad or rotenone for 6 h was used to treat mouse 
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primary nigral neurons to induce neuronal damage. TH-ICC analysis revealed 
significantly reduced neurite length of TH-positive neurons treated with medium from 
both rotenone and tebufenpyrad-treated primed cells, but not from unprimed cells (Fig. 
6a). Interestingly, TH-negative neurite length did not significantly decrease, 
suggesting that these pesticides are specifically toxic to TH-positive neurons 
(Supplementary Fig. 8). This evidence suggests that complex-1 inhibition-triggered 
NLRP3 inflammasome activation in microglia is capable of inducing DAergic neuronal 
loss. The conditioned medium from the unprimed cells exposed to pesticides also 
caused neuronal damage. Hence, to further determine that the DAergic neuronal 
injury results from pesticide-induced inflammasome activation and not the pesticides 
present in the conditioned medium, we washed the LPS-primed cells to completely 
remove all the pesticides following a 6-h pesticide treatment and then kept the cells in 
2% fresh medium for 18 h. Cells were also co-treated with MCC-950 (100 nM) during 
the 6-h pesticide exposure. When the pesticide-free medium was used to treat 
LUHMES cells, only cells incubated with conditioned medium from pesticide-treated, 
LPS-primed microglia, exhibited a significant loss of TH+ cells (Fig. 6b). Conditioned 
medium co-treated with MCC-950 protected against the loss of neurite length (Fig. 
6b). A Luminex bioassay of the cytokine profile further revealed that the conditioned 
medium collected from pesticide-treated, primed microglial cells, but not from the LPS-
priming alone cells, contained IL-1β (Fig. 6c). These results further support the 
hypothesis that inflammasome activation resulting from mitochondrial dysfunction in 





Recent studies suggest that the NLRP3 inflammasome plays an important role 
in mediating neuroinflammation41; however, the key upstream signaling mechanisms 
that govern inflammasome activation have yet to be elucidated. Despite ample 
evidence that mitochondrial dysfunction is a key player in neurodegeneration, the link 
between mitochondrial dysfunction and neuroinflammation is much weaker. Our study 
bridges that gap in the field with a major focus on understanding the role of 
mitochondrial complex-1 inhibition in microglial cells and its relevance to inflammation, 
more specifically to NLRP3 inflammasome signaling. Here, we demonstrate that the 
complex-1 inhibitors rotenone and tebufenpyrad induce NLRP3 inflammasome 
activation in primary microglial cells by modulating mitochondrial dynamics in 
microglia itself. We also show that mitochondrial superoxide generation in microglia 
plays an important role in NLRP3 inflammasome activation. Furthermore, mito-
apocynin, a derivative of mitochondria-targeted apocynin, attenuates inflammasome 
activation by decreasing superoxide generation. Finally, we demonstrate activation of 
the NLRP3 inflammasome in a chronic rotenone mouse model of PD. 
A recent study by Zhou et al.32 has linked NLRP3 inflammasome activation to 
mitochondrial dysfunction in macrophages. The authors reported that upon activation, 
the NLRP3 complex migrates to the mitochondria, though its role in mitochondria is 
not well understood. In our present study, we show that the potent complex-1 inhibitors 
rotenone and tebufenpyrad both induce NLRP3 inflammasome activation in LPS-
primed primary mouse microglia. As early as 3 h, both rotenone and tebufenpyrad 
induced a proteolytic conversion of pro-caspase-1 to active caspase-1 in LPS-primed 
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primary microglia (Fig. 1), the first step in inflammasome activation. Rotenone and 
tebufenpyrad also induced the next step in the inflammasome activation process, 
namely caspase-1-mediated conversion of pro-IL-1β to IL-1β. Tebufenpyrad is more 
potent than rotenone at the same dose and leads to more caspase-1 p20 production 
and IL-1β secretion (Fig. 1b-c). ASC, the adapter protein for the NLRP3 
inflammasome, forms spec-like structures and propagates in a “prionoid” fashion to 
propagate the inflammasome 33,49. As expected, both rotenone and tebufenpyrad 
treatments led to the formation of ASC specs (Fig. 1e). Furthermore, our results 
indicate that these complex-1 inhibitors induced the release of IL-1β in a dose-
dependent manner, beginning at an extremely low dose of 50 nM (Fig. 2). To 
determine which inflammasome is mediating the generation and release of IL-1β, we 
used the NLRP3-specific inhibitor MCC950 40. MCC950 completely abolished the 
rotenone- and tebufenpyrad-induced release of IL-1β from LPS-primed microglia, thus 
confirming that NLRP3 is the major inflammasome activated by complex-1 inhibition. 
In terms of understanding the role of these environmental toxicants in sustained 
inflammation, our study demonstrates that pesticides can activate the NLRP3 
inflammasome in primary microglial cells, thereby contributing to chronic 
inflammation.  
Recent studies have focused on the role of mitochondria in NLRP3 
inflammasome activation50,51 in different immune cells like bone marrow-derived 
macrophages (BMDMs). Shimada et al.52 revealed that mitochondrial DNA can 
activate the NLRP3 inflammasome. Inhibition of mitophagy has been shown to induce 
NLRP3 inflammasome activation. Furthermore, upon activation, NLRP3 translocates 
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to the mitochondria. Recent studies have further shown that during activation the 
mitochondrial adaptor MAVS, through a prion-like mechanism, facilitates this 
translocation and activation of the NLRP3 inflammasome 45. Other studies revealed 
that mitochondrially generated reactive oxygen species (mROS) can activate 
macrophagic NLRP3 inflammasomes in response to alum or Nigericin50,53. 
Mitochondrial dysfunction and mROS are druggable targets for reducing 
inflammasome activation54.Apart from mounting evidence that mitochondrial 
dysfunction is a major regulator signal for inflammasome activation in non-neuronal 
systems32,50,51,54,55, our study further strengthens the role of mitochondrial impairment 
in NLRP3 inflammasome activation in microglial cells. We show that NLRP3 
inflammasome activation is associated with altered mitochondrial dynamics, including 
functional and structural damage, as well as mitochondrial membrane potential 
changes (Fig. 3). Also, mitochondrial capacity for ATP generation was diminished 
when LPS-primed microglia were treated with complex-1-inhibiting pesticides. After 
prolonged exposure, structural damage to the mitochondria was manifested as 
increased mitochondrial circularity. Inhibiting inflammasome activation did not alter the 
mitochondrial dysfunction induced by the pesticides, indicating that the mitochondrial 
damage may be upstream of inflammasome activation. Superoxide generation 
preceded discernible mitochondrial damage 32, and interestingly, our studies show 
that NLRP3 translocates to and co-localizes with damaged mitochondria. These 
findings agree with Zhou et al. 32, who suggested NLRP3 localizes to superoxide-
concentrated domains. Recently, we demonstrated that a mitochondria-targeted 
derivative of apocynin, mito-apocynin, reduces neuroinflammation and prevents 
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DAergic neurodegeneration in an MPTP mouse model of PD 9. In the present study, 
mito-apocynin pre-treatment attenuated rotenone- and tebufenpyrad-induced 
superoxide generation, which in turn reduced secretion of IL-1β in primed microglia. 
Furthermore, reducing the superoxide generation reduces the translocation of NLRP3, 
indicating the probable upstream role of mitochondrial superoxide in NLRP3 
inflammasome activation.  
Although we observed in the Seahorse Mito Stress test that rotenone and 
tebufenpyrad could diminish mitochondrial activity in unprimed microglia, at other 
endpoints the effect of the pesticides in unprimed cells was not that dramatic. This 
could be due to the high sensitivity of the Seahorse assay compared to other tests. 
Another possible reason is that, unlike neuronal cells, microglial cells may 
compensate the bioenergy deficits from extra-mitochondrial energy sources. Future 
studies will address this issue. Sherer et al. 35 reported the loss of ATP in tebufenpyrad 
treated cells at 6 h. In this study, most of the functional assays were performed at the 
2-h to 3 h time point. Also, rotenone activates the p-38 MAPK and NFκB pathways in 
microglial cells 56, which may lead to proliferation of microglia. Further research needs 
to be performed to delineate the molecular mechanism that makes glial cells more 
resistant to mitochondrial inhibitors.    
Lysosomal dysfunction and dysregulation of autophagy have been linked to PD 
57. Downregulation of lysosomal function may lead to accumulation of misfolded 
proteins like -synuclein, which has been linked to PD pathology. Recent studies have 
shown that lysosomal dysfunction and destabilization can lead to inflammasome 
activation in macrophages in Gaucher disease models58,59. Furthermore, a 
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compromised lysosomal membrane leads to release of lysosomal cathepsins, which 
can induce NLRP3 inflammasome activation 48.  Here, we demonstrate that prolonged 
exposure to both rotenone and tebufenpyrad induced lysosomal dysfunction in primed 
microglial cells, pointing out a probable role for lysosome dysfunction in regulating 
neuroinflammation.  
Neuroinflammation and mitochondria-derived superoxide generation play key 
roles in degeneration of DAergic neurons in PD15,16,60,61. Inflammasome activation in 
glial cells has been shown to contribute to disease pathology in AD 28,62 and TBI, 
wherein treatment with anti-ASC antibody after TBI was beneficial in a mouse model 
63. Furthermore, induction of IL-1β and IL-18 was linked to higher susceptibility and 
progression of multiple sclerosis 25. Here, we show that conditioned media from 
primed microglial cells treated with complex-1 inhibitors triggered DAergic 
neurotoxicity in both primary mesencephalic cultures and differentiated LUHMES 
cells, suggesting that NLRP3 inflammasome activation in glial cells can potentially 
lead to neurodegeneration (Fig. 6). Furthermore, MCC-950, the NLRP3 
inflammasome inhibitor, reduced the loss of TH-positive neurite length, suggesting the 
inflammasome’s probable role in neurodegeneration. The mouse model of rotenone 
(30 mg/kg, gavaged daily for 28 days) exhibits motor deficits, selective loss of 
nigrostriatal DAergic neurons and increased -synuclein in DAergic neurons 64. The 
rotenone mouse model was re-evaluated by Inden et al. 38 who used two doses (30 
and 100 mg/kg) of rotenone for 56 days. But 100 mg/kg of rotenone for 28 days did 
not cause any change in DAergic neurons. Hence, for this study, we utilized the 
rotenone model and were able to demonstrate activation of the NLRP3 inflammasome 
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in vivo (Fig. 1F-K) during mitochondrial impairment. The major source of NLRP3 
activation leading to inflammation in brain are the microglial cells 65. In this study, we 
have also shown that rotenone exposure leads to increased NLRP3 in microglial cells 
in rats further solidifying the activation of NLRP3 in microglial cells in vivo.  
In various neurodegenerative disorders including PD, the underlying 
mechanism behind sustained chronic inflammation has still not been deciphered. In 
this study, we propose a mechanism for regulating chronic inflammation in PD. All our 
findings collectively show that microglial mitochondria play an important role in 
regulating the NLRP3 inflammasome pathway in PD models (Fig. 6d). In this study, 
we show that LPS priming induce NLRP3 and pro-IL-1β production but not capase-1 
cleavage or assembly of the inflammasome complex in microglia, which is consistent 
with the current literature on the NLRP3 inflammasome signaling pathway. Pesticide 
exposure leads to the inflammasome assembly and secretion of IL-1β. Furthermore, 
we show that the superoxides generated by mitochondrial dysfunction leads to NLRP3 
translocation. Reducing this superoxide generation lowers the translocation and 
inflammasome activation, but inhibiting the activation of NLRP3 does not reduce the 
mitochondrial damage, indicating that mitochondrial dysfunction is upstream of 
inflammasome formation. Additionally, the inflammatory cascade is intensified by 
lysosomal dysfunction, leading to the accumulation of more damaged mitochondria 
and thus greater superoxide generation. Collectively, our study points to the existence 
of a complex interplay between microglial mitochondrial impairment and NLRP3 
inflammasome signaling and its role in sustained neuroinflammation in DAergic 
neurodegenerative processes in PD. 
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Materials and Methods 
Chemicals and reagents 
Rotenone (95–98% purity), oligomycin, FCCP and antimycin were purchased 
from Sigma, and tebufenpyrad (96% purity) was purchased from AK Scientific Inc. 
DMSO was purchased from Fisher Scientific. We purchased DMEM-F12, fetal bovine 
serum (FBS), L-glutamine, penicillin, streptomycin, MitoTracker Red, LysoTracker 
Green, and MitoSox Red stains from Invitrogen. The CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay kit and CellTiter Glo Luminescent Cell Viability 
Assay kit were obtained from Promega. ASC, NLRP3 and Caspase-1 antibodies were 
purchased from Adipogen, and the TH antibody was obtained from Millipore. The 
CD11b magnetic separation kit was purchased from STEMCELL Technologies. LCIII, 
AIM2 and NLRC4 antibodies were purchased from Cell Signaling Technologies. IL-1β 
antibody was purchased from R&D Technologies, while LAMP2 antibody was from 
Santa Cruz Biotechnology. Acetylated α-tubulin antibody and Duolink PLA red were 
obtained from Sigma. The MAP2 and Tuj1 antibodies and Cathepsin D activity kit were 
obtained from Abcam. All the standards used for Luminex assay were purchased from 
PeproTech Inc. Streptavidin-biotin and biotinylated antibodies used for Luminex were 
purchased from eBioSciences. MCC950 was obtained from Dr. Trent Woodruff’s lab 
University of Queensland, Brisbane, Australia. Mito-Apocynin was obtained from Dr. 
Balaraman Kalyanaraman’s lab at the Medical College of Wisconsin in Milwaukee. 
Cell cultures and treatments 
For primary microglial culture, one-day-old C57BL/6 pups were sacrificed, their 
brains dissected out, and a single cell suspension was prepared. After growing in 
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culture for 16 days, the microglia were separated using a magnetic bead separation 
technique as previously described66,67. Primary microglial cells were cultured in 
DMEM-F12, 10% FBS, 5% sodium pyruvate, 5% glutamine, 5% penicillin-streptavidin, 
and 5% non-essential amino acids. We also obtained a wild-type microglial cell line 
as a kind donation from Dr. D.T. Golenbock (University of Massachusetts Medical 
School, Worcester, MA). The wild-type microglial cell line was characterized by Halle 
et al. 28 and cultured in DMEM medium, 10% FBS, 5%  glutamine, and 5%  penicillin-
streptavidin. The DAergic Lund human mesencephalic (LUHMES) cell line was 
differentiated and maintained as described in our recent publication 68.Treatments 
were done in 2% FBS-containing medium. For LPS-priming treatments, cells were 
treated with LPS (1 µg/mL) for 3 h. Next, the cells were triple-washed with full serum 
medium to remove any LPS, and then mitochondrial complex-1 inhibitors were added 
to the cells (50 nM to 1 µM) for 2 to 24 h.   
Primary mesensephalic neurons were isolated from gestational 15-day-old 
mouse embryos as described previously69. These plated cells have a viability ranging 
from 70-80%. The primary cultures used were enriched in neurons. Briefly, 
mesencephalic tissues from E15 mouse embryos were dissected and maintained in 
ice-cold DMEM media and then dissociated in 10 mls of trypsin-0.25% EDTA (TE) for 
15 min in a 37°C water bath with sporadic shaking. The action of TE was stopped 
using 20 mls DMEM containing 10% FBS. the trypsinized tissue was further washed 
twice in 10% DMEM followed by a final wash in Neurobasal media. Tissue was 
titurated using a 10 ml sterile pipette and the resulting suspension was passed through 
a 70 micron filter. The dissociated cells were then plated at an equal density of 0.1 
100 
 
million cells per well on 12-mm coverslips precoated with 0.1 mg/ml poly-D-lysine. 
Cultures were maintained in neurobasal media fortified with B-27 supplement, 500 
mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. The cells were 
maintained in a humidified CO2 incubator (5% CO2 and 37°C) for 24 h. One-half of 
the culture media was replaced every other day.  6-7 day old cultures were used for 
experiments. These cells were maintained in neurobasal medium which selectively 
inhibits glial proliferation. Cells were treated with conditioned medium from primed and 
unprimed microglial cells for 24 h. For neurite length analysis, NeuronJ plugin in 
ImageJ was utilized. Only neurites in contact with the cell body were measured; 
neurites without cell body contacts were not measured.   
Animal studies 
Eight-week-old male C57BL/6N mice (3-4 animals per group), obtained from 
Charles River, were housed under standard conditions: constant temperature (22 ± 
1°C), humidity (relative, 30%), and a 12-h light/dark cycle. From the in vitro data, we 
estimated 3-4 animals per group as sufficient to detect significant biochemical 
changes. All mice were pre-screened for normal baseline performance during 
behavioral assessments conducted before randomly assigning animals to 
experimental groups. Investigators involved with data collection and analysis were not 
blinded to group allocation. After acclimating for 3 days, mice were gavaged daily with 
30 mg/kg of rotenone for 28 days, after which the mice were sacrificed. This protocol 
for chronic administration of rotenone has been reported to cause a significant loss of 
nigrostriatal DAergic neurons and behavioral impairment in mice 38,64.  Sixteeen rats, 
age 6-7 months old, were purchased from Hilltop Lab Animals (Scottdale, PA). These 
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animals were administered either rotenone (2.8 mg/kg/day, n = 8) or vehicle (n = 8) 
for 4 consecutive days via intraperitoneal (i.p) injection. The rotenone solution was 
first prepared as a 50× stock in 100% dimethyl sulfoxide (DMSO) and diluted in the 
medium-chain triglyceride Miglyol 812 N. Vortexing the solution created a stable 
emulsion with a final concentration of 2.8 mg/mL rotenone in 98% Miglyol 812 N and 
2% DMSO. After the final injection, the animals were housed for 3 months. The 
animals were randomly assigned to treatment using an online randomization tool 
(random.org). Experimenters were blinded to each rat’s treatment allocation.   
Use of the animals and protocol procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Iowa State University (Ames, IA, USA) and all 
methods were performed in accordance with relevant guidelines and regulations. 
Western blotting 
Following the treatment of rotenone or tebufenpyrad for 3-6 h, primed or 
unprimed microglial cell pellets were lysed using modified RIPA buffer and sonicated. 
The proteins were normalized and 20-30 µg of protein was loaded in each lane and 
separated using a 12-15% SDS polyacrylamide gel as discussed previously 70,71. After 
transferring, nitro-cellulose membranes were blocked with LI-COR blocking buffer and 
washed with PBS mixed with 0.05% Tween. The membranes were then treated with 
the indicated primary antibodies, followed by incubation with IR-680 anti-mouse and 
IR-800 anti-rabbit secondary antibodies. The membranes were scanned using the 
Odyssey LI-COR Imaging System. The primary antibodies used for immunoblotting 
were NLRP3 (1:1000) (AB_2490202), Caspase-1 p20 (1:1000) (AB_2490248), and 





 Cells were plated on PDL-coated coverslips. After treatment for 2-6 h with a 
pesticide, primed or unprimed cells were fixed in 4% paraformaldehyde (PFA) for 30 
min followed by blocking with 1.5% BSA, 0.05% Tween, and 0.5% Triton for 1 h. 
Primary antibodies were prepared in 1% BSA and incubated overnight at 4°C. The 
following primary antibodies were used: ASC (1:400, AB_2490440), NLRP3 (1:500, 
AB_2490202), TH (1: 2000, AB_2201528), TH (1:1000, AB_696697), MAP2 (1:1000, 
AB_448205), Tuj1 (1:1000, AB_444319), LC3 (1:400, AB_2137716), acetylated α-
tubulin (1:400, AB_477585), SIRT2 (1:500, AB_1142864) and LAMP2 (1:400). After 
primary antibody incubation, each well was washed with PBS five times and then 
incubated with secondary antibody for 1 h. Cell nuclei were stained with Hoechst 
(1:5000) and mounted on slides using the Fluoromount mounting medium (Sigma). 
Slides were dried overnight and then imaged using a Nikon Eclipse C1 microscope.  
For co-localization, a 3D color plotter (Fiji image analysis software) was used to plot 
all the different colors seen in the RGB images. Briefly, RGB images were opened 
using Fiji and then analyzed using its 3D color plotter plug-in, which plots every colored 
pixel it picks up in the RGB image along x, y and z axes representing red, green and 
blue, respectively. For co-localization between the green and red channel, it plots the 
pixels along the diagonal of the red and green axes to visualize the co-localization. 
Furthermore, the resulting intensity from merging the red and green signals can also 




Cytokine levels were assessed via Luminex assays according to a protocol by 
Panicker et al. 8. Briefly, primary microglial cells were treated in 96-well plates (Fig. 2, 
4 and 6) or 6-well plates (Fig 1) with 100-900 L of 2% FBS-containing DMEM-F12 
medium for 6-24 h. After treatment, 40 l of treatment medium was collected and 
added to 40 L of primary antibody conjugated to magnetic microspheres and 
incubated overnight at 4°C in a clear-bottom, black 96-well plate.  After incubation, 
each well was triple-washed using a magnetic washer and then incubated for 1 h with 
secondary antibodies. Lastly, samples were incubated for 30 min with 
streptavidin/phycoerythrin. A Bio-Plex reader was used to read the 96-well plates. A 
standard curve of all the cytokines was prepared using standard cytokines. 
q-RT-PCR 
RNA was isolated using TRIzol extraction methods as previously described 72. 
Following treatment for 2 h with the pesticides, RNA concentration was measured 
using NanoDrop. One microgram of RNA was used to convert RNA into cDNA using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems #4368814) 
following the manufacturers’ protocol. For qPCR, 10 µL of SYBR Green Mastermix 
(Qiagen Cat #208056), 1-2 µL of primers, 6-7 µL of water and 1-2 µL of cDNA were 
used. The following genes were used for q-RT-PCR: NLRP3 (primer sequences: 
forward-TGCTCTTCACTGCTATCAAGCCCT, and reverse-
ACAAGCCTTTGCTCCAGACCCTAT, synthesized at Iowa State University’s DNA 
Facility), IL-1β, IL-18, NLRC4, and AIM2 (QuantiTect Primers, Qiagen). The house 
keeping gene 18S rRNA (Qiagen Cat #PPM57735E) was used in all qPCR 
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experiments. No-template controls (NTCs) and dissociation curves were run for all 
experiments to exclude cross-contamination. 
Live cell staining 
Cells were stained following the manufacturer’s protocol using 
tetramethylrhodamine methyl ester perchlorate (TMRM) (2-h treatment), MitoSox Red 
( 3- to 6-h treatment), MitoTracker Red (6-h treatment), and LysoTracker Green (6-h 
treatment), all obtained from Molecular Probes and used according to our previous 
publication 21. Briefly, cells were treated either on PDL-coated coverslips or in 96-well 
plates. Following treatment, cells were washed twice with HBSS and then the dye was 
added according to the dilution recommended by manufacturer. After staining, cells 
were washed and then either fixed for ICC or imaged directly. Following 2-h pesticide 
exposure for TMRM, non-fixed cells were imaged under the FLoid Cell Imaging 
system (Thermo Fisher Scientific). For MitoSox Red imaging, a Cytation 3 real-time 
imaging system (BioTek) was used to take hourly images. Changes in mitochondrial 
structure were quantified using the ImageJ plugin “mitochondrial morphology,” 
developed by Ruben K Dagda (2010). We selected parameters for quantifying 
damage to mitochondrial structure based on recent studies 21,31,73. 
ATP assay 
Cells were plated in opaque-walled 96-well plates and treated with the toxicants 
for 2 h. After treatment, 100 l of CellTiter-Glo Reagent was added to each well 
containing 100 l treatment media and incubated for 5 min. Readings were taken 




MTS mitochondrial activity assay  
Cells were plated in 96-well plates, and after treatment for 3-24 h, 10 l of MTS 
dye (Promega) was added to each well and incubated for 1.5 h. After incubation, a 
plate reader was used to take excitation and background (subtracted) readings at 490 
and 660 nm, respectively. 
Mitochondrial dynamics analysis 
A Seahorse XFe24 Analyzer was used to measure mitochondrial oxygen 
consumption rates (OCR) and extracellular acidification rates (ECAR) using the Mito 
Stress test following a previously published protocol 31. Primary mouse microglia were 
plated 90,000 cells/well on a Seahorse 24-well plate. The calibration plate was 
hydrated overnight in a non-CO2 incubator. All treatments were done in serum-free 
medium. Cells were primed with LPS for 3 h followed by pesticide exposure for 3 h.  
For the Mito-Stress test, 0.75 M oligomycin, 1 M FCCP, and 0.5 M 
rotenone/antimycin were used. Mito-Stress report generator was used for analysis. 
Duolink Proximal Ligation Assay (PLA) 
Duolink PLA assay was performed following the manufacturer’s protocol 74. 
Briefly, 15 k primary microglial cells were plated on PDL-coated coverslips in 96-well 
cell culture plates. Following treatment for 3 h, cells were washed and fixed using 4% 
poly-D-lysine, blocked with blocking buffer, and incubated in primary antibodies 
overnight. After primary antibody incubation, the Duolink in situ Detection Reagents 
Red (Sigma) was used according to manufacturer’s protocol. Confocal imaging was 
performed on these coverslips at the Iowa State University Microscope Facility using 
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a Leica DMEIR2 confocal microscope with 63X oil objective. For z-stacking, each 
image consisted of 0.5-µm sections and 5 slices. 
Cathepsin D assay 
One million primary microglial cells were plated in PDL-coated, 12-well cell 
culture plates. Following a 6-h treatment of rotenone or tebufenpyrad, cells were 
collected and the cathepsin activity assay was performed following manufacturer’s 
protocol (Abcam). 
Statistical Analysis 
All in vitro data were determined from three to eight biological replicates. 
GraphPad 5.0 was used for statistical analysis with p≤0.05 considered statistically 
significant. Two-way ANOVA was used for comparing multiple groups. In most cases, 
Bonferroni post analysis was applied. For comparing 2 groups, Student’s t-test was 
used. Where the normality assumption was violated, we conducted nonparametric 
tests, however, in no case did the nonparametric results change the overall 
interpretation of parametric results. 
Data Availability 
Raw data supporting the results reported in this article are in the figure source 
data files available upon request. 
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Fig 1: Rotenone and tebufenpyrad activate NLRP3 inflammasome in primary 
murine microglia. (a) MTS assay of cell viability after treating lipopolysaccharide 
(LPS)-primed primary microglia with the mitochondrial complex-1 inhibiting pesticides 
rotenone (rot) or tebufenpyrad (tebu) (both 1 µM) for 24 h. (b) Luminex assay showing 
an increased IL-1β release from LPS-primed microglia after pesticide treatments for 
24 h. Treatment with rotenone or tebufenpyrad did not alter TNFα release. (c) Western 
blot analysis of pesticide-treated primed microglial cells showing the cleavage of pro-
caspase-1 to its active form caspase-1 p20. (d) Duolink proximal ligation assay reveals 
ASC and NLRP3 interaction in pesticide-exposed, primed microglial cells but not in 
unprimed cells following 3 h of pesticide exposure. Scale bar, 15 μm. (e) ICC showing 
ASC speck formation in pesticide-treated primed microglial cells for 2 h. Scale bar, 
20 μm.  (f) q-RT-PCR analysis of vehicle- and rotenone-gavaged (n=4 each group, 30 
mg/kg for 28 days) mice for striatal NLRP3 gene expression. (g) Western blot analysis 
for vehicle- and rotenone-gavaged (30 mg/kg for 28 days) mice for NLRP3, Caspase 
1 and IL-1β. (H-K) Densitometric analysis of Western blot for NLRP3 (h), Caspase 1 
(i), Caspase 1 p20 (j), pro-IL-1β (k) and cleaved IL-1β (l). For all Western blots, 
samples derive from the same experiment and were processed in parallel. Data 
analyzed via Student’s t test, or via two-way ANOVA with Bonferroni adjustment, 






Fig 2: Rotenone and tebufenpyrad induce a dose-dependent release of IL-1β in 
primed microglial cells through the NLRP3 inflammasome pathway. (a-b) 
Luminex assay showing a dose-dependent increase in IL-1β release after treating 
primed primary microglial cells for 24 h with rotenone (a) and tebufenpyrad (b). (c) 
Luminex assay showing inhibition of IL-1β release after co-treating primed microglial 
cells with rotenone and MCC950, and showing no change in IL-12 release.  (d) 
Luminex assay showing inhibition of IL-1β release after co-treating primed microglial 
cells with MCC950 and tebufenpyrad, and showing no change in IL-12 release. (e) q-
RT-PCR analysis showing different inflammasome gene expression after treatment of 
LPS-primed primary mouse microglia with 1 µM rotenone and tebufenpyrad for 2 h. 
Data analyzed via two-way ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, 






Fig 3: NLRP3 inflammasome activation is accompanied by mitochondrial 
functional and structural damage. (a) Seahorse Mito-Stress assays showing 
impaired mitochondrial bioenergetics in LPS-primed primary microglial cells treated 
with pesticides. (b) Quantification of TMRM fluorescence staining showing 
mitochondrial potential in untreated and treated primary microglia. (c) ATP assays in 
LPS-primed mouse primary microglia treated with rotenone and tebufenpyrad. (d) 
MitoTracker assays show changes in mitochondrial morphology in LPS-primed 
primary microglia treated with pesticides. Scale bar, 15 μm. (e) Circularity, indicative 
of mitochondrial fragmentation, increased after pesticide treatment. Data analyzed via 
two-way ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, ***p<0.001 and are 






Fig 4: Mitochondrial superoxide generation plays a role in pesticide-induced 
NLRP3 inflammasome activation. (a) ICC showing MitoSox generation from 
pesticide-treated primed microglial cells. Lower panel shows interactive-3D surface 
plot from corresponding ICC, which shows the intensity of superoxide generation. 
Scale bar, 100 μm. (b) ICC showing co-localization of mitochondrial superoxide 
generation and NLRP3. The right-most panel is the representative 3D color plot. Mito-
apocynin reduced this co-localization between NLRP3 and MitoSox. Scale bar, 15 μm. 
(c-d) Luminex assays demonstrate that mito-apocynin reduced IL-1β secretion from 
primed microglial cells treated with rotenone (c) and tebufenpyrad (d). (e) MitoSox 
assays reveal that mito-apocynin reduced pesticide-induced superoxide generation in 
pesticide-treated primed microglial cells. Data analyzed via two-way ANOVA with 
Bonferroni adjustment, *p<0.05, **p<0.01, ***p<0.001 and are represented as 






Fig 5: Lysosomal dysfunction enhances pesticide-induced NLRP3 
inflammasome activation in microglia. (a) Confocal microscopy showing a lower 
LysoTracker fluorescence intensity in primed microglial cells treated with pesticides (1 
µM). Scale bar, 15 μm. (b) ICC for LAMP2 staining showing a lower LAMP2 
immunoreactivity in primed microglial cells treated with pesticides, implying lysosomal 
damage. Scale bar, 100 μm. (c) 60X imaging for LAMP2 ICC showing structural 
changes in lysosomes in primed microglial cells treated with pesticides. Scale bar, 
20 μm. (d) Western blot analysis reveals increased LC3-II in primed microglial cells 
exposed to 1 µM pesticides for 3 h. Samples derive from the same experiment and 
gels/blots were processed in parallel (e) Cathepsin activity assay revealed that 1 µM 
rotenone or tebufenpyrad for 6 h induced higher activity of this enzyme in primed 
microglial cells. Data analyzed via two-way ANOVA with Bonferroni adjustment, 





Fig 6: Conditioned medium from primary microglia treated with mitochondrial 
complex-1 inhibitors leads to DAergic neuronal toxicity. (a) ICC analysis of TH+ 
neurons treated with conditioned medium from primed microglial cells treated with 1 
µM rotenone or tebufenpyrad for 24 h. The length of TH+ neurites was determined 
using ImageJ. Conditioned medium from primed-microglial cells treated with 
tebufenpyrad reduced TH+ neurite length. Scale bar, 100 μm. (b) ICC analysis of 
differentiated LUHMES cells treated with conditioned medium from primed microglial 
cells treated with 1 µM tebufenpyrad or rotenone for 24 h and cotreated with MCC-
950. Scale bar, 100 μm. (c) Luminex analysis of the conditioned medium used to treat 
LUHMES cells. (d) A schematic representation illustrating the signaling cascade 
involved in pesticide-induced NLRP3 inflammasome activation in microglial cells; 
drawing created by S. Sarkar using biomedical PowerPoint toolkit from Motifolio. Data 
analyzed via two-way ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, 





Supplementary Fig. 1: LPS priming leads to NLRP3 upregulation in primary 
microglial cells. ICC showing the upregulation of NLRP3 and co-localization with 
ASC after treatment with rotenone or tebufenpyrad for 2 h. The right-most panel is the 






















Supplementary Fig 2: Pesticide-induced inflammasome activation induces IL-1β 
and pro-IL-18. q-RT-PCR analysis showing the gene levels of pro-IL-1β and pro-IL-
18 in LPS-primed primary mouse microglia treated with or without 1 µM rotenone or 
tebufenpyrad for 2 h. Data analyzed via two-way ANOVA with Bonferroni adjustment, 




Supplementary Fig. 3: Pesticide exposure does not induce acetylation of 
microtubules at early time points in microglial cells. ICC analysis reveals that 
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SIRT2 levels or acetylated α-tubulin did not significantly change after 2 h of 1-µM 




Supplementary Fig. 4: Pesticide exposure alone induced NLRP3 and pro-IL-β in 
presence of neurons. (A-B) qRT-PCR analysis showing gene level of NLRP3 (A) and 
pro-IL-1β (B) following 1 µM rotenone exposure for 6 h in presence of neurons. Data 
analyzed via two-way ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, 




Supplementary Fig. 5: Rotenone induced NLRP3 inflammasome activation in rat 
model. (A) qRT-PCR analysis revealed NLRP3 upregulation in rotenone-treated rats. 
(B) IHC analysis showing increased NLRP3 in IBA1-positive cells in the striatum of 
rotenone treated rats. Data analyzed via Student’s t-test, *p<0.05, **p<0.01, ***<0.001 







Supplementary Fig. 6:  MCC950, an NLRP3-specific inhibitor, does not affect cell 
viability in primary microglial culture. MTS assay of cell viability after treatment 
with MCC950. Data analyzed via two-way ANOVA with Bonferroni adjustment, 





Supplementary Fig. 7: MCC950 does not alter mitochondrial dynamics. (A-B) 
Seahorse Mito Stress assays showing MCC-950 does not alter impaired mitochondrial 
bioenergetics in LPS-primed primary microglial cells treated with pesticides for 3 h. 
Data analyzed via two-way ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, 





Supplementary Fig. 8: Conditioned medium from pesticide-exposed microglial 
cells does not alter TH-negative neurite length. ICC analysis showing that TH-
negative neurite length is not affected on exposure to conditioned medium from 
primed microglial cells exposed to rotenone or pesticides. Data analyzed via two-way 
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ANOVA with Bonferroni adjustment, *p<0.05, **p<0.01, ***<0.001 and are 






Supplementary Fig 9: Full length Western blots shown in Fig 1.  (A-B) Full length 
Western blots corresponding to Fig. 1C. (C-H) Full length Western blots corresponding 
to Fig. 1G.  (I-J) Full Western blots corresponding to Fig. 5D. Samples derive from the 
same experiment and gels/blots were processed in parallel. 
 
      
Supplementary Videos 1-3: Time-lapse videos of mitochondrial superoxide 
generation in primed microglial cells treated with vehicle, rotenone, and 





MANGANESE EXPOSURE ACTIVATES NLRP3 INFLAMMASOME SIGNALING 
AND PROPAGATES EXOSOMAL RELEASE OF ASC IN MICROGLIAL CELLS 
Manuscript to submitted to Science Signaling 
Souvarish Sarkar1, Dharmin Rokad1, Emir Malovic1, Jie Luo1, Dilshan Harischandra1, 
Huajun Jin1, Vellareddy Anantharam1, Xumei Huang2, Mechelle Lewis2, Arthi 
Kanthasamy1, Anumantha G. Kanthasamy1* 
 
1-Parkinson Disorders Research Laboratory, Iowa Center for Advanced 
Neurotoxicology, Department of Biomedical Sciences, 2062 Veterinary Medicine 
Building, Iowa State University, Ames, IA 50011 
2-Penn State Hershey Medical Center, Hershey, PA. 
 
*To whom correspondence should be addressed: Anumantha Kanthasamy, Ph.D., 
Distinguished Professor and Chair, Department of Biomedical Sciences, Iowa State 
University, Ames, IA 50011. Telephone: (515) 294-2516; Fax: (515) 294-2315, Email: 
akanthas@iastate.edu 
Abstract 
Abnormal metal homeostasis is a key hallmark of multiple neurodegenerative 
disorders including Alzheimer’s disease (AD), and Parkinson’s disease (PD). 
Overexposure to Manganese (Mn) have been linked to PD-like symptoms. Sustained 
neuroinflammation is now recognized as a key pathophysiological process of 
neurodegenerative conditions, but the inflammatory signaling mechanism underlying 
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Mn neurotoxicity is equivocal. In this study, we examined whether Mn mounts its 
neurotoxic effect by activating NLRP3 inflammasome signaling. Exposing microglial 
cells, primed with LPS, to Mn significantly increased NLRP3, caspase-1 cleavage, and 
IL-1β maturation, indicating that Mn can induce the NLRP3 inflammasome activation 
cascade. Mn exposure reduced the mitochondrial dynamics of microglia cells as 
measured via Seahorse Mito Stress assay and downregulated mitochondrial fusion. 
Furthermore, Mn reduced the expression of retromer pathway protein VPS35. 
CRISPR KD of VPS35 further regulated mitochondrial fusion protein by increasing 
mitochondrial ubiquitin ligase suggesting the probable role of VPS35 in maintaining 
mitochondrial health. Given that the inflammasome component ASC can propagate 
inflammasome activation in a “prionic” manner, we explored whether Mn exposure 
induces cell-to-cell transfer of ASC via exosomes. Exosomes isolated from Mn-treated 
LPS-primed microglial cells contained higher amounts of ASC, suggesting exosomal 
release of ASC. Furthermore, exosomes isolated from microglial cells exposed to Mn 
induced pro-IL-1β, and NLRP3 expression further suggesting the role of exosomal-
ASC in inflammasome propagation. Importantly, we confirmed a significantly higher 
ASC content in exosomes collected from welders when compared to exosomes from 
matched controls. Collectively, these results demonstrate that Mn neurotoxicity 




Overexposure to transition metals like manganese (Mn), iron (Fe), copper (Cu), 
and zinc (Zn) from occupational or environmental sources (e.g., various food products 
and well-water) has been linked to various neurodegenerative disorders, including 
Alzheimer’s disease (AD) and Parkinson’s disease (PD). Imbalance in metal 
homeostasis have been shown to modulate various cellular functions, including 
generation of oxidative stress, mitochondrial dysfunction, and exosome biogenesis; 
the processes which have been all linked to various neurodegenerative disorders (1, 
2).  
Chronic exposure to Mn in occupational settings was first noted in miners (3, 
4), followed by welders (5). Recent studies of welder populations revealed that 
occupational exposure to Mn increases the risk of developing PD (6). Mn toxicity can 
also manifest as a disease called manganism, which shares similar symptoms as PD 
(7, 8). Mn accumulates mainly in the globus pallidus as well as in the striatum leading 
to the PD-like phenotype (9). 
The etiology of PD is multifactorial. One of the major hallmarks of Parkinsonian 
syndromes, including manganism, is chronic and sustained inflammation (10-15). 
Inflammation in PD patients was first implicated by McGeer et al. (16). Various 
inflammatory factors including tumor necrosis factor-α (TNF-α) and IL-1β have been 
shown to be upregulated in PD patients (17). Microglia, the brain’s frontline immune-
responders, have been implicated as a key player in modulating neuroinflammation 
(13, 18). Blocking microglial activation was shown to be neuroprotective in the MPTP 
model of PD (19). Furthermore, based on recent studies from our group and others, 
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use of anti-inflammatory agents is protective in cell culture and animal models of PD 
(20-24). Though the effects of chronic inflammation have been well documented in 
neurodegenerative disorders like PD, the mechanism underlying this sustained 
immune response is not well understood (25). 
The cell-derived vesicles exosomes contain diverse cargo known to induce 
inflammation. Aggregated α-synuclein preformed fibrils (αSynPFF) have been shown to 
be transmitted from cell-to-cell via exosomes, propagate inflammation, and induce cell 
death (26, 27). Exosomes from lung cancer can induce NFκB signaling (28). Recently, 
various inflammasome activations, including NLRP3 (nucleotide binding and 
oligomerization domain-like receptor family pyrin domain containing 3), NLRC4 (NLR 
family CARD domain-containing protein 4), and AIM2 (absent in melanoma 2) among 
others, have been implicated as mechanisms underlying inflammation in 
neurodegenerative disorders, like PD, AD, and traumatic brain injury (TBI) (29). The 
NLRP3 inflammasome is a multiprotein oligomeric complex comprising an adapter 
protein ASC (apoptosis-associated speck-like protein containing a CARD), Caspase 
1, and NLRP3. Multiple external signals, including misfolded β-amyloid (30) and 
αSynPFF (31), have been shown to activate the NLRP3 inflammasome complex. 
NLRP3 inflammasome signaling requires two signals for its activation. 
Lipopolysaccharide (LPS), TNF-α, or any signal capable of activating NFκB can act 
as signal 1 (or a priming signal) to upregulate the expression of NLRP3 and pro-IL-
1β. A second NLRP3-specific activation signal (signal 2, such as mitochondrial 
dysfunction and lysosomal damage), triggers the assembly and activation of the 
NLRP3 inflammasome complex. The adapter molecule ASC links the NLRP3 protein 
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to the recruited caspase-1, leading to caspase-1 dimerization, autocatalytic 
processing and the generation of active caspase-1. Active caspase-1 processes the 
maturation of pro-IL-1β to IL-1β, promoting inflammation (32, 33). Recent studies have 
indicated that NLRP3 inflammasome propagation is modulated by a cell-to-cell 
transmission of the ASC adaptor protein by an unknown mechanism (34). Despite 
these information, the exact mechanisms of inflammasome activation and propagation 
remain elusive. 
Mn toxicity has been well documented in neurodegeneration and glial biology 
(9, 35-39). More specifically, Mn induces TNF-α and inducible nitrogen synthase 
(iNOS) in astrocytes (40, 41), causes mitochondrial dysfunction by its accumulation in 
mitochondria (42), and it was shown to induce neurotoxicity in a rat model of 
manganism by modulating microgliosis (43). Mn exposure has been shown to induce 
classical activation in microglial cells (44) as well as astrocytes(39) in the central 
nervous system, leading to production of pro-inflammatory cytokines. The plethora of 
pro-inflammatory factors have been shown to cause neuronal damage (45). 
Furthermore, Mn has been shown to enhance, LPS-induced production of pro-
inflammatory factors in microglial cells (37). Recently, Mn-induced microglial activation 
has been shown to activate astrocytes, leading to enhanced production of pro-
inflammatory factors (46).However, the molecular signaling mechanism of Mn-
induced microglial activation is still not well understood. Microglia express multiple 
functional inflammasomes, including NLRP3, NLRC4 and AIM2 inflammasomes 
(47).However, the effect of Mn on microglial inflammasome activation and propagation 
remains equivocal.  
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This current study characterizes whether Mn activates inflammasome signaling 
in microglial cells and the mechanisms involved in activation in propagation. 
Furthermore, this study aims to bridge the gap between Mn-induced inflammation and 
mitochondrial damage in microglial cells. Moreover, there is a lack of understanding 
in the signaling mechanism of inflammasome propagation which we aimed to address 
in this study. Here, we elucidate that Mn can act as signal 2 to activate the NLRP3 
inflammasome in microglial cells. In our studies reported here, we show that 1) Mn 
induces mitochondrial dysfunction  and reduces mitochondrial fusion protein 2, or 
Mitofusin 2 (Mfn2); 2) Mn downregulates vacuolar protein sorting-associated protein 
35 (VPS35), a retromer complex protein which regulates Mfn2 ubiquitination; 3) 
uptake of ASC-containing exosomes plays a role in Mn-induced inflammasome 
propagation; and finally, welder serum exosomes have a higher ASC load compared 
to age-matched controls and have higher serum pro-inflammatory cytokine levels.  
Results 
Mn induces NLRP3 inflammasome activation in microglial cells in vitro and in 
vivo 
The NLRP3 inflammasome can be activated by various external signals 
including, ATP, pathogen-activated molecular patterns (PAMP’s), and danger-
associated molecular patterns (DAMP’s) (30). However, the role of environmental PD 
neurotoxicants, like Mn, in inducing inflammasome activation has not been fully 
elucidated till date. Therefore, in the first set of experiments we investigated the ability 
of Mn to stimulate the processing and release of IL-1β and caspase-1 cleavage from 
LPS-primed microglial cells. Microglial cells were primed with 100 ng/ml of LPS for 3 
147 
 
h, after which the cells were treated with 100 μM Mn for 24 h. As shown in Fig. 1A, 
there was no detectable mature IL-1β in unstimulated or LPS priming alone cells; 
however, a significant amount of mature IL-1β was detected in LPS-primed, Mn-
treated microglial cells (Fig. 1A and Supplementary Fig. 1A-B). Similarly, a multiplexed 
Luminex assay confirmed that Mn exposure induced a dramatic release of IL-1β from 
LPS-primed cells (Fig. 1B). Of note, Mn treatment alone had no effect on inducing IL-
1β processing and release. Furthermore, Western blot analysis revealed that Mn 
significantly stimulated the cleavage of caspase-1 in LPS-primed cells when 
compared to unstimulated and LPS priming alone cells (Fig. 1A). Interestingly, we 
observed a slightly but not significantly increased amount of cleaved caspase-1 in Mn-
treated unprimed cells (Fig. 1A and Supplementary Fig. 1C). These results suggest 
that Mn exposure can serve as a signal 2 to activate microglial inflammasome 
signaling.  Recent studies have shown that ASC, a component of inflammasome 
activation, can form speck-like structures and helps to propagate the inflammasome 
from cell-to-cell (34). Our ICC analysis revealed that ASC was evenly distributed 
throughout the unstimulated and LPS priming alone cells. In contrast, the LPS-primed 
microglial cells exposed to Mn formed intesnse ASC specks, further indicative of 
inflammasome activation (Fig. 1C). Next, to identify which inflammasome was 
activated by Mn, we treated LPS-primed microglial cells with Mn for 6 h. Western blot 
analysis revealed that NLRP3 was significantly upregulated in LPS-primed cells 
stimulated with or without Mn (Fig. 1D), whereas NLRC4 and AIM2 proteins were not 
detectable (data not shown). ICC further confirmed this upregulation of NLRP3 (Fig. 
1E) in both LPS priming alone and Mn-treated, LPS-primed cells. These results 
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provide evidence for a specific effect of Mn on NLRP3 inflammasome activation. 
Supporting this view, qRT-PCR analysis showed significantly increased mRNA levels 
of NLRP3 and pro-IL-1β (Fig. 1F). Mn-treated unprimed cells did not show any 
significant upregulation of pro-IL-1β and NLRP3, indicating that Mn exposure had no 
effect on the priming step of NLRP3 inflammsome.  To further verify the specificity of 
Mn in metal-induced inflammasome activation, primary microglial cells were treated 
with Mn, copper (Cu), and zinc (Zn). Since Zn is toxic at 100 μM, a non-toxic dose of 
Zn (30 μM) was used. Cu was used at the same dose as Mn (100 μM). An MTS assay 
revealed that Mn treatment did not show obvious cytotoxicity in LPS-primed cells while 
Cu and Zn cause more cell death (Supplementary Fig. 2A). Regarding the capacity 
for inflammasome activation, again, our Luminex data revealed that Mn elicited a 
significant increase in  IL-1β release in LPS-primed cells, whereas Cu and Zn did not 
(Supplementary Fig. 2B). On the other hand, LPS-treated cells stimulated with Mn, Cu 
or Zn released comparable amounts of TNF-α (Supplementary Fig. 2C). This data 
validates that inflammasome activation is not a property of all divalent transition 
metals. Moreover, Mn exposure potentiated LPS-induced Nos2 mRNA 
(Supplementary Fig. 3A) and protein levels (Supplementary Fig. 3B and Fig. 3C) as 
well as nitrite release (Supplementary Fig. 3D). All these findings together show Mn 
can activate the NLRP3 inflammasome in primed microglial cells.   
The etiology of PD is complex and multifactorial. The role of environment-gene 
interaction has been implicated in PD pathogenesis (48-50). Not only is aggregated 
αSyn an important component of Lewy bodies and Lewy neurites in PD, it has also 
been shown to induce NLRP3 inflammasome activation (31). We hypothesized that 
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Mn potentiates αSynPFF-induced microglial NRLP3 inflammasome activation. Co-
treatment of Mn with αSynPFF potentiated αSynPFF-induced upregulation of NLRP3 and 
iNOS proteins (Fig. 1G). Luminex assay revealed that Mn further potentiated the 
αSynPFF-induced release of IL-1β (Fig. 1H) but not IL-6 (Supplementary Fig. 4A) or 
TNF-α (Supplementary Fig. 4B). These findings indicate that Mn can further potentiate 
αSynPFF-induced inflammasome activation in microglial cells. 
To add in vivo relevance, we wanted to verify if Mn can induce the NLRP3 
inflammasome in animals. C57BL mice were gavaged with 15 mg/kg Mn for 30 days 
followed by immunoblot analysis, qRT-PCR, and IHC of the striatum. Mn specifically 
induced NLRP3 mRNA expression, but not AIM2 and NLRC4, as revealed by qRT-
PCR (Fig. 1I). IHC studies further revealed that this NLRP3 increase occurred in IBA1 
(microglia marker)-positive cells (Fig. 1J). Our Western blot analysis showed that Mn 
significantly increased caspase-1 cleavage, and mature IL-1β (Fig. 1K and 
Supplementary Fig. 5A). Interestingly we did not observe an increase in pro-IL-1β 
level. The Mn-induced increase in cleaved caspase-1 is strongly correlated with an 
increase in the level of released IL-1β (Supplementary Fig. 5B). Collectively, all these 
findings show for the first time that Mn can activate the NLRP3 inflammasome in 
microglial cells both in vitro and in vivo. This NLRP3 signaling cascade could be the 







Mn leads to mitochondrial dysfunction in primed microglial cells 
The mechanism underlying inflammasome activation is currently being 
debated. Recent studies have attributed this activation to mitochondrial dysfunction 
and mitochondrial superoxide generation (32, 33, 51-53). Mn is known to more 
severely impair mitochondria under stress conditions (54-57). Hence, we ran the Mito 
Stress assay on an extracellular flux analysis system (Seahorse Bioscience, XFe24) 
to determine the effects of Mn on mitochondrial bioenergetics of LPS-primed 
microglia. Primary microglial cells were primed with LPS for 3 h followed by 24 h of 
treatment with Mn (100 μM). Interestingly, exposing LPS-primed microglia to Mn 
significantly impaired mitochondrial function (Fig. 2A) as depicted by decreased 
mitochondrial ATP production (Fig. 2B), basal respiration rate (Fig. 2C), maximal 
respiration (Fig. 2D), and spare respiratory capacity (Fig. 2E). Interestingly, Mn 
exposure in unprimed microglial cells showed no significant changes in mitochondrial 
dynamics. A previous study by Dodd et al. also showed that 250 µM Mn exposure in 
N9 microglia for 24 h caused little or no increase in ooxidative stress (37).Furthermore, 
cell phenotype analysis revealed that Mn altered the cellular metabolic phenotype in 
LPS-primed microglial cells. Exposure of LPS-primed primary mcirlgia to Mn 
significantly decreased stressed oxygen consumption rate (OCR) without significantly 
changing the stressed extracellular acidification rate (ECAR), as measured by the cell 
energy phenotype test, suggesting that Mn exposure reduced the mitochondrial 




Mitochondrial dysfunction leads to superoxide generation. Thus, as expected, 
our MitoSox assay revealed that LPS-primed microglial cell line treated with 100 µM 
Mn for 24 h generated significant superoxide levels (Fig. 2F), futher confirming the 
effcts of Mn treatment on mitochondrial dysfunction in primed microglia. Since LPS-
primed cells and unprimed microglial cells exposed to Mn both exhibited minimal or 
no changes in mitochondrial superoxide production (Fig. 2F), we hypothesized that 
LPS is modulating Mn transporters in microglia. Indeed, qRT-PCR analysis revealed 
that LPS significantly increased Mn importer SLC11A2 (Supplementary Fig. 7A), while 
Mn exposure alone induced the expression level of Mn exporter SLC30A10 
(Supplementary Fig. 7B) without changing the importer expression.As a result, we 
observed an increased Mn uptake in LPS-primed, Mn-treated microglial cells 
compared to unprimed Mn-treated cells as revealed by ICP-MS analysis 
(Supplementary Fig. 7C). These data suggest that LPS priming modulates the uptake 
of Mn by changing Mn receptor levels. 
Links to mitochondrial dysfunction were recently established for Mfn2 (58-60), 
including Mfn2 degradation by ubiquitination. Although our qRT-PCR analysis, in LPS-
primed microglial cell line, showed no significant change in Mfn2 levels (Fig. 2G), our 
immunoblot analysis (Fig. 2H) and ICC (Fig. 2I) showed that Mfn2 decreased in 
primed microglial cells treated with Mn, suggesting that the Mn-induced mitochondrial 
dysfunction in primed microglia may be due to Mfn2 degradation. One candidate for 
ubiquitinating Mfn2 is mitochondrial ubiquitin ligase 1(Mul1). In fact, the mRNA level 
of Mul1 in Mn-treated, LPS-primed cells doubled when compared to other groups (Fig. 
2J). Also, ICC analysis revealed an increase in the Mul1 protein level in Mn-treated, 
152 
 
LPS-primed cells (Fig. 2K). Collectively, these data suggest that Mn-induced 
inflammasome activation in microglia is related to mitochondrial dysfunction and that 
this mitochondrial dysfunction is through the degradation of Mfn2 by Mul1.  
 
Retromer complex proteins are involved in Mn-induced mitochondrial 
dysfunction in LPS-primed microglia 
Tang et al. (61) showed that mutating or downregulating the retromer complex 
protein VPS35 (Park 17) induces mitochondrial dysfunction by increasing Mul1 in 
dopaminergic neurons. Since we observed that Mn exposure can increase the level 
of Mul1 in LPS-primed microglia, we further investigated whether this increased Mul1 
might be due to VPS35 downregulation. We treated LPS-primed microglial cell line 
with Mn for 24 h in preparation for qRT-PCR, ICC, and immunoblot analyses. Our 
qRT-PCR analysis revealed that Mn exposure downregulated VPS35 in LPS-primed 
microglial cells when compared to other groups (Fig. 3A). Another retromer complex 
protein, VPS29, was also downregulated in primed microglial cells treated with Mn 
(Fig. 3B). Further, ICC (Fig. 3C) and Western blot analyses (Fig. 3D) confirmed that 
VPS35 is downregulated in Mn-exposed, LPS-primed microglial cells. We further 
validated our cell culture findings in an animal model of Mn toxicity. Animal were 
similary treated with Mn as described above. Striatal VPS35 mRNA was 
downregulated in Mn-gavaged mice (Fig. 4E).  
To further elucidate the role of VPS35 in maintaining microglial mitochondria, 
we developed a VPS35 stable knockdown (KD) microglial cell using the CRISPR-
Cas9 system (Supplementary Fig. 8). Surprisingly, our Western blot analysis showed 
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VPS35 KD cells have less Mfn2 (Fig. 3F). Moreover, qRT-PCR revealed that Mul1 
mRNA was significantly elevated in the VPS35 KD cells (Fig. 4G). These data 
collectively suggest that VPS35 is upstream of Mfn2 and the Mul1 pathway and may 
play a role in maintaining mitochondrial integrity. 
Exosomes mediate Mn-induced cell-to-cell transmission of the inflammasome 
component ASC in LPS-primed microglia  
Retromer deficiency can lead to an increase in the amyloid precursor protein 
(APP) cargo of exosomes in AD (62). ASC, the inflammasome adaptor component, 
has been recently shown to propagate inflammasomes through cell-to-cell 
transmission (34). Hence, we hypothesized that ASC migrates from one cell to another 
via exosomes and that Mn modulates inflammasome propagation by increasing the 
exosomal ASC cargo. To verify if exosomal uptake plays a role in inflammasome 
propagation, we knocked down two endosomal pathways, caveolin and clathrin, 
responsible for exosomal uptake from microglial cells using the CRISPR-Cas9 
system. CRISPR control, caveolin KD, and clathrin KD microglial cells were treated 
with Mn for 24 h following LPS priming. Interestingly, caveolin KD significantly blocked 
Mn-stimulated upregulation of pro-IL-1β (Fig. 4A) and NLRP3 (Fig. 4B) mRNA levels 
in LPS-primed cells while clathrin KD cells no significant difference (data not shown). 
Both caveolin and clathrin KD cells showed reduced nos2 mRNA levels 
(Supplementary Fig. 9A). Furthermore, Luminex assay revealed that Mn-exposed, 
LPS-primed caveolin and clathrin KD cells produced significantly diminished matured 
IL-1β (Fig. 4C) but not TNF-α (Supplementary Fig. 9B). These data suggest that 
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blocking exosomal uptake reduces Mn-induced inflammasome propagation. This also 
indicates that exosomal cargo can be important for inflammasome activation.  
To further identify the importance of exosome cargo for inflammasome 
propagation, exosomes were isolated from treatment media of microglial cells treated 
with 100 μM Mn for 24 h.  Immunoblot analysis showed that Mn exposure induced 
exosomal release of ASC from LPS-primed microglial cells (Fig. 4D), while LPS and 
Mn alone had only minimal effect. Furthermore, Mn treatment significantly enhanced 
the number of exosomes released from primed microglial cells (Fig. 4E) without 
altering exosome size (Supplementary Fig. 10). ASC KO cell line exposed to Mn also 
induced an increase in exosome number (Fig. 4E), suggesting that increase in 
exosome number is independent of inflammasome activation. To further validate the 
cell-to-cell transmission of ASC, an ASC-CFP overexpression microglial cell line was 
utilized. ASC-CFP-overexpressing microglial cells were treated with 100 μM Mn for 24 
h following LPS-priming, and exosomes were collected from the treatment medium 
and counted. An equal number of exosomes were used to treat wild-type microglial 
cells lacking CFP. After 24 h post-treatment, the cells were washed properly and 
imaged using confocal microscopy. Imaging revealed that cells treated with exosomes 
from Mn-treated, LPS-primed cells expressed significantly more CFP than the cells 
treated with exosomes collected from control medium (Fig. 4F). The exosomes used 
to treat wild-type cells were the only probable source of the CFP signal. Since this 
CFP was tagged to ASC, the CFP expression in exosome-treated cells confirms that 
ASC can migrate from cell-to-cell via exosomes and that Mn can upregulate the 
exosomal ASC content. When we treated LPS-primed microglial cells with exosomes 
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isolated 24 h post-Mn treatment, qRT-PCR analysis revealed significantly increased 
mRNA levels of NLRP3 (Fig. 4G) and pro-IL-1β (Fig. 4H) relative to control exosome-
treated microglial cells. This increase in NLRP3 and pro-IL-1β level was not seen 
when wild-type microglial cells were treated with exosomes isolated from Mn-treated, 
LPS-primed ASC KO cell line (Fig. 4G-H), further validating that exosomal transfer of 
ASC is involved in propagation of inflammasome.  Also, exosomes isolated from 
serum of Mn-gavaged animals significantly elevated the release of IL-1β when 
administered to LPS-primed primary microglial cells for 24 and 48 h (Fig. 4I); no 
significant change in IL-6 or TNF-α release was observed (Supplementary Fig. 11A-
B). Collectively, these findings suggest that Mn induces cell-to-cell transmission of 
ASC through exosomes, further propagating inflammasome activation.  
Serum exosomes and serum from welder population have higher load of ASC 
and higher pro-inflammatory cytokines, respectively, compared to age-matched 
controls 
Welders exposed to Mn have shown a dose-dependent progression of 
Parkinsonian syndrome (63). To demonstrate the human relevance of our findings 
from cell culture and animal models of Mn exposure, we utilized serum exosomes 
collected from welders. First, the exosomes were counted and the Western blot was 
normalized to the number of exosomes isolated from an equal volume of serum. Our 
Western blot analysis (Fig. 5A) revealed that welders’ serum exosomes had 
significantly more ASC compared to age-matched controls (Fig. 5B). This data further 
corroborates our in vitro and in vivo data, suggesting that Mn exposure upregulates 
exosomal release of ASC. 
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Finally, we analyzed welder serum for cytokine and chemokine profiling (Fig. 5C-F 
and Supplementary Fig. 12). Interestingly, we found significant upregulation of the 
serum pro-inflammatory cytokines TNF-α (Fig. 5C) and IL-17(Fig. 5D), and the 
chemokines RANTES (Fig. 5E) and MIP1b (Fig. 5F) in welders, compared to age-
matched controls. The small amount of IL-1β (Supplementary Fig. 11A) detected in 
the serum of welders and control subjects may be attributed to the short half-life of IL-
1β. The IL-17 response has been shown to be driven by inflammasome-derived IL-1β 
(64).  Furthermore, MIP1b is known to be reduced in the ASC-/- mouse (65), 
suggesting the inflammasome plays a role in MIP1b upregulation. Together, these 
data suggest that exosomal ASC is upregulated in human populations occupationally 
exposed to Mn. Furthermore, industrial exposure to Mn may lead to systemic 
inflammation. 
Discussion 
A diverse variety of signals including ATP (66), various crystals (67, 68), 
mitochondrial inhibitors (32), and misfolded proteins (30, 31) have been shown to 
induce NLRP3 inflammasome activation. In recent years, inflammasome activation 
has been linked to various neurodegenerative disorders including PD, AD, and TBI 
(29). In the present study, we show for the first time that the environmental toxicant 
Mn can induce NLRP3 inflammasome activation in microglial cells in vitro and in vivo. 
Furthermore, this inflammasome activation in microglial cells is associated with 
mitochondrial dysfunction induced by Mfn2 degradation. We also show for the first 
time that Mn-stimulated exosomes contain the inflammasome component ASC and 
are involved in propagating the NLRP3 inflammasome. Finally, we demonstrate that 
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welders exposed to Mn fumes have a higher serum exosomal ASC load and more 
pro-inflammatory cytokines compared to age-matched controls.  
The link between Mn and neurodegenerative and neuroimmune processes is 
becoming clearer. Chronic Mn exposure has been shown to reduce TH-positive 
neurons in the substantia nigra (SN) region (69). Furthermore, Mn induces microglial 
activation in the SNpc region in a primate model (70), while another recent study 
showed that microglial exposure to Mn modulates astroglial inflammation (46). Mn 
exposure also induces the pro-inflammatory cytokine profile in glial cells (71-73) and 
modulates the NFκB pro-inflammatory signaling pathway and p-38 MAPK pathway in 
glial cells (45, 72). However, the mechanism underlying sustained and chronic 
inflammation in Mn-induced neurotoxicity is not well understood. The inflammasome’s 
role in modulating inflammatory responses in various disease models and in 
developing new therapeutics has been gaining importance in recent years (47).  
Exposure to silica and asbestos induces NLRP3 inflammasome activation in various 
cell types including lymphocytes and macrophages, among others (68). Furthermore, 
NLRP3 inflammasome activation has been linked to Parkinsonian syndrome (31, 74). 
Here, using cell culture and animal models of Mn toxicity, we show that Mn exposure 
can activate the NLRP3 inflammasome specifically in microglial cells.  
Though a variety of stimuli has been shown to act as signal 2 in activating the 
NLRP3 inflammasome cascade, the exact mechanism underlying its assembly is not 
well understood. Various factors, including mitochondrial dysfunction (32), 
mitochondrial superoxide generation (33), and lysosomal dysfunction (75), have been 
implicated as mechanisms underlying NLRP3 inflammasome assembly. A recent 
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study by our group has further elucidated that mitochondrial superoxide generation 
plays an important role in NLRP3 inflammasome activation (76). Mn exposure causes 
mitochondrial dysfunction by accumulating in mitochondria (9, 42, 57, 77) in neurons 
and astrocytes. In this study, we show that Mn exposure leads to mitochondrial 
dysfunction and mitochondrial superoxide generation in microglial cells. Mfn2 plays 
an important role in mitochondrial fusion and is one of the targets of the PD-associated 
gene PARKIN (78, 79). Mfn2 overexpression and downregulation has been linked to 
the modulation of mitochondrial dynamics (60, 61, 80). Furthermore, Mfn2 has been 
shown to play a role in Mn-induced neurotoxicity in neuronal cells (81). In this study, 
we demonstrate that Mn exposure leads to Mfn2 downregulation in microglial cells 
and is accompanied by mitochondrial dysfunction and inflammasome activation.  
Most studies with VPS35 have focused on neurons, while largely ignoring the 
role of this retromer complex protein in microglia. Recent studies have shown that 
VPS35 mutation or downregulation can induce mitochondrial dysfunction either by 
modulating Mfn2 degradation in dopaminergic neurons (61) or by recycling the 
dynamin-like protein 1 (DLP1) complex (82). Here we show that Mn exposure 
downregulates VPS35 in LPS-primed microglial cells and that VPS35 modulates Mfn2 
degradation through Mul1. The exact mechanism of Mn-induced VPS35 
downregulation is not clear. Previous studies reported that VPS29, another retromer 
complex protein, contain Mn binding sites, and that VPS35 wraps around these metal 
binding sites (83, 84). Thus Mn-induced downregulation of retromer complex proteins 
may be due to excessive binding of Mn to these metal binding sites, but more studies 
are required to confirm the exact mechanism. Still others have shown VPS35, part of 
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the retromer protein complex, modulates the cellular biogenesis and release of 
exosomes (85, 86). Retromer pathway dysfunction has been shown to promote 
amyloid precursor protein processing (62). Exosomes, which were presumed to be 
the “garbage bag” of cells, have gained importance in recent years due to their role in 
the progression of neurodegenerative disorders including AD and PD. Exosomes are 
now known to export aggregated α-Syn to other cells (87, 88), thereby acting as 
messengers. Intercellular communication via exosome cargo can also modulate 
neuroinflammation (89). NLRP3 inflammasome propagation has become an active 
area of research. A novel pyroptotic-phagocytic cascade has been shown to spread 
ASC and the NLRP3 inflammasome assembly between cells, in a “prionoid” fashion, 
thus propagating the inflammasome (34). In this study, we demonstrate for the first 
time that ASC can communicate cell-to-cell via exosomes. Mn exposure induced the 
exosomal release of ASC from LPS-primed microglial cells, whereas blocking 
exosomal uptake reduced IL-1β release indicating a reduction in inflammasome 
activation (Fig 4). 
First reports of occupational exposure to Mn date back to 1837 (90). Due to their 
exposure to welding-derived nanoparticles, Swedish welders have an increased 
inflammatory profile (91). In this study, we have shown a probable mechanism for 
inflammation stemming from occupational exposure to Mn. Though we were not able 
to detect significant amounts of IL-1β in welder serum, we do show an increased ASC 
load in welder serum exosomes. The lack of elevated IL-1β may be attributed to its 
short half-life (Fig. 5).  
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Collectively, our study demonstrates for the first time that Mn exposure leads 
to NLRP3 inflammasome activation in microglial cells, thereby leading to inflammation. 
This inflammasome activation is accompanied by mitochondrial dysfunction that is 
manifested by Mfn2 degradation by Mul1. VPS35 is an upstream regulator of Mfn2 
ubiquitination that is downregulated by Mn exposure. We further demonstrate for the 
first time that exosomes play an important role in Mn-induced NLRP3 inflammasome 
propagation. In this study, we show that ASC can migrate from cell-to-cell via 
exosomes. This finding may have broad implications for the field of immunology as 
exosomes can cross the blood-brain-barrier and can communicate to various organs. 
Our novel findings may provide some insight into the mechanism of communication 
between peripheral inflammation and CNS inflammation in neurodegenerative 
disorders, including AD and Parkinsonian syndrome. Future studies should explore 
the role of exosomal biogenesis during inflammation in different disease models. 
Overall, our novel findings suggest a probable mechanism underlying Mn-induced 
Parkinsonism.  
 
Materials and Methods 
Cell culture, Primary culture and Treatments 
Primary microglial cells were isolated using a magnetic bead separation 
technique described in our previous publications (92, 93). Primary microglial cells 
were cultured in DMEM-F12, 10% FBS, 1% sodium pyruvate, 1% glutamine, 1% 
penicillin-streptavidin, and 1% non-essential amino acids. The wild-type microglial cell 
line and ASC-CFP microglial cell line were kind donations from Dr. D.T. Golenbock 
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(University of Massachusetts Medical School, Worcester, MA). ASC KO macrophage 
cell line were kind donations from Dr. K. Fitzgerald (University of Massachusetts).  The 
wild-type microglial cell line was characterized by Halle et al. (30) and cultured in 
DMEM medium, 10% FBS, 1% glutamine, and 1% penicillin-streptavidin. Treatments 
were done in 2% FBS-containing medium. For LPS-priming treatments, cells were 
treated with LPS (100 ng/mL) for 3 h. Next, the cells were triple-washed with full serum 
medium to remove any excess LPS, and then treated with 100 μM Mn for 6-24 h.  
CRISPR-Cas9 knockdown (KD) cell generation 
CRSPR guide RNA was obtained for VPS35, clathrin, and caveolin from Sigma 
and transfected using protocols from our previous publications (12, 23).  Following 
transfection, cells were incubated for 48 h before treatment. The lentivirus-based 
CRISPR/Cas9 KO plasmid against gene Vps35, with target site 
CAAGTCATTTCCTCAATCCAGG, in a U6gRNA-Cas9-2A-RFP vector, was 
purchased from Sigma-Aldrich. The lentivirus-based CRISPR/Cas9 plasmids, pLV-
U6g-EPCG-Cav1 and pLV-U6g-EPCG-Cltc with the Caveolin-1 and Clathrin gRNA 
target sequences GTTGAGATGCTTGGGGTCGCGG and 
TACTGAAGCCAATGTTTGCTGG, respectively, were purchased from Sigma-Aldrich. 
To make the lentivirus, the lenti-CRISPR/Cas9 Vps35 KO plasmid and nontarget 
control plasmid were transfected into 293FT cells using the Mission Lentiviral 
Packaging Mix from Sigma-Aldrich according to manufacturer’s instructions. The 
lentivirus was harvested 48 h post-transfection and added to the microglial cell line at 
an MOI of 100 to knockdown VPS35, Caveolin-1, and Clathrin expression. 
Animal study  
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Eight-week-old male C57BL/6Ncrl mice, obtained from Charles River, were 
housed under standard conditions of constant temperature (22 ± 1°C), humidity 
(relative, 30%), and a 12 h light/dark cycle. After acclimating for 3 days, mice were 
gavaged with 15 mg/kg body weight Mn for 30 days, and then sacrificed. This Mn dose 
regimen was chosen based on previous studies in humans and animals (94-96). Use 
of the animals and protocol procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Iowa State University (Ames, IA, USA). 
Western blot 
Western Blot analyses were performed following our previous publications (12, 
97). Briefly, cells or tissues were lysed using modified RIPA buffer. Proteins were 
normalized using Bradford assay before loading on SDS-acrylamide gels. For 
separation of proteins, 20-40 μg of protein was loaded in each well of 10-15% 
acrylamide gels. Acrylamide gels were run at 110 V for 2 h at 4°C. Following 
separation, proteins were transferred on a nitrocellulose membrane at 27 V for 18 h 
at 4°C. After transfer, the membranes were blocked with Li-COR blocking buffer for 
45 mins and incubated in primary antibodies following manufacturer’s protocol. 
Following primary antibody incubation, membranes were washed with PBS-TWEEN 
20 (0.05%) for 1 h and incubated in Li-COR IR secondary antibodies for 1 h at room 
temperature, washed with PBS-TWEEN for 1 h, and imaged using an Odyssey 
scanner. The primary antibodies used are as follows: anti-caspase-1 (Adipogen, 
1:1000) (AB_2490248), anti-NLRP3 (Adipogen, 1:1000), anti-iNOS (SantaCruz, 
1:1000), anti-IL-1β (R&D systems, 1:500), anti-Mfn2 (Cell Signaling, 1:1000), anti-
VPS35 (Santa Cruz, 1:500), and anti-ASC (Adipogen, 1:1000) (AB_2490440). The 
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secondary antibodies used are as follows: IR-800 conjugated goat anti-mouse IgG (Li-
COR, 1:20000) and IR-700 conjugated goat anti-rabbit IgG (Li-COR 1:20000). For 
loading control, β-actin (Sigma, 1:10000) antibody was used.  
 
qRT-PCR 
RNA was isolated from tissues and cells according to a previous publication 
(98). In short, cells or tissues were lysed in 1 mL of TRIzol reagent and incubated for 
5 min. After incubation, 0.2 mL of chloroform was added to each tube, incubated for 2 
min and centrifuged at 12,000 g for 15 min at 4°C. After centrifugation, the top clear 
layer containing RNA was transferred to a fresh tube containing 0.7 mL of isopropanol, 
incubated for 15 min and centrifuged at 12,000 g for 10 min at 4°C to precipitate the 
RNA. After precipitation, the supernatant was discarded, the pellet was washed with 
75% ethanol, air-dried, and dissolved in water. A NanoDrop was used to quantify the 
RNA and 1 μg of RNA was utilized for converting into cDNA. For cDNA synthesis, the 
high capacity cDNA synthesis kit from Applied Biosystems (Cat#4368814) was used 
according to manufacturer’s protocol. Quantitative SYBR green PCR assay was 
performed using qRT2PCR SYBR Green Mastermix (Agilent) and pre-validated 
primers. The following validated primers from Qiagen were used: pro-IL-1β 
(QT01048355), NLRP3 (QT00122458), NLRC4 (QT00264670), AIM2 (QT00266819
 ), Nos2 (QT00100275), Mfn2 (QT00134295 ), Mul1 (QT00132734), 
SLC30A10 (QT01199009), SLC11A2 (QT01047368), VPS35 (QT00160258), VPS29 
(QT00137228), and 18S (QT02448075). The fold change in gene level was 
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determined by ΔΔCt method where Ct is the threshold value. 18S was used as the 
housekeeping gene.   
Immunohistochemistry and Immunocytochemistry 
Immunohistochemistry (IHC) was performed on striatal sections as described 
in our previous publications (20, 22). Striatal sections (30 μm) were used for IHC. 
Citrate buffer was used to perform antigen retrieval (10 mM sodium citrate, pH 8.5). 
Following antigen retrieval, sections were washed with PBS, blocked with blocking 
buffer (2% BSA, 0.5% Triton 100X, and 0.05% TWEEN 20), and incubated in primary 
antibodies overnight at 4°C. Next, sections were washed with PBS, incubated in 
secondary antibodies for 1 h and stained with the nuclear dye Hoechst. Finally, 
sections were mounted on pre-coated slides and dried overnight before visualizing 
them under microscope. Confocal imaging was performed on these sections at the 
Iowa State University Microscopy Facility using a Leica DMEIR2 confocal microscope 
with 63X oil objective. For z-stacking, each section consisted of 10-15, 0.5-μm slices.  
For immunocytochemical (ICC) studies on microglial cells and microglial 
primary culture, 4% paraformaldehyde (PFA) was used to fix the cells. Next, fixed cells 
were washed with PBS, blocked using blocking buffer, and incubated in primary 
antibodies following manufacturer’s protocol. Following primary antibody incubation, 
cells were washed with PBS, incubated in secondary antibody and mounted on slides 
using Fluoromount aqueous mounting medium (Sigma). Samples were visualized 
using an inverted fluorescence microscope (Nikon TE-2000U). The following primary 
antibodies were used: IBA1 (Wako, 1:1000) (AB_2314667), IBA1 (Abcam, 1:500) 
(AB_870576), Mul1 (Abcam, 1:500) (AB_1860863), NLRP3 (Adipogen, 1:500) 
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(AB_2490202), ASC (Adipogen, 1:500), Nos2 (Santa Cruz, 1:500) (AB_2152867), 
VPS35 (Santa Cruz, 1:500) (AB_2215220), and Mfn2 (Cell Signaling, 1:500). Alexa 
dye-conjugated secondary antibodies were used for ICC and IHC experiments.  
Multiplex cytokine assay 
Multiple cytokine assay was performed according to our previous publication 
(12). Briefly, 40 μL of treatment media was incubated overnight with 40 μL of primary 
antibodies conjugated with magnetic beads. Following incubation with primary 
antibodies, samples were washed, incubated with a biotinylated antibody and 
biotin/streptavidin, and then read in a Bio-Plex plate reader. Standards were obtained 
from PeproTech.  
For welder serum cytokine analysis, Bio-Plex Pro Human Cytokine 27-plex 
Assay (M500KCAF0Y, Bio-Rad) was performed according to manufacturer’s protocol.  
 
MTS mitochondrial activity assay 
Cells were plated in 96-well tissue plates. Following treatment, 10 μL of MTS 
reagent (Promega) was added and incubated at 37°C for 1.5 h. After incubation, a 
plate reader was used to quantify the absorbance at 490 nm. 
Griess assay 
Griess assay was performed as previously described in our publication (12). 
50,000-100,000k microglial cells were plated in 96-well plates and treated in 2% FBS 
containing medium. After treatment, 50 μL of medium was collected, and incubated 
with 50 μL of Griess reagent for 10 min. A plate reader was used to read the 





Wild type microglial cell line-produced exosomes were isolated by filtering the 
cell-culture supernatant through 0.22-µm filters, followed by high-speed 
ultracentrifugation. Briefly, cells were grown in T-175 cell culture flasks and treated 
with 100 µM Mn. For each exosome sample, conditioned media from two T175 flasks 
were pooled with an original seeding density of 8x106 cells per flask. Post treatment, 
the media was collected and centrifuged at 300 x g for 10 min, and 10,000 x g for 15 
min successively to get rid of any cell debris before passing it through a 0.22-µm 
syringe filter. The filtrate was then centrifuged at 100,000 x g for 90 min using a 
Beckman Optima L-100 XP ultracentrifuge. The pellet containing exosomes was 
washed once with cold PBS and centrifuged again at 100,000 x g for 90 min using a 
Beckman optima MAX ultracentrifuge. 
Inductively coupled plasma mass spectroscopy (ICP-MS)  
Microglial cell line samples were carefully scraped and counted prior to sample 
preparation. Samples were analyzed for different metals including, Cd, Ca, Cr, Co, 
Cu, Fe, Mg, Mn, Mo, P, K, Se, Na, and Zn using ICP-MS (Analytik Jena Inc. Woburn, 
MA, USA) in CRI mode with hydrogen as the skimmer gas. Standards for elemental 
analyses were obtained from Inorganic Ventures (Christiansburg, VA) while digestion 
vessels; trace mineral grade nitric acid and hydrochloric acid were obtained from 
Fisher Scientific (Pittsburgh, PA). Briefly, samples were digested in 70 % nitric acid at 
60˚C for ≥12 hours. Pre-weighed samples were transferred to 15mL tubes and 0.25 
mL of 70% nitric acid was added.  All samples were digested overnight at 60˚C. After 
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digestion, all samples were diluted to 5 mL using 1% nitric acid with 0.5% hydrochloric 
acid and then analyzed by ICP-MS. For quality control, Bi, Sc, In, Li, Y, and Tb were 
used as internal standards for the ICP-MS. 
NanoSight 
Ultracentrifuged exosome samples were used for nanoparticle tracking 
analysis (NTA), as previously described (99). Briefly, isolated exosomes were 
resuspended in 500-1000 µL of PBS, from which approximately 300 μL was loaded 
into the sample chamber of an LM10 unit (NanoSight, Amesbury, UK) using a 
disposable syringe. Sample durations of 30-60 sec per sample were analyzed with 
NTA 2.3 software (NanoSight). Samples containing higher numbers of exosomes 
were diluted before the analysis and their relative concentrations were then calculated 
according to the dilution factor. 
Mitochondrial dynamics analysis 
A Seahorse XFe24 Analyzer was used to measure mitochondrial oxygen 
consumption rates (OCR) and extracellular acidification rates (ECAR) using the Mito-
Stress test following a previously published protocol (100). Primary mouse microglia 
were plated 90,000 cells/well of a 24-well, Seahorse plate. All treatments were done 
in serum-free medium. For the Mito-Stress test, 0.75 µM oligomycin, 1 µM FCCP, and 
0.5 μM rotenone/antimycin were used. The Seahorse’s Mito-Stress report generator 
and cell phenotype report generator were used for analysis. 
Statistical analysis 
GraphPad 5.0 was used for statistical analysis with p≤0.05 considered 
statistically significant. One-way ANOVA was used for comparing multiple groups with 
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Tukey post analysis unless otherwise mentioned. For comparing 2 groups, Student’s 
t-test was used. “n” represents number of biological replicates unless other mentioned. 
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Fig. 1: Manganese induced NLRP3 inflammasome activation in microglial cells 
in vivo and in vitro. Microglial cell line was primed with LPS for 3 h and exposed to 
100 µM Mn for 6-24 h. A) Western blot analysis showing Mn exposure led to Caspase 
1 cleavage and cleavage of IL-1β in an LPS-primed microglial cell line. n=4 B) Luminex 
analysis revealing Mn (24 h) exposure led to IL-1β release in primed microglial cells, 
n=8. C) ICC analysis reveals that 100 µM Mn exposure led to formation of ASC specs 
in microglial cells. D-E) Western blot (D) and ICC (E) analyses showing LPS-priming 
induced NLRP3 protein expression, n=3. F) qRT-PCR analysis shows increased 
NLRP3 and pro-IL-1β mRNA expression following LPS priming, n=3. G) Wild-type 
microglial cells were cotreated with 100 µM Mn and 1 µM αSynAgg. Western Blot 
analysis reveals that Mn exposure potentiated αSynAgg-induced NLRP3 expression. 
H) Luminex analysis demonstrates that Mn potentiated IL-1β release induced by 
αSynAgg, n=4. I) Mn exposure induced mRNA expression of NLRP3, but not NLRC4 
or AIM2, in the striata of C57BL mice gavaged with 15 mg/Kg Mn for 30 days as 
revealed by qRT-PCR, n=5. J) IHC analysis revealing increased level of NLRP3 in 
IBA1-positive microglial cells in striatal region of Mn-exposed mice compared to 
controls, n=3. K) Western blot analysis demonstrating that Mn exposure leads to 
increased matured IL-1β and cleaved caspase-1p20 in striatum, n=6. Data analyzed 
via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, ***p<0.001. Data 






Fig. 2: Mn induced mitochondrial damage by modulating Mfn2 and Mul1 
expression in microglial cells.  Primary microglial culture and microglial cell line was 
primed with LPS for 3 h and exposed to 100 µM Mn for 6-24 h. A) Seahorse Mito 
Stress showing change in mitochondrial dynamics in Mn-exposed LPS-primed 
primary microglial cells. Mn exposure lead to diminished B) mitochondrial ATP 
production, C) basal respiration rate, D) maximal respiration, and E) spare respiratory 
capacity. n=5 F) Mn exposure increased mitochondrial superoxide generation as 
demonstrated by MitoSOX dye. G) qRT-PCR analysis demonstrates no change in 
Mfn2 mRNA level on Mn exposure in microglial cells. n=3 H) ICC and I) Western blot 
analyses revealing that Mn exposure reduced Mfn2 protein level in microglial cells. 
n=4 J) qRT-PCR analysis reveals that Mul1, the protein which ubiquitinates Mfn2, was 
upregulated on Mn exposure in microglial cells. n=3 K) ICC analysis revealing 
increased Mul1 protein on Mn exposure. Data analyzed via ANOVA with Tukey post 






Fig. 3: VPS35, a retromer complex protein, can modulate Mfn2 degradation 
during Mn-induced inflammasome activation. Microglial cell line was primed with 
LPS for 3 h and exposed to 100 µM Mn for 24 h. A-B) qRT-PCR analysis reveals that 
Mn exposure led to downregulation of the retromer complex components VPS35 and 
VPS29. n=3 C) ICC analysis and D) Western blot analysis revealing that Mn exposure 
downregulates VPS35 protein level in microglial cell line. n=3 E) C57BL mice were 
gavaged with 15 mg/Kg Mn for 30 days. qRT-PCR reveals that Mn exposure reduced 
VPS35 mRNA expression in striatum. n=6 F) Western blot analysis from VPS35 
CRISPR-cas9 KD cells demonstrates lower Mfn2 protein level compared to wild-type 
microglial cells. G) qRT-PCR analysis reveals increased Mul1 mRNA level in VPS35 
KD microglial cells compared to wild-type cells. n=3 Data analyzed via ANOVA with 







Fig. 4: Exosomal release of the inflammasome component ASC propagates Mn-
induced inflammasome activation. Caveolae and clathrin KD cells were treated with 
100 µM Mn for 24 h. A) qRT-PCR analysis demonstrating that Mn exposure led to 
diminished mRNA production of NLRP3 and B) pro-IL-1β in caveolae KD cells 
compared to wild-type microglial cells. n=3 C) Luminex analysis demonstrates both 
caveolae and clathrin KD microglial cells attenuated release of IL-1β on Mn exposure. 
n=8 D) Western blot analysis of exosomes isolated from Mn-treated microglial cells 
reveals increased exosomal release of ASC. E) NanoSight analysis reveals that Mn 
increased the number of exosomes released from wild-type and ASC KO microglial 
cells. n=3 F) Exosomes were collected from ASC-CFP-overexpressing microglial cells 
treated with 100 µM Mn. Wild-type cells were treated with these isolated exosomes. 
ICC analysis demonstrates that Mn exposure led to cell-to-cell transmission of ASC. 
G) Exosomes isolated from Mn-exposed wild type and ASC KO cells were used to 
treat wild-type microglial cells. qRT-PCR analysis reveals that exosomes isolated from 
wild-type cells treated with Mn induced NLRP3, and H) pro-IL-1β expression 
compared to exosomes isolated from control cells, while exosomes isolated from ASC 
KO cells failed to elicit this response. n=3 I) Exosomes were isolated from serum of 
Mn-gavaged animals and used to treat primary microglial cells. Luminex multiplex 
assay reveals that exosomes isolated from Mn-gavaged animals elicited significantly 
higher IL-1β production than did exosomes isolated from control animals. n=8. Data 
analyzed via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, ***p<0.001. Data 
represented as mean±SEM. 
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Fig. 5: Serum exosomes and serum from welder population have higher load of 
ASC and higher pro-inflammatory cytokines, respectively, when compared to 
age-matched controls. A) Western blot analysis and B) densitometric analysis of 
Western blot show increased level of exosomal ASC load in welder population. C-F) 
Multiplex assay revealing increased level of pro-inflammatory cytokines and 
chemokines. C) TNF-α, D) IL-17, E) Rantes, and F) MIP-1b in welder serum 
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population. Data analyzed via Student-t test, *p<0.05, **p <0.01, ***p<0.001. Data 






Fig. 6. Working Hypothesis. Mn induces mitochondrial dysfunction leading to 
inflammasome activation by degradation of Mfn2. Mn also induces the release of 




Supplementary Fig. 1: Mn leads to NLRP3 inflammasome activation in LPS-
primed microglial cells: A-D) Densitometric analysis of western blots from Fig.1 A 
and Fig. 1D. Data analyzed via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, 





Supplementary Fig. 2: Mn specifically induced inflammasome activation in 
primary microglial culture. A) MTS assay shows that divalent metal exposure did 
not lead to significant cell death. B) Luminex assay reveals that Mn exposure 
significantly induced IL-1β release over Cu, or Zn, but C) TNF-α secretion was not 
altered.  Data analyzed via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, 




Supplementary Fig. 3: Mn potentiated LPS-induced nitrite generation.  A) qRT-
PCR analysis reveals that Mn exposure potentiated Nos2 mRNA level in LPS-primed 
microglial cells. B) Western blot and C) ICC analyses show upregulation of Nos2 in 
microglial cells on Mn exposure. D) Griess assay reveals that Mn potentiated Nitrite 
release in primed microglial cells. Data analyzed via ANOVA with Tukey post analysis, 




Supplementary Fig. 4: Mn exposure failed to potentiate αSynAgg-induced release 
of the pro-inflammatory factors TNF-α and IL-6. Luminex assay reveals that Mn 
failed to potentiate A) TNF-α, or B) IL-6 secretion induced by αSynAgg. Data analyzed 
via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, ***p<0.001. Data 





Supplementary Fig. 5: Caspase-1p20 induced cleavage of pro-IL-1β. A) 
Densitometric analysis of Western blot represented in Fig. 1J. B) Correlation plot 
showing the relation between cleaved caspase-1p20 and cleaved IL-1β. Data 
analyzed via ANOVA with Tukey post analysis, *p<0.05, **p <0.01, ***p<0.001. Data 
represented as mean±SEM. 
 
Supplementary Fig. 6: Mn exposure modulated metabolic cellular phenotype in 
primary microglial cells. A) Mn exposure changed metabolic phenotype in LPS-
primed microglial cells. B) Mn changed the metabolic potential with respect to OCR 
but it did not alter stressed ECAR. C) Mn altered stressed OCAR and D) ECAR in 
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primed microglial cells. Data analyzed via ANOVA with Tukey post analysis, *p<0.05, 
**p <0.01, ***p<0.001. Data represented as mean±SEM. 
 
Supplementary Fig. 7: LPS modulated Mn transporters and Mn uptake in 
microglial cells. A) qRT-PCR analysis reveals that Mn increased the divalent metal 
exporter SLC30A10 level, while B) LPS priming led to an increased level of the Mn 
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importer in microglial cells. Data analyzed via ANOVA with Tukey post analysis, 
*p<0.05, **p <0.01, ***p<0.001. Data represented as mean±SEM. 
 
 
Supplementary Fig. 8: Generation of CRISPR-Cas9 VPS35 KD cells. Western blot 
analysis showing VPS35 KD using CRISPR-cas9 system. Data analyzed via Student-




Supplementary Fig. 9: Caveolae and clathrin KD cells modulated Mn-induced 
Nos2 but not the pro-inflammatory factor TNF-α.  A) qRT-PCR analysis reveals 
that Mn-induced Nos2 upregulation was attenuated in caveolae and clathrin KD cells. 
B) Luminex analysis reveals that clathrin or caveolae KD did not alter TNF-α secretion 
induced by Mn in a primed microglial cell line.  Data analyzed via ANOVA with Tukey 





Supplementary Fig. 10: Mn exposure did not change the size distribution of the 





Supplementary Fig. 11: Exposure to exosomes isolated from Mn-gavaged 
animals did not alter release of the pro-inflammatory factors IL-6 and TNF-α. 
Luminex assay reveals that exosomes isolated from Mn-gavaged animals failed to 




Supplementary Fig. 12: Pro-inflammatory cytokine profile of welder and age-
matched control population.  A-P) Pro-inflammatory serum cytokine profile of 
welders compared to age-matched controls. Data analyzed via Student-t test, 
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Chronic neuroinflammation mediated by persistent microglia activation has 
been well recognized as a major pathophysiological contributor to the progression of 
neurodegenerative processes in Parkinson’s disease (PD). Identification of key 
targets contributing to sustained microglia activation and the regulation of these 
targets could provide potential treatments to halt disease progression. In this study, 
we show that microglial Kv1.3, a voltage-gated potassium channel, was highly 
upregulated in aggregated α-synuclein (αSyn)-stimulated primary microglia cultures, 
animal models of PD, as well as in human PD postmortem samples. Importantly, 
patch-clamp electrophysiological studies confirm that the observed Kv1.3 
upregulation translates to increased Kv1.3 channel activity. We further demonstrate 
that Fyn, a non-receptor tyrosine kinase, modulated the transcriptional upregulation 
of microglial Kv1.3. Using multiple state-of-the-art techniques, including DuoLink PLA 
technology, we show that Fyn directly binds to Kv1.3 and post-translationally modified 
its channel activity. Furthermore, we demonstrate the functional relevance of Kv1.3 
with respect to neuroinflammation by using Kv1.3 knockout (KO) microglia and the 
Kv1.3-specific small molecule inhibitor PAP-1. Kv1.3 KO microglial cells treated with 
aggregated αSyn produced fewer pro-inflammatory cytokines. PAP-1 significantly 
attenuated aggregated αSyn-induced inflammation in both a microglial cell line and 
primary microglia, thus highlighting Kv1.3’s importance in inflammation. 
Administration of PAP-1 significantly inhibited MPTP-induced neurodegeneration and 
inflammation in vivo.  PAP-1 also significantly reversed behavioral deficits and 
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dopamine loss in MitoPark mice, a progressive model of PD. Our results collectively 
show that the Fyn-dependent Kv1.3 channel plays an important role in inflammation 
in PD and has potential therapeutic significance. 
 
Introduction 
Parkinson’s disease (PD) is a neurodegenerative motor disorder that is 
characterized by the slow and progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) region of the brain. This progressive loss of 
neurons is characterized by the release of a misfolded and aggregated protein, α-
synuclein (αSyn), which is predominantly expressed in neurons throughout the brain.  
Recent studies have also shown the loss of extra-striatal neurons and the presence 
of non-motor deficits in PD (1, 2). Though the underlying cause of this neuronal loss 
is not completely clear, recent post-mortem studies have implicated nigral 
inflammation characterized by persistent and excessive microgliosis and astrogliosis. 
Various lines of evidence, including cell culture, animal models, and post-mortem 
tissue analysis, have implicated sustained neuroinflammation as being critical to PD 
progression (3-6). Currently, there are no treatments for preventing the progression of 
PD and the only available therapies are directed towards mitigating the symptoms of 
the disorder.  
Gene mutations (e.g., PARK1/4) can lead to misfolding and aggregation of 
αSyn, whose accumulation into Lewy bodies and neurites is the hallmark of both 
sporadic and genetically inherited PD. Interaction between aggregated αSyn 
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(αSynAgg) and microglial immune receptors, such as the pattern recognition receptors 
TLR2 and CD36, on microglial plasma membranes can lead to microglial activation 
(7). Furthermore, αSyn has been demonstrated to induce IL-1β production in 
monocytes (8, 9) and in microglia (10). However, much remains unknown regarding 
the key signaling pathways involved in either αSynAgg-mediated neuroinflammation in 
the nigral dopaminergic system (11, 12) or the chronic inflammation in microglia.  
The voltage-gated potassium channel Kv1.3 was first identified in T cells (13-
15), but has since been identified in other lymphocytes such as B cells and 
macrophages, retinal ganglion cells, microglia, and various other cell types. Similar to 
the other 40 Kv channels found in humans, Kv1.3 is a tetrameric protein consisting of  
α-subunits, each with six six transmembrane segments (S1-S6) and a voltage sensor 
in the S4 segment that is responsible for opening the channel in response to 
membrane depolarization. Kv1.3 knockout (KO) mice are resistant to diet-induced 
obesity (16, 17), immune to experimental autoimmune encephalomyelitis (EAE)(18), 
and also exhibit enhance olfaction (19). These findings reveal the diverse functions of 
this voltage-gated channel, though its investigation has mostly been limited to 
autoimmune disease, ischemia, and the development of retinal ganglion cells. Kv1.3 
also reportedly plays an important role in microglia mediated neuronal killing(20). 
Recently, Kv1.3 was shown to be upregulated in the post-mortem brains of 
Alzheimer’s disease (AD) patients (21). Interestingly, Kv1.3 contains multiple proline-
rich sequences to which Src homology (SH) domains can bind, and recently, our lab 
showed that Fyn, a src family kinase, is upregulated in PD models and plays an 
important role in microglial inflammation (22). Furthermore, Fyn inhibition has been 
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shown to reduce inflammation in AD (23). Clearly, the potential role of Kv1.3 in 
neuroinflammatory and neurodegenerative processes needs to be elucidated.  
In this study, we have aimed to show the importance of microglial Kv1.3 in PD, 
and to further demonstrate the transcriptional and post-translational modification of 
this channel in PD models. Our in vitro studies show that Kv1.3 is highly upregulated 
in microglial cells treated with αSynAgg. Kv1.3 is also upregulated in multiple animal 
models of PD, and in post-mortem human PD brains. Kv1.3 upregulation was not 
confined to the brain, as monocytes isolated from PD patients contain higher levels of 
Kv1.3, making it a potential biomarker. Furthermore, we report that Fyn can regulate 
Kv1.3 both transcriptionally and post-translationally, thereby modulating channel 
activity. Lastly, PAP-1, a small molecule inhibitor of Kv1.3 that can cross the blood 
brain barrier, was able to reduce neuroinflammation and neurodegeneration in cell 
culture and animal models of PD. Our findings have significant pre-clinical potential 
and therapeutic implications for the treatment of PD. 
Materials and Methods 
Cell Culture, Primary Culture and Treatments 
Primary microglial cells were isolated from mixed glial culture using a magnetic 
bead separation protocol published by our lab (24, 25). Primary cells were maintained 
in Dulbecco's modified Eagle's medium (DMEM)-F12, 10% fetal bovine serum (FBS), 
1% sodium pyruvate, 1% glutamine, 1% penicillin-streptavidin, and 1% non-essential 
amino acids. A Mouse microglial cell (MMC) line was donated by Dr. D.T. Golenbock 
(University of Massachusetts Medical School, Worcester, MA). The MMC line was 
characterized by our group (26) and Halle et al. (27) and cultured in DMEM medium, 
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10% FBS, 1% glutamine, and 1% penicillin-streptavidin. Treatments were performed 
in 2% FBS-containing medium. Green fluorescent protein (GFP) and human αSyn 
overexpressing adeno-associated viruses (AAV-GFP, 0.95 X 1013 viral particles per 
mL and AAV-SYN, 1 X 1013 viral particles per mL) were obtained from The University 
of North Carolina Viral Vector Core. Both viral vectors were of the AAV-5 serotype and 
coded for GFP and human αSyn, respectively, under a chicken β-actin promoter. 
 
Animal Studies  
All animals were housed under standard conditions of constant temperature 
(22 ± 1°C), humidity (relative, 30%), and a 12 h light/dark cycle. Use of the animals 
and protocol procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Iowa State University (ISU), Ames, IA, USA. 
αSyn-AAV Study 
8-week old, male C57BL/6Ncrl mice were anesthetized with a 
xylazine/ketamine cocktail. Toe pinch was used to gauge a surgical depth of 
anesthesia. An incision was made at the back of the head and the area was disinfected 
using povidone-iodine. Mice were mounted on the Angle 2 stereotaxic apparatus 
(Leica Biosystems, St. Louis, MO). The bregma was found and the injection into the 
SN subsequently performed. The coordinates indicating distance (mm) from bregma 
were: anteroposterior (AP) -3.1, mediolateral (ML) -1.2, and dorsoventral (DV) -4.0. 
The injection rate for GFP-AAV or αSyn-AAV solution was 0.2 µL/min. The needle 
was left in for 5 min post-injection to maximize forward tissue diffusion and to minimize 
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backflow up needle track. The needle was retracted at the rate of 1 mm/min.  Lactated 
Ringer’s solution was subcutaneously injected post-surgery to assist recovery. 
MitoPark Animal Study 
MitoPark mice were originally generated and provided by Dr. Nils-Goran Larson 
at the Karolinska Institute in Stockholm (28). All mice for this study were bred, 
maintained, genotyped, and further characterized at ISU. MitoPark mice (DAT+/Cre, 
TFAMLoxP/LoxP) and their littermate controls (DAT+/+, TFAM+/LoxP) were fed ad libitum 
and housed under standard conditions approved and supervised by IACUC at ISU.  
Mice were weighed weekly and subjected to behavior tests every two weeks. 
Neurochemical, biochemical, and histological studies were performed following 
sacrifice at 24 weeks. 
MPTP Animal Study 
8 weeks old male C57BL/6NCrl mice were injected intraperitoneally (i.p.) with 
either 20 mg/kg MPTP or equal volumes of saline (vehicle) once daily for four 
consecutive days and sacrificed 24 h after the last MPTP injection (29). 
αSynAgg Injection in Fyn+/+ and Fyn-/- Mice 
8-10 weeks old male Fyn+/+ and Fyn-/- mice used in these studies were bred in 
our animal facility. Fyn-/- mice were originally obtained from Dr. Dorit Ron’s laboratory 
at the University of California, San Francisco, and are available from Jackson 
Laboratory (stock number 002271). Mice were anesthetized as previously described 
and then injected with 4 μL of αSynAgg or vehicle. The coordinates indicating distance 
(mm) from bregma were: AP 0.7, ML 2 and DV 2.4. 
MitoPark Animal Study with Saracatinib 
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8-week-old MitoPark mice were gavaged with saracatinib (25 mg/kg) or vehicle 
(0.5% HPMC in 0.1% Polysorbate 80) every alternate day for 8 weeks. Mice were 
weighed weekly. Neurochemical, biochemical, and histological studies were 
performed following sacrifice at 20 weeks. 
MitoPark Animal Study with PAP-1 
All mice for this study were bred, maintained, genotyped, and further 
characterized at Iowa State University. C57BL/6J and MitoPark mice were fed ad 
libitum and housed under standard conditions approved and supervised by IACUC at 
ISU.  Fourteen-week-old mice (n=7-10/group) received either vehicle or 40 mg/kg/day 
PAP-1 for 30 days by i.p injection. Mice were weighed weekly and subjected to 
behavior tests biweekly. Neurochemical, biochemical, and histological studies were 
performed following sacrifice at 20 weeks. 
MPTP Animal Study with PAP-1 
Eight-week-old male C57BL/6NCrl mice (7 animals per group) were obtained 
from Charles River. From the in vitro data, we estimated 3-4 animals per group as 
sufficient to detect significant biochemical changes. All mice were pre-screened for 
normal baseline performance during behavioral assessments conducted before 
randomly assigning animals to experimental groups. All treatments were blinded and 
randomized. After acclimating for 3 days, mice were injected with 20 mg/kg daily for 5 
days. After 2 h post-MPTP injections, mice were injected daily with either PAP-1 (i.p) 
at 40 mg/kg or vehicle (Miglyol-812) with these treatments continuing for 1 week after 
the last MPTP injection, after which the mice were sacrificed. This paradigm of MPTP 




Immunoblot analyses were performed following our previously published 
studies (22, 30). Briefly, cells or tissues were homogenized and lysed using modified 
RIPA buffer. Proteins were normalized using Bradford assay before loading on an 
SDS-acrylamide gel. Ten to 40 μg of protein was loaded in each well of 10-18% 
acrylamide gels, which were ran at 110 V for 2-3 h at 4°C. Following separation, 
proteins were transferred on a nitrocellulose membrane at 27 V for 18 h at 4°C.  After 
transfer, the membranes were blocked with LI-COR (Lincoln, NE) blocking buffer for 
45 min and incubated in primary antibodies and secondary antibodies following 
manufacturer’s protocol. The primary antibodies included: anti-Kv1.3 (Alomone Labs, 
1:1000) (AB_2040151), Kv1.3 (Sigma 1:1000) (AB_2265087) phospho-p38 (Cell 
Signaling Technologies, 1:1000) (AB_331641), p38 (Cell Signaling Technologies, 
1:1000) (AB_330713), phospho-Kv1.3 (Sigma, 1:1000) (SAB4504254), and PKCδ 
(Santa Cruz, 1:500) (AB_628145) . The secondary antibodies included: IR-800 
conjugated goat anti-mouse IgG (LI-COR, 1:20000), IR-700 conjugated goat anti-
rabbit IgG (LI-COR 1:20000).  
qRT-PCR 
For RNA isolation, we followed previously published protocols (26, 31). Briefly, 
TriZol reagent was used to isolate total RNA from cells or tissues. NanoDrop was used 
to quantify RNA and 1 μg of RNA was converted to cDNA using the high capacity 
cDNA synthesis kit from Applied Biosystems (# 4368814, Foster City, CA). 
Quantitative SYBR green PCR assay was performed using qRT2PCR SYBR Green 
Master Mix (Agilent Technologies, Santa Clara, CA) using pre-validated primers. The 
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following validated primers from Qiagen (Germantown, MD) were used: pro-IL-1β 
(QT01048355), Nos2 (QT00100275), Mfn2 (QT00134295), CSF2 (QT00251286), IL-
6 (QT00098875), TNFα (QT00104006), mouse Kv1.3 (QT00257467), human Kv1.3 
(QT00211197), Kv1.1 (QT01537263), Kv1.5 (QT00268387), KCa3.1 (QT00105672), 
Fyn (QT00176666), and 18S (QT02448075). The primers for MRC1 and IRF4 were 
synthesized at ISU’s DNA facility. The fold change in gene expression was determined 
by ΔΔCt method where Ct is the threshold value. 18S was used as the housekeeping 
gene. 
 
Immunohistochemistry and Immunocytochemistry 
Immunohistochemistry (IHC) was performed on 30-μm mouse striatal and 
nigral sections as well as human nigral sections as described in our previous 
publications (32, 33). For antigen retrieval, 10 mM citrate buffer at pH 7.4 was used 
for animal samples, whereas citraconic anhydride was used for human samples. 
Following antigen retrieval, sections were washed with PBS, blocked with blocking 
buffer (2% BSA, 0.5% Triton-X100, and 0.05% Tween 20) and incubated in primary 
antibodies overnight at 4°C. Next, sections were washed with PBS, incubated in 
secondary antibodies for 1 h and stained with Hoechst nuclear dye. Finally, sections 
were mounted on pre-coated slides and dried overnight before visualizing them under 
microscope. Confocal imaging was performed on these sections at ISU’s Microscope 
Facility using a Leica DMEIR2 confocal microscope with 63X oil objective. For z-
stacking, each optical section consisted of 10-15, 0.5-μm thick slices.  
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For immunocytochemistry (ICC) on immortalized and primary microglia, 4% 
PFA was used to fix the cells. Next, fixed cells were washed with PBS, blocked using 
blocking buffer and incubated in primary antibodies following manufacturer’s protocol. 
Following overnight primary antibody incubation, cells were washed with PBS, 
incubated in secondary antibody for 75 min, and mounted on slides using Fluoromount 
aqueous mounting medium (Sigma, St. Louis, MO). Samples were visualized using 
an inverted fluorescence microscope (TE-2000U, Nikon, Tokyo, Japan). For DAB 
staining, we followed previously published protocols from our lab (22, 30, 34). The 
following primary antibodies were used: Iba1 (Wako, 1:1000) (AB_2314667), Iba1 
(abcam, 1:500) (AB_870576), Kv1.3 (Alomone Labs, 1:500) (AB_2040151), Kv1.3 
(Millipore, 1:500)( AB_11212692), phospho-Kv1.3 (Sigma 1:500) (SAB4504254), p38 
(Cell Signaling Technology, 1:500) (AB_330713), and tyrosine hydroxylase (TH) 
(Millipore, 1:1000) (AB_2201526). Alexa dye-conjugated secondary antibodies were 
used for both ICC and IHC.  
Flow Cytometry 
We plated 50,000 MMCs per well in 12-well cell culture plates. Cells were 
treated with 1 µg/mL LPS or 1 µM αSynAgg for 24 h. Following treatment, cells were 
doubled washed with HBSS, and blocked with 2% BSA in HBSS for 30 min at 37° C. 
After blocking, cells were incubated in the Kv1.3 antibody conjugated to FITC (1:1000, 
in 1% BSA in HBSS) (AB_2040147) for 1 h at 37° C. Following incubation, any 
unbound antibody was double washed with HBSS and the cells were scraped from 
the plate and suspended in 500 µL HBSS. A FACSCanto cell analyzer (BD 
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Biosciences, San Jose, CA) was used for flow cytometry analysis at ISU’s flow 
cytometry facility.   
DuoLink Proximal Ligation Assay (PLA) 
DuoLink PLA was performed according to previously published methods (35). 
Briefly, 10,000 primary microglial cells/well were plated on coverslips in 96-well cell 
culture plates. Cells were treated with 1 µM αSynAgg for 24 h, after which the cells were 
fixed with 4% PFA, blocked (2% BSA, 0.5% Triton-X100, 0.05% Tween20 in PBS), 
and incubated overnight in primary antibody. Following primary antibody incubation, 
Duolink In Situ Red Starter Kit (#DUO92101) was used according to manufacturer’s 
protocol. Mouse Fyn monoclonal antibody (Thermo-Fisher, 1:500) (AB_1074491) and 
rabbit Kv1.3 antibody (Alomone Labs, 1:500) (AB_2040151) were used as primary 
antibodies. Slides were imaged using a Leica DMEIR2 confocal microscope with 63X 
oil objective. For z-stacking, each optical section consisted of 10-15, 0.5-μm thick 
slices. 
Immunoprecipitation 
Immunoprecipitation was performed following our lab’s previously published 
protocol (22). Briefly, 5x106 microglial cells were homogenized using NP40 lysis 
buffer. Lysates were incubated overnight with Fyn antibody (Thermo-Fisher) 
(AB_1074491) and Kv1.3 antibody Kv1.3 (Alomone Labs) (AB_2040151) separately. 
Protein G-sepharose beads were used for pull down. The lysates were incubated with 
the protein G-sepharose beads and then washed 4 times before loading.  
Multiple Sequence Alignment 
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Kv1.3 sequences were downloaded from NCBI. T-Coffee was used for multiple 
sequence alignment of Kv1.3. 
Whole-cell Patch Clamp 
Primary microglia cultures were prepared as mixed glia cultures derived from 
P0 to P1 postnatal C57BL/6J wild-type, Fyn kinase KO, and PKCδ KO mice, as 
described in (35), and maintained in DMEM and 25 mM glucose supplemented with 
10% FBS, 1 mM Na+ pyruvate, 100 units/mL penicillin, and 100 μg/mL streptomycin. 
Cultures were maintained in a humidified, 5% CO2 incubator at 37° C.  Microglia were 
gently shaken off from their feeding astrocyte layer and harvested between 14 and 21 
days in culture and plated at 100,000 – 150,000 cells per well in 24-well plates for 8 
to 12 h before stimulation with either 300 ng/mL LPS or 1 μM αSynAgg in the presence 
or absence of 10 µM saracatinib.  After 40-48 h post-stimulation, microglial cells were 
detached by trypsinization, washed, attached to poly-L-lysine-coated glass coverslips, 
and then studied within 20 to 90 min after plating in the whole-cell mode of the patch-
clamp technique with an EPC-10 HEKA amplifier. B lymphocytes were thawed, plated, 
and maintained in a tissue culture incubator for 30 to 60 min before recording. All 
currents were recorded in normal Ringer’s solution containing (in mM): 160 NaCl, 4.5 
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES (adjusted to pH 7.4 and 290–310 mOsm).  Patch 
pipettes were pulled from soda lime glass (micro-hematocrit tubes, Kimble Chase, 
Rochester, NY) to resistances of 2-3 MΩ when submerged in the bath solution and 
filled with a KF-based Ca2+-free internal pipette solution containing (in mM): 145 KF, 
2 MgCl2, 10 HEPES, 10 EGTA (pH 7.2, 290–310 mOsm). K+ currents were elicited 
with voltage ramps from −120 to 40 mV of 200 ms duration applied every 10 s and 
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Kv1.3 current was identified as an outward rectifying current component at 
depolarized membrane potentials positive to -20 mV and sensitive to the selective 
inhibitor PAP-1.  Additionally, Kv1.3 currents were identified by their distinct use-
dependent C-type current inactivation induced by repeated stimulation to +40 mV at 
a frequency of 1 Hz. Cell capacitance, a direct measurement of cell surface area, and 
access resistance were continuously monitored during recordings. Kv1.3 current 
density is calculated as current amplitude divided by the cell capacitance measured 
for individual cells.  
LC/MS for PAP-1 detection 
Stock  and working standard solutions of PAP-1 were prepared in acetonitrile.. 
Spiked serum samples for a calibration curve were obtained by spiking 180 μL of drug-
free serum with PAP-1 solutions (final volume 200 μL) to yield a final concentration 
range of 5 nM to 5 μM and were used immediately. Commercial SPE cartridges 
(Hypersep C18, 100 mg, 1 mL) were purchased from Thermo Scientific (Houston, TX, 
U.S.A). Before the extraction, cartridges were conditioned with acetonitrile (2 × 1 mL), 
followed by water (2 × 1 mL). After loading the SPE cartridges with serum samples, 
they were washed successively with 1 mL each of 20% and 40% acetonitrile in water 
followed by elution with 2 mL of acetonitrile. Eluted fractions were collected and 
evaporated to dryness. The residues were reconstituted to solution with 200 μL 
acetonitrile and were used for LC-MS analysis.  
Brain samples were treated as follows: 4.0 mL of acetonitrile was added to 200 
mg of brain sample, which was homogenized thoroughly using a T25 digital ULTRA-
TURRAX homogenizer (IKA Works Inc., NC, USA). The homogenized samples were 
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centrifuged for 10 min at 4000 rpm, and then the supernatant was separated and 
evaporated under a constant air flow as described above. The residues were 
reconstituted in 200 μL acetonitrile. The reconstituted material was loaded onto the 
preconditioned SPE cartridges and then eluted with 2 mL of acetonitrile. Load and 
eluted fractions were collected and evaporated to dryness. The residues were 
reconstituted in solution with 200 μL acetonitrile and were used for LC/MS analysis. 
LC/MS analysis was performed with a Waters Acquity UPLC (Waters, NY, USA) 
equipped with an Acquity UPLC BEH 1.7μM C-18 column (Waters, New York, NY) 
interfaced to a TSQ Quantum Access Max mass spectrometer (MS) (Thermo Fisher 
Scientific, Waltham, MA, USA). The isocratic mobile phase consisted of 80% 
acetonitrile and 20% water, both containing 0.1% formic acid with a flow rate of 0.25 
mL/min. Under these conditions, PAP-1 had a retention time of 1.05 minute. 
Using heated electrospray ionization source (HESI II) in positive ion mode, capillary 
temperature 270° C, vaporizer temperature 350° C, spray voltage 3000 V, sheath gas 
pressure (N2) 30 units, PAP-1 was analyzed by the selective reaction monitoring 
(SRM) transition of its molecular ion peak 351.16 (M+1) into 107.19 m/z. A 10-point 
calibration curve ranging from 5 nM to 10 μM was developed for quantification. 
HPLC 
HPLC for neurotransmitters was performed following previously published 
methods (26). Briefly, the left striatum was weighed and lysed using an extraction 
solution (0.1 M perchloric acid containing 0.05% Na2EDTA and 0.1% Na2S2O5) and 
isoproterenol (internal standard). A C-18 reversed phase column isocratically 
separated dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
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(HVA) and norepinephrine (NE) using a Dionex Ultimate 3000 HPLC system (pump 
ISO-3100SD, Thermo Scientific, Bannockburn, IL), and a detector equipped with a 
CoulArray model 5600A coupled with an analytical cell (microdialysis cell 5014B) and 
a guard cell (model 5020) with potentials set at 350, 0, -150, and 220 mV. Chromeleon 




Multiplex cytokine assays 
Multiple cytokine assay was performed according to our previous publication 
(22). Briefly, 40 μL of treatment media was incubated overnight with 40 μL of primary 
antibodies conjugated with magnetic beads. Following incubation with primary 
antibodies, samples were washed, incubated with biotinylated antibody and with 
biotin/streptavidin, and then assayed on a Bio-Plex plate reader. Standards were 
obtained from Peprotech.  
Griess Assay 
Griess assay was performed as previously described in our publication (22). 
Briefly, after treatment, 50 μL of medium was incubated with 50 μL of Griess reagent 
for 10 min and a plate reader was used to read the absorbance at 540 nm. 
Statistical Analysis 
GraphPad 5.0 was used for statistical analysis with p≤0.05 considered 
statistically significant. One-way ANOVA was used for comparing multiple groups. In 
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most cases, Tukey post analysis was applied. Student’s t-test was used for comparing 
2 groups. 
Results 
Upregulation of Kv1.3 potassium channel expression upon αSynAgg stimulation 
in microglial cells in vitro  
Since αSynAgg contributes to chronic neuroinflammation by activating microglia 
(36), and since microglial Kv1.3 plays an important role in neuronal death and damage 
(20) and is also upregulated in AD brains (21), we characterized changes in Kv1.3 
levels in primary microglia treated with αSynAgg for 24 h. Whole-cell patch clamping 
revealed that the αSynAgg treatment increased functional Kv1.3 channel activity (Fig. 
1A). Our qRT-PCR analysis showed that αSynAgg specifically induced Kv1.3 mRNA 
expression without inducing other potassium channels such as KCa3.1, Kv1.1, or 
Kv1.5 (Fig. 1B). Likewise, Kv1.3 protein level also increased as revealed by Western 
blot analysis (Fig. 1C) and ICC (Fig. 1D). Next, we corroborated each of our primary 
microglia findings using MMCs by both qRT-PCR analysis (Supplementary Fig. 1A), 
ICC (Supplementary Fig. 1B) and Western blot analysis (Supplementary Fig. 1C). 
Moreover, whole-cell patch clamping revealed that LPS-induced Kv1.3 channel 
activity (Supplementary Fig. 1D) in primary microglial cells. Furthermore, flow 
cytometry analysis using a FITC-labelled Kv1.3 antibody against an extracellular 
epitope revealed that αSynAgg (Fig. 1E) induced surface expression of Kv1.3. After 
treating the MMCs with LPS (1 µg/mL) and IL-4 (20 ng/mL) for 6 h to induce classical 
and alternative activation, respectively, we observed LPS-induced Kv1.3 mRNA 
expression, while IL-4 did not alter Kv1.3 expression (Supplementary Fig. 1F), further 
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validating that this voltage-gated potassium channel is related to the classical, pro-
inflammatory activation of microglia which also corroborates previously published data 
(10). Flow cytometry also confirmed that LPS induces surface Kv1.3 expression in 
MMCs (Supplementary Fig. 1E). Following our in vitro studies of microglia cultures, 
we next adopted an ex vivo organotypic midbrain slice culture model, wherein qRT-
PCR found that a 24-h exposure to 1 µM of αSynAgg significantly induced expression 
of Kv1.3 mRNA (Fig. 1F) and the pro-inflammatory genes Nos2, CSF2, IL-6, IL-1β and 
TNFα (Supplementary Fig. 1G). The αSynAgg-induced Kv1.3 expression in the 
midbrain slice culture was also revealed by immunoblot analysis (Fig. 1G). Our series 
of in vitro models of synucleinopathy also included experiments on human-derived 
lymphocytes obtained from PD patients, which showed higher expression of Kv1.3 
when compared to lymphocytes from age-matched controls (Fig. 1H). Lastly, whole-
cell patch clamping revealed that lymphocytes from PD patients had higher Kv1.3 
channel activity than did lymphocytes from age-matched controls (Fig. 1I). 
Collectively, these findings demonstrate that inflammatory stimuli, such as LPS or 
αSynAgg, induce functionally relevant increases in microglial Kv1.3 protein and mRNA 
levels as indicated by enhanced channel activity in microglial cells. Taken together, 
these data suggest a possible role of Kv1.3 in PD pathogenesis and progression. 
Kv1.3 channel expression is highly induced in microglial cells in experimental 
in vivo models of PD and in postmortem human PD brains 
PD is a multifactorial disease and to date no in vivo model can reproduce all 
the symptoms of PD. Hence, to better understand the potential role of Kv1.3, we 
utilized multiple animal models of PD to recapitulate various clinical and pathological 
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aspects of the disease. One of the major pathological hallmarks in PD is protein 
aggregation, which can be recapitulated in the αSyn-AAV mouse model (37), wherein 
αSyn-AAV was stereotaxically injected into the striatum and the mice were sacrificed 
6 mo later (Supplementary Fig. 2A). Western blot analysis revealed a rapid induction 
of KV1.3 in this animal model of PD (Fig. 2A).  
To verify whether Kv1.3 channel expression is induced in a more gradually 
progressive PD model, we utilized the recently developed MitoPark transgenic mouse 
model. MitoPark mice were developed by inactivating the mitochondrial transcription 
factor A (TFAM) in dopaminergic neurons (28) to model the mitochondrial dysfunction 
exhibited by the progressively neurodegenerative Parkinsonian syndrome with its 
diverse spectrum of motor and nonmotor symptoms. In this model, progressive 
dopaminergic degeneration and PD-like motor deficits begin at around 12 weeks of 
age, and these motor deficits are accompanied by a progressive loss of striatal 
dopamine beginning at 20 weeks (28, 34, 38, 39). Herein, we show that Kv1.3 gene 
expression was highly induced in the SN of 16- and 24-week old MitoParks as 
compared to age-matched littermate controls (Fig. 2B). Our Western blot analysis 
further revealed that Kv1.3 was upregulated in 24-week-old MitoPark mice (Fig. 2C), 
and we confirm that this upregulation was localized to Iba-1-positive SN microglia (Fig. 
2D).  
Next, we adopted the well-characterized subacute MPTP paradigm where mice 
received 20 mg/kg MPTP daily for 4 consecutive days and were sacrificed on the 5th 
day (Supplementary Fig 2B). This subacute MPTP paradigm has been associated 
with significant CNS neuroinflammation and dopaminergic degeneration (33, 40-42). 
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In line with our in vitro results, MPTP significantly increased mRNA and protein 
expression of nigral Kv1.3 (Fig. 2E-2F).  
To further establish Kv1.3’s clinical relevance in the Parkinsonian syndrome, 
we assessed Kv1.3 channel expression in postmortem human brains from patients 
with PD and dementia with Lewy bodies. When comparing striatal brain sections, we 
observed Kv1.3 mRNA levels that were higher in postmortem human PD than in 
control brains (Fig. 2G). Western blot analysis of PD and age-matched controls further 
showed increased Kv1.3 levels in the substantia nigra (Fig. 2H). Immunostaining for 
Kv1.3 and Iba-1 further showed upregulated Kv1.3 immunoreactivity in the SN of PD 
brain sections that was localized to Iba-1-positive microglia (Fig. 2I). Histochemical 
analysis of DLB postmortem brains revealed significantly increased Kv1.3 expression 
in HLA-DR-positive microglial cells (Fig. 2J). Together, these findings demonstrate 
that microglial Kv1.3 is highly induced in both animal models and PD patients. 
Fyn modulates transcriptional regulation of Kv1.3 in microglial cells through the 
Fyn-PKCδ kinase signaling cascade 
After confirming the expression of Kv1.3 in various animal models and cell 
culture models of PD, we investigated the molecular mechanism behind the 
transcriptional upregulation of the Kv1.3 gene. Though a recent study demonstrated 
the epigenetic regulation of Kv1.3 (43), its transcriptional regulation is not well 
understood. Our in silico analysis of the Kv1.3 promoter revealed multiple NFκB and 
SP1 binding sites (Fig. 3A), and D'Addario et al. (44) showed that SP1 phosphorylation 
is dependent on the p38 MAPK pathway. Hence, we used the cell-permeable NFκB 
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inhibitor SN50 and the p38 MAPK inhibitor SB203580. Both inhibitors independently 
attenuated αSynAgg-induced Kv1.3 upregulation in the microglial cell line (Fig. 3B).  
We previously demonstrated that Fyn acts as a regulator of the NFκB 
transcription factor by regulating the nuclear translocation of p-65 (22). Fyn has also 
been shown to modulate LPS-induced activation of the p38 MAPK pathway. Our 
Western blot analysis of primary microglial cultures revealed that Fyn KO attenuated 
αSynAgg-induced p38 phosphorylation (Fig. 3C), further demonstrating the probable 
role of Fyn upstream of the p38 MAPK pathway.  Fyn KO in primary microglial cultures 
also attenuated αSynAgg-induced Kv1.3 expression as revealed by qRT-PCR (Fig 3D) 
and ICC (Fig. 3F) analyses. Our whole-cell patch clamp study on LPS-treated 
microglial cells revealed that Fyn KO microglia have lower Kv1.3 current density 
compared to wild-type (Fig. 3E). Next, we pharmacologically inhibited Fyn in αSynAgg-
microglial cells by co-treating them with Saracatinib (1 µM) for 6 h. 
Electrophysiological analysis revealed that Saracatinib reduced both LPS and 
αSynAgg-induced Kv1.3 channel activity, suggesting the probable role of Fyn in 
modulating Kv1.3 activity (Supplementary Fig. 3A). Western blot and qRT-PCR 
analyses revealed that Saracatinib reduced αSynAgg-induced p38 activation 
(Supplementary Fig. 3B), Kv1.3 expression (Supplementary Fig. 3E), as well as the 
pro-inflammatory gene Nos2 (Supplementary Fig. 3D) and the cytokines TNF-α and 
IL-1β (Supplementary Fig. 3F-G), without altering the mRNA expression of Fyn itself 
(Supplementary Fig. 3C). When we injected αSynAgg in Fyn WT and KO animals, IHC 
analysis revealed 6 mo post-injection that Fyn KO had attenuated αSynAgg-induced 
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Kv1.3 protein expression in the SN (Fig. 3G), further suggesting a probable role of 
Fyn kinase in modulating Kv1.3 upregulation.  
Our group recently showed that PKCδ, a serine/threonine kinase involved in 
microglial inflammation (30), is modulated by Fyn (22). In this study, we demonstrate 
that PKCδ is significantly induced in primary microglial culture (Supplementary Fig. 
4A), as well as in the previously described αSyn-AAV (Supplementary Fig. 4B) and 
MPTP (Supplementary Fig. 4C) mouse models of PD. In microglial cells, PKCδ KO 
attenuated the αSynAgg-induced production of the pro-inflammatory cytokines IL-1β, 
TNF-α, and IL-6 (Supplementary Fig. 4D-F), solidifying the role of this novel PKC 
kinase in inflammation.  To further validate the role of the Fyn-PKCδ proinflammatory 
cascade in mediating p38 MAPK pathway activation, we treated WT and PKC KO 
primary microglial cells with 1 µM αSynAgg for 5-30 min. PKCδ KO in primary microglial 
culture attenuated αSynAgg-induced p38 phosphorylation as revealed by Western blot 
(Fig. 3H), while ICC revealed reduced nuclear translocation of p65 (Supplementary 
Fig. 4G). Next, primary microglial cells were treated with 1 µM αSynAgg for 1 h, after 
which qRT-PCR (Fig 3I) and ICC (Supplementary Fig. 4H) revealed that PKCδ KO 
attenuated αSynAgg-induced Kv1.3 mRNA and protein expression. Moreover, whole-
cell patch clamp revealed that PKCδ KO reduced Kv1.3 current density in microglia 
treated with either αSynAgg (1µM) for 24 h or LPS (300 ng/mL) for 48 h (Fig. 3J). These 
findings collectively suggest that the Fyn-PKCδ kinase signaling cascade plays a 





Fyn modulates post-translational modification of Kv1.3 
Post-translational modification of Kv1.3 activities and other cellular functions 
have been attributed to phosphorylation of serine/threonine residues or tyrosine 
residues by various kinases, and de-phosphorylation by phosphatases (45-48). As 
part of its N-terminal and C terminal end, Kv1.3 has a proline-rich region, which can 
bind to the src-homology domain 3 (SH3) of src kinases. Our group has recently linked 
Fyn to the regulation of microglial inflammation (22), which prompted us to 
hypothesize that Fyn plays an important role in regulating the phosphorylation profile 
of Kv1.3 (49). Our multiple sequence alignment using T-Coffee (50) to align N-terminal 
of Kv1.3 sequences from seven different organisms demonstrated that Kv1.3 is highly 
conserved and that the tyrosine residue at 139 is conserved in all species 
(Supplementary Fig. 5A). Our in silico docking analysis revealed a probable interaction 
between Fyn and Kv1.3 (Fig. 4A). 
To further verify if Fyn directly interacts with Kv1.3, we performed co-
immunoprecipitation (IP). Primary microglial cells were treated with αSynAgg for 24 h 
following which Fyn and Kv1.3 were pulled down and probed for Kv1.3 and Fyn, 
respectively. Our immunoblot analysis revealed that following αSynAgg exposure Fyn 
interacted with Kv1.3 (Fig. 4B). We performed a proximal ligation assay using 
DuoLink, which further verified the interaction of Fyn with Kv1.3 (Fig. 4C). We also 
treated primary microglial from Fyn+/+ and Fyn-/- mice with αSynAgg and both our 
Western blot (Fig. 4D) and ICC (Supplementary Fig. 6A) analyses revealed that the 
αSynAgg-induced upregulation of phosphorylation of Kv1.3 at 139-residue is 
diminished in Fyn-/- microglia. Whole-cell patch clamp revealed that αSynAgg and LPS-
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treated Fyn-/- primary microglial cells exhibited reduced current amplitudes compared 
to Fyn+/+ (Fig. 4E). To confirm that these in vitro Fyn-Kv1.3 interactions also apply in 
vivo, we gavaged MitoPark mice with the Fyn inhibitor saracatinib daily from 8 to 16 
weeks of age. IHC analysis revealed that Fyn inhibition had increased pKv1.3 in the 
SN region of 16-week-old MitoPark mice, specifically by reducing the induction of 
pY139Kv1.3 (Fig. 4F). These data collectively suggest that Fyn modulates the 
phosphorylation of Kv1.3 at tyrosine residue 139 in PD models. 
To further evaluate the role of this phosphorylation at residue 139, we utilized 
site-directed mutagenesis. MMCs were transfected with a Kv1.3 plasmid where the 
tyrosine residue at 139 was mutated to alanine. Following transfection, cells were 
treated with 1 µM αSynAgg for 24 h. Western blot analysis revealed that the mutation 
attenuated the αSynAgg-induced upregulation of Kv1.3 phosphorylation 
(Supplementary Fig. 6B), while qPCR, Griess assay and Luminex analyses further 
revealed reduced αSynAgg-induced upregulation of Nos2 mRNA (Fig. 4G), nitrite 
release (Fig. 4H) and the pro-inflammatory cytokine IL-1β (Fig. 4I-J). Together, these 
results suggest that Fyn phosphorylates Kv1.3 at residue 139 and that Fyn-induced 
tyrosine phosphorylation plays a role in Kv1.3-mediated inflammation in PD models. 
Kv1.3 modulates neuroinflammation in a cell culture model of PD 
Given the potential role of Kv1.3 in modulating inflammation in various disease 
models including MS and AD (21, 51), we performed a series of Kv1.3 knockout and 
overexpression studies to demonstrate the role of Kv1.3 in αSynAgg-induced microglial 
activation. Primary microglial cells were isolated from Kv1.3 WT and KO animals, and 
treated with αSynAgg for 24 h. Luminex assays of the αSynAgg-treated WT and KO 
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media revealed that primary microglial cells from Kv1.3 KO mice secreted significantly 
less TNF-α (Fig. 5A), IL-12 (Fig. 5B) and IL-1β (Fig. 5C) compared to WT microglial 
cells. Next, we overexpressed Kv1.3 in MMCs, and treated with αSynAgg for 24 h. Our 
qRT-PCR analys s revealed that Kv1.3 overexpression (Supplementary Fig. 7) 
significantly increased αSynAgg-induced mRNA levels of Nos2 (Fig. 5D, pro-IL-1β (Fig. 
5E), and TNF-α (Fig. 5F). Multiplex assays further revealed that Kv1.3 overexpression 
significantly induced the secretion of IL-6 (Fig. 5G) and IL-12 (Fig. 5H). These data 
collectively suggest that Kv1.3 plays an important role in αSynAgg-induced microglial 
inflammation.  
The small molecule PAP-1 is a pharmacological inhibitor that specifically blocks 
Kv1.3 activity (52), and is known to reduce inflammation in various model systems (53, 
54). We co-treated primary murine microglia with αSynAgg. Patch clamping showed 
that PAP-1 blocked Kv1.3 currents in αSynAgg-stimulated microglia (Fig. 5I). An LDH 
assay revealed that PAP-1 blocked the αSynAgg-induced increased release of LDH 
into the extracellular space (Fig. 5J). PAP-1 also significantly reduced the αSynAgg-
induced pro-inflammatory cytokines IL-12 (Fig. 5K), TNF-α (Fig. 5L), and IL-6 (Fig. 
5M) as revealed by Luminex multiplex cytokine analysis. To further demonstrate the 
efficacy of PAP-1 in reducing microglial inflammation, MMCs were co-treated with 
PAP-1 (1 µM) and αSynAgg. The Griess assay showed that PAP-1 reduced αSynAgg-
induced nitrite release in these immortalized microglial cells (Supplementary Fig. 8A), 
while our qRT-PCR analysis revealed that PAP-1 reduced expression of the αSynAgg-
induced inflammatory genes Nos2 (Supplementary Fig. 8B), IL-6 (Supplementary Fig. 
8C), TNF-α (Supplementary Fig. 8D) and IL-1β (Supplementary Fig. 8E). However, 
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PAP-1 treatment did not induce the markers for alternative activation of microglia, 
IRF4 (Supplementary Fig. 8F) and MRC1 (Supplementary Fig. 8G). Luminex assays 
further demonstrated that PAP-1 can significantly attenuate αSynAgg-induced release 
of the pro-inflammatory cytokines IL-1β (Supplementary Fig. 8H), TNF-α 
(Supplementary Fig. 8I) and IL-6 (Supplementary Fig. 8J). Together, these findings 
suggest that the microglial channel Kv1.3 contributes to classical microglial activation, 
which can be attenuated by PAP-1, but Kv1.3 inhibition does not promote the 
alternative activation.  
PAP-1 reduced inflammation and neurodegeneration in mouse models of PD 
PAP-1 has been widely used in animal models of various diseases including 
psoriasis, obesity, and ischemic stroke (53) and its chronic administration is well 
tolerated in mice, rats, adn primates (17). To validate the therapeutic potential of PAP-
1 in Parkinsonian syndrome, we utilized the transgenic MitoPark and the toxin-based 
MPTP mouse models of PD.  
MitoPark mice were injected daily with 40 mg/kg PAP-1 from 14 to 20 weeks of 
age (Supplementary Fig. 9A). During treatment, no significant weight loss was 
observed (Supplementary Fig. 9B). Furthermore, blood chemistry revealed no 
significant changes between PAP-1- and vehicle-treated MitoPark groups or between 
MitoPark and littermate control groups (Supplementary Fig. 9C). To verify the 
bioavailability and brain penetrance of PAP-1, LC-MS analysiss was performed on 
serum and brain samples taken at the end of the study, revealing that treated animals 
had average total plasma concentrations of 322±122 and brain concentrations of 
848±295 at 24 hours after the last administration (Fig. 6A). No PAP-1 was detectable 
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in the plasma and brain of vehicle treated animals. Behavioral tests revealed that PAP-
1 significantly reduced motor deficits in MitoPark mice. As evident from the VersaPlot 
(Fig. 6B), PAP-1 treatment significantly increased horizontal activity in the open-field 
test (Fig. 6C). PAP-1 also significantly increased the time spent on the rotarod by 
MitoPark mice (Fig. 6D). Biochemical analysis of the striatum revealed that PAP-1 
reduced the loss of the neurotransmitter dopamine (Fig. 6E) and its derivatives 
DOPAC (Fig. 6F) and homovanillic acid (HVA) (Fig. 6G) in MitoPark mice, however, 
no significant changes in norepinephrine (Fig. 6H) were observed. 
Next, we evaluated the efficacy of PAP-1 in protecting against MPTP-induced 
neuronal loss and inflammation (Supplementary Fig. 10A). IHC analysis further 
demonstrated that PAP-1 reduced MPTP-induced microgliosis in both the striatum 
and SN (Fig. 6I). Skeletonization analysis revealed that PAP-1 reduced microglial 
soma size and increased the number of branches compared to MPTP alone (Fig. 6J). 
Increased microglial soma size and decreased branch number are indicative of 
classical activation of microglia. Moreover, qRT-PCR analysis revealed that Kv1.3 
inhibition reduced the MPTP-induced expression of the pro-inflammatory cytokines 
TNF-α and pro-IL-1β (Fig. 6K). Biochemical analysis revealed that PAP-1 significantly 
increased the amount of dopamine (Supplementary Fig. 10E) and its metabolites 
DOPAC (Supplementary Fig. 10C) and HVA (Supplementary Fig. 10D) as compared 
to MPTP alone. TH neuronal staining further demonstrated that PAP-1 protected 
against MPTP-induced TH loss in the SN (Fig. 6L). Stereology analysis revealed that 
pharmacological inhibition of Kv1.3 protected against the MPTP-induced loss of TH-
positive neurons (Fig. 6M). Collectively, these pre-clinical studies suggest that PAP-1 
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can reduce microgliosis, inflammation, and neuronal loss in PD models and that 
inhibition of Kv1.3 by a brain penetrant small molecule has clinical potential for PD 
treatment.  
Discussion 
Although neuroinflammation is one of the key pathophysiological hallmarks of 
neurodegenerative disorders, including PD, the molecular mechanisms and the key 
regulators of this chronic, sustained inflammation are not well understood (4). 
Recently, various anti-inflammatory drugs targeting cellular pathways modulating 
inflammation have gained importance in clinical and preclinical trials in AD and PD 
(23, 55). In the present study, we demonstrate for the first time that the microglial 
voltage-gated potassium channel KV1.3 is upregulated in Parkinsonian syndrome. We 
showed previously that exposure to an inflammagen activates the SFK kinase Fyn, 
which regulates the p38 MAPK and the NFκB pathways in microglial cells (22) and 
that Fyn phosphorylates PKCδ, a novel PKC isoform that also regulates the microglial 
NfκB pathway (30). In this study, we reveal that both the p38 MAPK and the classical 
NfκB pathways mediate the transcriptional regulation of Kv1.3. Furthermore, we 
identify the Fyn-PKCδ inflammatory pathway as one of the key regulators of Kv1.3 
transcription. We demonstrate that the phosphorylation profile of Kv1.3 can be 
modulated by αSynAgg and that Fyn kinase plays an important role in this αSynAgg-
induced Kv1.3 phosphorylation. Finally, we show that PAP-1, a brain penetrant small 
molecule Kv1.3 inhibitor, can reduce neuroinflammation and neurodegeneration in 
multiple animal models of PD.   
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The role of microglia in mediating neurodegeneration in PD was first identified 
in 1988 (56), and neuroinflammation has since then been an active area of PD 
research. Although the exact molecular mechanism of this sustained inflammation 
remains equivocal, meta-analyses have revealed that non-steroidal anti-inflammatory 
drugs (NSAIDs) can protecting against neurodegenerative disorders (57). Recent 
studies have shown that αSynAgg, a major component of Lewy bodies and neurites, 
can be transferred from cell-to-cell in a prion-like manner, leading to the spread of 
disease pathology (58). Although αSynAgg can induce inflammation in cell culture and 
animal models of PD, the downstream signaling mechanism is not well understood 
(30). In this study, we show that microglial Kv1.3 is upregulated in response to 
αSynAgg. This induction of Kv1.3 is seen in multiple in vivo models of PD, recapitulating 
various key hallmarks of PD. Moreover, Kv1.3 is also upregulated in Parkinsonian 
syndrome patients (PD and DLB). 
Ion channels play an important role in the immune system by regulating 
membrane potential and calcium signaling. The potassium channels Kv1.3 in 
particular is widely regarded as promising target for immunosuppression (59) and has 
been demonstrated to constitute a valid target for treating T cell mediated autoimmune 
diseases in animal models of multiple sclerosis, autoimmune diabetes, rheumatoid 
arthritis, and psoriasis (54). Kv1.3 blockers have also been shown rescue 
neurogenesis by inhibiting gramizydine granzyme B releasing CD8+ T cells (60). In 
microglial cells, the resident immune cells of the brain, Fordyce et al. (20) 
demonstrated in 2005 that Kv1.3 is involved in microglia mediated neuronal killing, 
while others (61) have implicated Kv1.3 in HIV-induced microglial neurotoxicity. More 
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recently, two studies, including us, have shown that increased Kv1.3 expression in 
microglia is associated with classical “M1-like” activation (10)  and that Kv1.3 is 
involved in modulating microglia-induced inflammation, phagocytosis and antigen 
presentation (62). In humans, increased microglial Kv1.3 expression has further been 
demonstrated in postmortem AD and stroke brains, while the Kv1.3 blocker PAP-1 
has been found to reduce neuroinflammation and improve cognition or neurological 
deficit in rodent models of Alzheimers disease and ischemic stroke (63).  Interestingly, 
Kv1.3-mediated current has been reported to be reduced in striatal cholinergic 
neurons (64) in PD mouse model, similar to the finding that ion channel activity 
decreases in dopaminergic neurons in PD animal models (65). However, it is not clear 
how this observation relates to our proof-of-concept animal studies reported here that 
demonstrate that Kv1.3 inhibition with PAP-1 protects from neuronal loss and 
inflammation in PD models and which further support an important role for Kv1.3 in 
neuroinflammation.  
Research on the transcriptional regulation of Kv1.3 has been limited. Recent 
Kv1.3 studies have implicated the enzyme cereblon in its epigenetic regulation (43), 
its age-dependent methylation in colorectal cancer patients (66), and DNA methylation 
of its promoter in breast cancer (67). Also, p38 MAPK in microglia has been shown to 
modulate Kv1.3 expression in HIV-glycoprotein 120-induced neurotoxicity (61). In this 
study, we identified the NfκB and p38 MAPK pathways as contributing to the αSynAgg-
induced transcriptional upregulation of Kv1.3. Our group showed previously that Fyn 
is induced in cell culture and animal models of PD, and is important in modulating 
microglial inflammation by mediating the NfκB and p38 MAPK pathways (22). We also 
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showed that Fyn is upstream of the pro-apoptotic and pro-inflammatory kinase PKCδ 
(22, 30). Fyn also has a role in regulating inflammation in AD, wherein inhibiting Fyn 
kinase with saracatinib protects against neurodegeneration in rodent models of AD 
(23). We report here that Fyn and PKCδ regulate Kv1.3 transcription by regulating 
NfκB and p38 MAPK signaling. We significantly reduced Kv1.3 expression as well as 
its transcriptional upregulation by pharmacologically inhibiting Fyn. Our results 
collectively show that the Fyn-PKCδ inflammatory signaling cascade modulates Kv1.3 
transcriptional upregulation.  
Post-translational modification of potassium channels, leading to modulation of 
channel activity, has been actively researched. Kv1.3 has multiple phosphorylation 
sites, including both tyrosine and serine/threonine (45, 46). Jimenez-Perez et al. (68) 
implicated Kv1.3’s tyrosine phosphorylation sites in modulating proliferation. Holmes 
et al. (45) demonstrated that endogenous kinases and phosphates continuously 
phosphorylate and dephosphorylate Kv1.3 and any change in this dynamic 
phosphorylation/ dephosphorylation can drastically alter Kv1.3 activity. Various 
tyrosine kinase proteins, including v-Src, are known to phosphorylate Kv1.3, and 
different adaptor proteins, including Grb10, modulate this phosphorylation of Kv1.3, 
thereby differentially regulating its activity (19, 48). We show here that Fyn, a non-
receptor tyrosine kinase, can phosphorylate Kv1.3, thereby modulating its function.   
Collectively, we demonstrate that Kv1.3 is upregulated in Parkinsonian 
syndrome models. This upregulation is controlled by the Fyn-PKCδ kinase signaling 
cascade through the NFκB and p38 MAPK pathways. Fyn can further phosphorylate 
Kv1.3, which modulates Kv1.3 channel activity. Kv1.3 upregulation in PD models plays 
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a major role in neuroinflammation-mediated neurodegeneration. These findings 
further demonstrate a probable Kv1.3-mediated signaling cascade (Supplementary 
Fig. 11) that can modulate microglial inflammation in a Parkinsonian syndrome. The 
diverse roles of Kv1.3 emerging from our findings together with other studies have 
potential therapeutic implications. 
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Fig. 1: Upregulated expression of the potassium channel Kv1.3 upon 
aggregated αSyn stimulation in microglial cells in vitro. A) Whole-cell patch 
clamping of primary microglial cells treated with 1 µM αSynAgg for 24-48 h showing 
αSynAgg-induced increased Kv1.3 activity. Voltage-ramp from -120 mV to 40 mV 
elicited characteristic outward rectifying current in αSynAgg-treated microglia. B) qRT-
PCR showing that αSynAgg induced Kv1.3 mRNA expression without significantly 
altering other potassium channels. C) Western blot of αSynAgg-induced Kv1.3 protein 
expression in primary microglial cells. D) ICC of αSynAgg-induced Kv1.3 protein 
expression in primary microglial cells. E) Flow cytometry of MMC treated with 1 µM 
αSynAgg for 24 h showing αSynAgg-induced Kv1.3 surface expression. F-G) Midbrain 
slice cultures were treated with 1 µM αSynAgg for 24 h. F) qRT-PCR showing 
upregulated Kv1.3 mRNA. G) Western blot showing upregulated Kv1.3 protein. H) 
qRT-PCR showing increased Kv1.3 mRNA expression in B cell lymphocytes isolated 
from PD patients compared to age-matched controls. I) Whole-cell patch clamping of 
B cell lymphocytes isolated from PD patients showing higher Kv1.3 channel activity 
compared to age-matched control. Data represented as mean±SEM with 3-4 







Fig. 2: Kv1.3 expression is highly induced in microglial cells in experimental 
models of PD and postmortem PD brains. A) Western blot showing increased Kv1.3 
protein level in substantia nigra of Syn-AAV mouse model of PD. B) qRT-PCR of 8- to 
24-week-old nigral tissues from MitoPark mouse model of PD showing Kv1.3 
induction. C)  Western blot of 24-week-old nigral tissues from MitoPark mouse model 
of PD showing induction of Kv1.3 protein expression compared to age-matched 
controls. D) IHC of 24-week-old nigral tissues from MitoPark mouse model of PD 
showing higher Kv1.3 protein level in IBA1-positive microglial cells compared to age-
matched controls. E) qRT-PCR of nigral tissues from MPTP mouse model revealing 
induction of Kv1.3 mRNA expression. F) Western blot showing increased Kv1.3 
protein level in substantia nigra of MPTP mouse model of PD. G) qRT-PCR of post-
mortem PD brains showing elevated Kv1.3 mRNA. H)  Western blot of post-mortem 
PD patients showing induction of Kv1.3 protein expression compared to age-matched 
controls. n=6-8. I) Dual immunostaining revealing higher Kv1.3 level in microglial cells 
in post-mortem PD brains compared to age matched controls. J) Dual DAB-staining 
showing induction of Kv1.3 expression in HLA-DR-positive microglial cells in DLB 
patients compared to age-matched controls. Data represented as mean±SEM with 3-







Fig. 3: Fyn modulates transcriptional regulation of Kv1.3 in microglial cells 
through the Fyn-PKCδ kinase signaling cascade. A) In-silico analysis of promoter 
sequence of Kv1.3 revealing probable site of NfκB and SP1 binding sites. B) qRT-
PCR of MMC co-treated with αSynAgg and either SN50 or SB203580 showing that both 
SN50 and SB203580 attenuated αSynAgg-induced Kv1.3 expression. C) Western blot 
of Fyn WT and KO primary microglial cells treated with αSynAgg showing that Fyn KO 
reduced induction of the p38 MAPK pathway. D) qRT-PCR revealing that Fyn KO 
reduced αSynAgg-induced Kv1.3 mRNA level. E) Whole-cell patch-clamp showing that 
Fyn KO attenuated αSynAgg- and LPS-induced Kv1.3 activity compared to Fyn WT 
microglial cells. F) ICC showing Fyn KO reduced αSynAgg-induced Kv1.3 protein levels 
in primary microglial cells. G) IHC of substantia nigra 6 mo post-αSynPFF injection 
showing Fyn KO mice with reduced induction of Kv1.3 protein. H) Western blot of 
primary microglial cells treated with αSynAgg showing that PKC KO reduced induction 
of the p38 MAPK pathway. I) qRT-PCR of microglial cells showing that PKC KO 
reduced expression of αSynAgg-induced Kv1.3 mRNA. J) Whole-cell patch-clamping 
of microglial cells showing that PKC KO attenuated αSynAgg- and LPS-induced Kv1.3 
activity compared to PKC WT microglial cells. Data represented as mean±SEM with 







Fig. 4: Fyn modulates post translational modification of Kv1.3. A) In silico docking 
analysis of Kv1.3 and SH domain of Fyn. B) Immunoprecipitation of Fyn and Kv1.3 
showing direct Fyn-Kv1.3 interaction post-αSynAgg treatment. C) Duolink proximal 
ligation assay showing αSynAgg-induced interaction between Kv1.3 and Fyn. D)  
Western blot of Fyn WT and KO primary microglia reveals that Kv1.3 phosphorylation 
at residue 139 is Fyn-dependent. E) Whole-cell patch clamping of LPS- or SynAgg-
treated microglia showing that Fyn KO lowered the amplitude of Kv1.3 currents 
compared to Fyn WT microglial cells. F) IHC of substantia nigra from MitoPark mice 
and their littermate controls showing that pharmacological inhibition of Fyn by 
saracatinib reduced Kv1.3 phosphorylation. G-J) MMC were either transfected with 
WT or Y130A Kv1.3 plasmid. G) qRT-PCR and H) Griess assay showing reduced 
levels of iNOS and Nitrite release, respectively, in Y139A Kv1.3 transfected cells 
compared to WT. I) qRT-PCR showing reduced IL-1β production in Y139A Kv1.3-
transfected versus WT Kv1.3-transfected MMCs. J) Luminex assay showing reduced 
IL-1β secretion in Y139A Kv1.3-transfected compared to WT Kv1.3-transfected 
MMCs. Data represented as mean±SEM with 3-4 biological replicates from 2-3 




Fig. 5: Kv1.3 modulates neuroinflammation in cell culture model of PD. A-C) 
Kv1.3 WT and KO primary microglial cells were treated with 1 µM αSynAgg for 24 h. 
Luminex analysis showing that Kv1.3 KO reduced release of the αSynAgg-induced pro-
inflammatory factors A) TNFα, B) IL-12, and C) IL-1β. D-H) MMCs were transfected 
with WT Kv1.3 plasmid, and then 48-h post-transfection, cells were treated with 1 µM 
αSynAgg for 24 h. D-F) qRT-PCR showing that Kv1.3 overexpression aggravated 
αSynAgg-induced production of the pro-inflammatory factors D) Nos2, E) pro-IL-1β, and 
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F) TNFα. G-H) Luminex analysis showing Kv1.3 overexpression potentiated release 
of the pro-inflammatory factors G) IL-6, and H) IL-12. I) Voltage-ramp from -120 mV 
to 40 mV elicited characteristic outward rectifying current in αSynAgg-treated microglia 
that was sensitive to the Kv1.3-selective inhibitor PAP-1 and displayed voltage-
dependent activation by voltage-steps from -80 mV to 60 mV. J) LDH assay showing 
PAP-1 reduced αSynAgg-induced LDH release from microglial cells. K-M) Luminex 
assay revealing that PAP-1 attenuated the αSynAgg-induced proinflammatory factors 
K) IL-6, L) TNFα, and M) IL-12. Data represented as mean±SEM with 3-4 biological 




Fig. 6: PAP-1 reduced inflammation and neurodegeneration in mouse models of 
PD. A-H) MitoPark Mouse Model. A) LC-MS of Serum and Brian concentration of PAP-
1 in MitoPark mice 6 weeks post-injection. B) Representative VersaPlots showing 
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PAP-1 rescued movement deficits of MitoPark mice at 20 weeks. C) VersaMax open-
field test showing increased horizontal activity of MitoParks treated with PAP-1 
compared to vehicle group. D) Rotarod behavior test revealing increased time spent 
on the rotarod by MitoParks treated with PAP-1 compared to vehicle group. E-H) 
HPLC showing that PAP-1 treatment protected MitoPark mice from loss of E) 
Dopamine, F) DOPAC, and G) HVA, but did not alter H) Norepinephrine levels. I-M) 
MPTP mouse model. I) IHC of MPTP-exposed substantia nigra and striatum showing 
that PAP-1 altered microgliosis. J) ImageJ analysis of MPTP-exposed substantia nigra 
showing PAP-1 reduced soma size and increased the number of microglial branches. 
K) qRT-PCR of striatum post-MPTP showing reduced proinflammatory factors IL-1β 
and TNFα. L) IHC of SNpc showing that PAP-1 protected against MPTP-induced loss 
of TH-positive neurons. M) Stereology analysis of the SNpc showing that PAP-1 
decreased the loss of TH-positive neurons post-MPTP treatment. Data represented 





Supplementary Fig. 1: Kv1.3 is upregulated in microglia inflammatory models. 
MMCs were treated with 1 µM αSynAgg for 24-48 h. A) qRT-PCR revealing αSynAgg-
induced Kv1.3 mRNA expression. B) ICC of primary microglial cells revealing αSynAgg-
induced Kv1.3 protein expression. C) Western blot of primary microglial cells showing 
αSynAgg-induced Kv1.3 protein expression. D)  Whole-cell patch clamping of primary 
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microglial cells showing LPS-induced Kv1.3 activity. E) Flow cytometry of MMCs 
treated with 1 µg/mL LPS for 24 h revealing LPS-induced surface expression of Kv1.3 
protein. F) qRT PCR of MMCs treated with LPS (1 µg/mL) and IL-4 (20 ng/mL) for 6 h 
showing LPS-induced Kv1.3 expression.  G) qRT-PCR of midbrain slice culture 
treated with 1 µM αSynAgg for 24 h revealing upregulation of the pro-inflammatory 
factors Nos2, CSF-2, IL-6, IL-1β and TNFα. Data represented as mean±SEM with 3-








Supplementary Fig. 2: Animal treatment paradigm corresponding to Fig. 2.  A) 
Treatment paradigm corresponding to Syn-AAV mouse model of PD in Fig. 2A. B) 




Supplementary Fig. 3: Pharmacological inhibition of Fyn reduces αSynAgg-
induced Kv1.3 expression. A) Whole cell patch clamping of primary microglial cells 
showing that saracatinib attenuated the αSynAgg- and LPS-induced Kv1.3 activity. B) 
Western blot showing saracatinib-reduced induction of the p38 MAPK pathway post-
αSynAgg treatment. C-E) qRT-PCR showing that saracatinib did not alter C) Fyn mRNA 
but attenuated the αSynAgg-induced pro-inflammatory factor D) Nos2 and E) Kv1.3 
expression. F-G) Luminex analysis showing that saracatinib treatment attenuated 
production of the pro-inflammatory factors F) TNFα and G) IL-1β post-αSynAgg 
treatment. Data represented as mean±SEM with 3-4 biological replicates from 2-3 




Supplementary Fig. 4: PKCδ is upregulated in cell culture and animal models of 
PD and regulates inflammation. A) Western blot showing increased PKC-δ protein 
expression 24 h post-αSynAgg treatment in primary mouse microglial cells. B) Western 
blot showing increased PKCδ protein level in striatum of αSyn AAV-injected mice. C) 
Western blot showing increased PKCδ protein level in MPTP mouse model of PD. D-
F) Luminex analysis of αSynAgg-treated primary microglial cells showing that PKCδ 
KO attenuated production of the pro-inflammatory factors D) IL-1β, E) TNFα, and F) 
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IL-6. G) ICC of primary microglial cells revealing that αSynAgg-induced p65 nuclear 
translocation is reduced by PKCδ KO.  H) ICC of primary microglial cells revealing that 
αSynAgg-induced Kv1.3 protein expression is reduced by PKCδ KO. Data represented 





Supplementary Fig. 5: Multiple Sequence Alignment of Kv1.3. Multiple sequence 
alignment of N-terminal of Kv1.3 protein sequence from multiple organisms using T-




Supplementary Fig. 6: Fyn modifies Kv1.3 post-translationally. A) ICC of αSynAgg-
treated Fyn WT and KO microglia showing that Fyn KO reduced Kv1.3 
phosphorylation. B) Western blot revealing that αSynAgg induced Kv1.3 
phosphorylation in MMCs transfected with WT Kv1.3 but not in MMCs transfected with 






Supplementary Fig. 7: Overexpression of Kv1.3 in MMC. Western Blot showing 





Supplementary Fig. 8: PAP-1 reduces inflammation in MMC. A) Griess assay 
showing PAP-1 reduced αSynAgg-induced release of nitrites from MMC. B-G) qRT-
PCR revealing PAP-1 reduced the αSynAgg-induced proinflammatory factors B) Nos2, 
C) IL-6, D) TNFα, and E) IL-1β, but did not significantly alter the markers of alternative 
microglial activation of F) IRF4, and G) MRC1. H-J) Luminex assay revealing that 
PAP-1 attenuated the αSynAgg-induced proinflammatory factors H) IL-1β, I) TNFα, and 
J) IL-6. Data represented as mean±SEM with 3-4 biological replicates from 2-3 






Supplementary Fig. 9: PAP-1 does not alter blood chemistry in MitoPark 
mouse model of PD.  A) Treatment paradigm corresponding to MitoPark mouse 
model of PD in Fig. 6A-H. B) Stable body weight throughout the course of treatment. 
C-D) Whole blood analysis showing unchanging blood chemistry between C) 
littermate control and MitoPark mice or between D) vehicle and PAP-1 treatment 





Supplementary Fig. 10: PAP-1 reduces neurotransmitter loss in MPTP model of 
PD. A) Treatment paradigm corresponding to MPTP mouse model of PD in Fig. 6I-M. 
B) LC-MS of amount of PAP-1 detected in brains post-sacrifice. C-E) HPLC of striatum 
showing that PAP-1 reduced the MPTP-induced loss of C) DOPAC, D) HVA, and E) 




Supplementary Fig. 11: Working Hypothesis. Kv1.3 modulates microglial 
inflammation, leading to neurodegeneration in PD models, and is regulated by Fyn 





 CHAPTER V 
GENERAL CONCLUSION AND FUTURE DIRECTIONS 
This section presents a general overview of the results and findings described 
in the thesis, with a special emphasis on future directions and overall implications of 
these findings for the pathogenesis and progression of Parkinson’s disease.  The 
major findings pertaining to each research manuscript and their specific implications 
are covered in the ‘results and discussion’ sections of the relevant chapter. 
 
Pesticide exposure leads to NLRP3 inflammasome activation in microglial cells 
in vitro and in vivo.  
The primary finding from Chapter 2 of the thesis is that rotenone and 
tebufenpyrad, pesticides inhibiting mitochondrial complex 1, exposure leads to 
activation of NLRP3 inflammasome pathway in microglial cells. Further we showed, 
that NLRP3 activation is related to mitochondrial superoxide generation and lysosomal 
dysfunction. NLRP3 is recruited to the mitochondria post activation. Moreover, 
conditioned medium from glial cells post NLRP3 activation induced TH neuronal loss 
and inhibition of NLRP3 inflammasome reduced the neuronal loss in culture (Sarkar 
et al., 2017). Although we have demonstrated conclusively that mitochondrial 
dysfunction is important for NLRP3 inflammasome activation in glial cells future 
studies will identify key molecular pathways which are involved in the glial 
mitochondrial dynamics. Mitochondrial fusion and fission play an important role in 
regulating mitochondrial dynamics. Recent studies, have shown that Mfn2 
degradation may lead to mitochondrial dysfunction (Tang et al., 2015). Moreover, 
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mitochondria associated adaptor molecule MAVS, have been implicated in 
recruitment of NLRP3 to the mitochondria during activation (Subramanian et al., 
2013). We will generate CRISPR- Cas9 KD cells for these targets and study the role 
of these molecules in the recruitment of NLRP3 to mitochondria, and NLRP3 activation 
in glia.  
Manganese leads to NLRP3 inflammasome activation in glial cells 
In Chapter 3, we also showed that manganese induces mitochondrial 
dysfunction leading to NLRP3 inflammasome activation. We further show that 
manganese leads to downregulation of retromer protein VPS35 which leads to 
mitochondrial dysfunction by regulation of Mfn2. But it was not clear how manganese 
reduced the expression of VPS35 or other retromer complex protein VPS29.  It is 
known that manganese can bind VPS29 (Swarbrick et al., 2011). Further, in retromer 
complex VPS35 wraps around the metal binding site of VPS29 (Hierro et al., 2007). 
We intend to build upon these studies. We will use recombinant proteins and in vitro 
cell free studies to show that excessive metal binding to VPS29 may lead to collapse 
of the retromer complex hence leading to downregulation of the retromer proteins. We 
will also study the promoter sequence of VPS35 to understand the probable role of 
metals in regulating the transcription of VPS35 
 
Manganese plays a role in exosomal release ASC and propagation of NLRP3 
inflammasome   
Chapter 3 further demonstrates that manganese not only contributes to the 
activation of inflammasome but also propagates inflammasome by exosomal release 
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of ASC from microglia. Though we conclusively showed that manganese promotes 
exosomal release of ASC, we have not yet studied the mechanism of exosome 
release from glial cells. Various Rab proteins including Rab27 and Rab11 have been 
implicated in various steps of exosome biogenesis (Chen et al., 2017; Ostrowski et 
al., 2010). We will conduct studies looking into the probable role of Rab proteins in 
regulating manganese induced exosomal release of ASC. 
Together, the first two research chapter demonstrated the role of environmental 
factors regulating inflammasome activation and regulating neuroinflammation in PD 
models (Refer to Fig 3 Page 51).  
Kv1.3 plays a role in regulating neuroinflammation and neurodegeneration in 
PD 
In Chapter 4, we utilized various in vivo and in vitro models of PD, as well as 
post mortem PD brains to conclusively show that Kv1.3, a voltage gated potassium 
channel is upregulated in microglial cells. Further, we showed in multiple animal 
models as well as cell culture models of PD that PAP-1, a small molecule inhibitor of 
Kv1.3, reduced neuroinflammation and neurodegeneration. Though we conclusively 
showed that Kv1.3 inhibition reduced neuroinflammation, the mechanism is still not 
clearly understood. We will perform whole cell and post translational proteome 
analysis to identify key Kv1.3 dependent microglial functions and validate them. Kv1.3 
have been implicated in clearing of amyloid β plaques (Maezawa et al., 2017). Hence, 
to verify the role of Kv1.3 in synuclein uptake and clearance by glial cells we will 
perform RT-QUIC assay from Kv1.3 WT and KO microglia treated with αSynAgg. 
Further, to verify the role of Kv1.3 in aggregation of synuclein in vivo, we will generate 
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double transgenic mice by crossing A53T mouse with Kv1.3 KO mice to generate 
A53T Kv1.3 KO mice and characterize the mouse model.      
Fyn, a src family kinase, transcriptionally and post-translationally modulated 
Kv1.3  
 In Chapter 4, we further showed that Kv1.3 is regulated transcriptionally by 
Fyn-PKCδ signaling pathway by regulating p38 and NFκb. Further, we have 
demonstrated that Fyn directly phosphorylate Kv1.3 modulating its channel activity. 
To further understand other key players in regulating Kv1.3 activity, we will perform 
immunoprecipitation studies and then perform mass spectrometry analysis to identify 
novel Kv1.3 binding partners. We will also mutate other probable phosphorylation 
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Here, we present a protocol to isolate microglia from postnatal mouse pups 
(day 1) for in vitro experimentation. This improvised method of isolation generates 
both high yield and purity, a significant advantage over alternate methods that allows 
broad range experimentation for the purposes of elucidating microglial biology. 
 
LONG ABSTRACT 
Microglia are the primary responders to central nervous system  insults; 
however, much remains unknown about their role in regulating neuroinflammation. 
Microglia are mesodermal cells that function similarly to macrophages in surveying 
inflammatory stress. The classical (M1-type) and alternative (M2-type) activations of 
macrophages have also been extended to microglia in an effort to better understand 
the underlying interplay these phenotypes have in neuroinflammatory conditions such 
as Parkinson’s, Alzheimer’s, and Huntington’s diseases. In vitro experimentation 
utilizing primary microglia offers rapid and reliable results that may be extended to the 
in vivo environment. Although this is a clear advantage over in vivo experimentation, 
isolating microglia while achieving adequate yields of optimal purity has been a 
challenge. Common methods currently in use either suffer from low recovery, low 
purity, or both. Herein, we demonstrate a refinement of the column-free CD11b 
magnetic separation method that achieves a high cell recovery and enhanced purity 
in half the amount of time. We propose this optimized method as a highly useful model 
285 
 





Microglia are Myb-independent resident macrophages of mesodermal origin, 
which differentiate from c-kit+/CD45- erythromyeloid progenitors in the blood islands 
of the yolk sac1,2. Once embryological microglia have colonized the central nervous 
system (CNS), they transition from an amoeboid to a ramified form3. These adult 
microglia are classified as surveillant since their dynamic ramifications probe the 
healthy brain parenchyma for potential insults4. Although microglia only contribute to 
approximately 10% of the CNS cell population, their ability to tile amongst each other 
ensures maximal scanning of the parenchyma4,5. Danger-associated molecular 
patterns (DAMPs), such as α-synuclein6,7 and amyloid-β8, or pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide (LPS)9, classically activate 
microglia to promote an inflammatory response characterized by reversion to the 
amoeboid active state and the production of nitric oxide, tumor necrosis factor-α 
(TNFα), interleukin 1β (IL-1β), IL-6, IL-12, and the chemokine C-C motif ligand 29-11. 
In neuroinflammatory conditions such as Parkinson’s disease, in which pathogenic α-
synuclein has accumulated, a neurodegenerative cycle is created from the death of 
dopaminergic neurons, which release more aggregated α-synuclein, further promoting 
classical activation of microglia7. Similar to peripheral macrophages, microglia may 
also have the ability to alternatively activate in the presence of the anti-inflammatory 
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cytokines IL-4 and IL-10, giving them the potential of promoting neural repair and 
attenuating inflammation2,11. Aside from their immunological roles in the CNS, 
microglia have been described as vital regulators of neuronal circuitry by pruning 
synapses during development. For example, Cx3cr1-KO mice have less dense 
microglia and reduced synaptic pruning, which leads to an overabundance of dendritic 
spines, immature synapses, and the electrophysiological patterns of an 
underdeveloped CNS12. Understanding these physiological complexities and the 
diverse functional roles of microglia in the homeostasis of the CNS are critical to the 
search for therapeutics targeting neurodegenerative disorders.  
 
In the area of neuroimmunology, in vitro experiments are highly desirable 
because of greater feasibility for mechanistic studies, lower maintenance costs, and 
for being less time- and labor-intensive. Furthermore, the ability to isolate cell 
populations is critical to delineating the functionality of those target cells under 
prescribed conditions. Numerous microglial isolation methods exist, but they are 
limited by their ability to obtain relatively high numbers and purity for broad 
experimentation13-15. For example, cluster of differentiation 11b (CD11b) is a common 
surface marker of monocytes, macrophages, and microglia16. By exploiting CD11b, a 
method of magnetic separation was first described as a column-based approach that 
yielded ~99.5% purity and ~1.6 x 106 microglia per neonatal brain17. Our laboratory 
recently developed a column-free CD11b magnetic separation method15, which we 
performed in a polystyrene tube by tagging CD11b with a monoclonal antibody 
conjugated to phycoerythrin (PE). A bispecific secondary antibody to PE and dextran 
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complexes with the PE. Once bound, dextran-coated magnetic particles are 
introduced, which bind to the dextran end of the antibody complex. Lastly, the 
polystyrene tube is placed in a magnet for microglial isolation. This approach doubled 
the yield to ~3.2 x 106 microglia per neonatal brain but at the cost of reducing purity to 
~97%. 
Herein, we demonstrate a rapid and refined column-free CD11b magnetic 
separation protocol (Figure 1). This improved method remains as feasible as our 
original column-free method since the price of the CD11b magnetic separation kit is 
the same. The completion time is reduced by half, which can be crucial to maximizing 
cell survival and yield. Notably, the purity achieved from this optimized method is 
~>99%, a marked improvement over the purity achieved from the original column-free 
method developed by our laboratory15. Most importantly, CD11b-PE is not utilized, 
eliminating the need to incubate away from light and allowing use of the red channel 
for fluorescence microscopy. Lastly, as in the original CD11b method, an astrocytic 
fraction of high yield and purity is obtained with this improved method. Astrocytes are 
the most numerous glial cells in the CNS, leading to the idea that their homeostatic 
functions are indispensable in relation to pathophysiology18. These glial cells play a 
role in diverse physiological functions such as forming the blood-brain barrier, 
providing nutrient support, maintaining neurotransmitter homeostasis, forming glial 
scars in response to injury, neuroprotection, learning and memory, and 
neuroinflammation, exemplifying their investigatory potential in glial biology19. 
Morphology and functionality of microglia and astrocytes have been ascertained via 
confocal microscopy, Western blotting, quantitative real-time polymerase chain 
288 
 
reaction (qRT-PCR), Griess nitrite assay, and the Luminex multiplex cytokine assay. 
The refinement provided by this protocol offers increased confidence pertaining to 
microglial or astrocytic purity, broader application of fluorescence microscopy with the 





Use of the animals and protocol procedures were approved and supervised by the 
Institutional Animal Care and Use Committee (IACUC) at Iowa State University (Ames, 
IA, USA) 
 
1.  Growing of mixed glial cultures. 
1.1 Decapitate one-to-two-day old pups quickly with 5.5 inch operating scissors, 
and place the heads immediately in a 50 mL Corning Centristar tube  on ice. Note, 
this decapitation is the mode of euthanasia. 
 
1.2  In a laminar airflow hood, make a small incision in the skull and meninges using 
4.5 inch straight micro-dissecting scissors. Begin cutting from the caudal end to the 
rostral end (nose). Get underneath the skin by using the opening formed by the 
decapitation.  
1.2.1 After the incision, peel one of the hemispheres to the side. 




1.3 Immerse the brain(s) in a new 50 mL tube containing trypsin-
ethylenedinitrilotetraacetic acid (EDTA) for 15 min in a 37 °C water bath. Use 2 mL of 
trypsin-EDTA per brain. 
 
1.4 Wash the brain(s) with fresh Growth Media (10% FBS, DMEM/F12, 1% 
penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate, and 1% non-essential 
amino acids) by adding and aspirating or discarding the  fresh media 4 different times. 
 
1.5 For each brain, two T-75 flasks containing growth media will be plated. 
Therefore, add 2 mL of growth media per brain to the tube. Thus, it will be an 
equivalent of 1 mL of homogenized brain with 8-9 mL of growth media per T-75 flask. 
 
1.6 Homogenize by triturating the brain(s) with pipettes of differing aperture size, 
in order from largest to smallest. When it is visible that the brain tissue is not getting 
smaller, transition to the next pipette. At the end of the trituration, the suspension 
should be clear, with no visible chunks. 
1.6.1 Use a 25 mL pipette, 5 mL pipette, and then a 10 mL pipette sequentially. 
 
1.7 Pass each homogenous brain suspension through a 70 μm cell strainer to 




1.8 For each homogenized brain, plate two T-75 flasks containing growth media, 
as described in step 1.5 (1 mL of homogenized brain with 8-9 mL of growth media per 
T-75 flask). 
 
1.9 Change growth media after 6 days and grow until isolation on the 16th day. 
 
2. Isolation of microglial cells. 
2.1 After 16 days, remove the growth media from the flask and place it in a fresh 
50mL tube. 
2.1.1 Next, add 3 mL trypsin-EDTA to each T-75 flask. 
2.1.2 Shake the flasks for 5 min at room temperature on an orbital shaker such as a 
belly dancer.  
2.1.3 The removed growth media may be centrifuged at 0.4 x g for 5min and used to 
stop the trypsin-EDTA reaction in the subsequent step. 
 
2.2 After shaking for 5 min, add a minimum of 4 mL of growth media (fresh or the 
used media) to stop the trypsin-EDTA reaction.  
 
2.3 Triturate to ensure that all the cells have been detached. 
 
2.4 After trituration, pass the cells through a 70 μm cell strainer to make it into a 




2.5 For every 100 million cells (roughly 15 T-75 flasks) use 1 mL of Recommended 
Media (2% FBS, DPBS (Calicum and Magnesium Chloride free), 1 mM EDTA) to re-
suspend the cell pellet. 
 
2.6 All following steps are tailored for a 1mL separation. Take a 5 mL 
polystyrene tube, add 1 mL of recommended media, and mark the meniscus. 
2.6.1 Next, add recommended media up to 2.5 mL and mark it as well.  
2.6.2 Finally, discard the recommended media and transfer the re-suspended cells 
to the 5 mL polystyrene tube. 
 
2.7 Add 50 µL of rat serum for every 1 mL of suspended cells. 
2.7.1 Incubate for 5 min at room temperature.  
 
2.8 Prepare selection cocktail by mixing 25 µL of component A and 25 µL of 
component B. These components are proprietary. 
 
2.9 Add 50 µL of the selection cocktail to the cells. 
 
2.10 Incubate for 5 min at room temperature. 
2.10.1 For purer cultures, repeat steps 2.9 and 2.10 (recommended but not 
mandatory). 
 




2.13 Incubate for 3 min at room temperature. 
 
2.14 Bring the volume to 2.5 mL in polystyrene tube by adding recommended 
medium.  
 
2.15 Put the tube in the magnet for 3 min at room temperature. Incubation may be 
adjusted for the purposes of increasing purity. 
 
2.16 Slowly pour out the recommended medium into a 15 mL tube with the 
polystyrene tube still in magnet. 
 
2.17 Repeat steps 15-17 three more times. Additional magnetic incubations may be 
performed for the purposes of increasing purity. 
 
2.18 Add 3 mL of growth media and count the number of cells using cell counter. 
 
2.19 Plate cells accordingly in poly-D-lysine-coated plates for treatments. Begin 
treating the cells 48 h after seeding in poly-D-lysine-coated plates. This allows the 
cells to recover from the stress of separation. 
 





2.21 Plate the negative fraction (collected in a 15 mL tube), which mostly contains 
astrocytes, in T-75 flasks in the growth medium. 
 
2.22 After at least 6 h of incubation in 37 °C incubator, change the medium and let 
it grow overnight. 
 
2.23 Split the astrocytes the next day for treatments. 
 
REPRESENTATIVE RESULTS 
Microglia isolated using CD11b Positive Selection kit II have high purity 
Primary mouse microglia were isolated using the above mentioned protocol 
and plated on poly-D-lysine-coated coverslips to check the purity of isolation. Ten 
thousand cells were plated per well and immunocytochemical analysis was performed 
using ionized calcium-binding adaptor molecule 1 (Iba1) as a marker of microglia and 
glial fibrillary acidic protein (GFAP) as a marker of astrocytes to check for the purity of 
the isolated microglia. The isolated culture only expressed Iba1 without GFAP 
expression (Figure 2A), suggesting that the culture isolated was pure microglia. Unlike 
other previously published methods for primary microglial separation, which achieve 
~97% purity, using this method we obtained ~>99% purity in half the time. To further 
validate the purity of this culture, we ran a Western blot 20 for Iba1 and GFAP. 
Immunoblot analysis further revealed that this isolation from the mixed glial cultures 




The modified isolation procedure does not have any auto-fluorescence from 
magnetic beads 
The red channel cannot be used for immunocytochemistry (ICC) when using 
the previous CD11b isolation kit for microglial separation as mentioned by Gordon et 
al. (2011)15 because of the use of PE labeling during separation. Using this new PE-
free isolation kit, we can use the red channel for immunocytochemical analysis (Figure 
3). From this ICC, it is evident that this new method enables us to use all the channels 
for flow cytometry or other fluorescent imaging studies. 
 
Isolated microglial cultures functionally respond to LPS stimulus 
To verify that the isolated microglia are functionally active, we treated the cells 
with LPS, a widely used stimulant9 to activate microglia, for 24 h before probing for 
various pro-inflammatory factors. Classical microglial activation is accompanied by the 
release of nitrite and various pro-inflammatory cytokines into the media. Hence, we 
used multiple complementary assays to confirm the functional activity of our isolated 
microglia. First, we used the Griess assay to show that LPS dramatically induced 
nitrite secretion from the isolated microglia (Figure 4A). To further validate the activity 
of isolated microglia, we used qRT-PCR to show (messenger ribonucleic acid) mRNA 
levels of NOS2, another hallmark of microglial inflammation, significantly enhanced 
with LPS treatment (Figure 4B). Next, we used a bead-based multiplex assay, 
Luminex21, to verify that LPS significantly stimulated the secretion of pro-inflammatory 
cytokines from the microglial culture (Figure 5A). Furthermore, we verified via qRT-
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PCR analysis that LPS treatment enhanced the gene expression levels of several pro-
inflammatory cytokines including IL-1β and TNFα (Figure 5B). All these data together 
suggest that primary microglia isolated using this newly refined method are 
functionally active and show a similar activation profile as primary microglia isolated 
using previously published methods.  
 
Isolated microglia can be used for signaling studies 
Using the previous methods of microglial isolation, running Western blot for 
signaling studies was difficult and infeasible due to low yield and purity. Previously, 
we have shown that Fyn, a Src family kinase, is involved in a pro-inflammatory 
signaling cascade in microglial cells9. Here we plated one million microglial cells in a 
12-well plate and after 48 h collected the cells to run Western blots for native Fyn and 
Src kinases phosphorylated at tyrosine residue 416 (p-Src-Y416). We were able to 
detect both Fyn and p-Src-Y416 levels in our isolated microglial cells (Figure 6), 
showing that this method is applicable to Western blotting techniques for signaling 
studies. 
 
The negative fraction from the microglial separation contains astrocytes that 
can be used for signaling studies 
Astrocytes are key players in neuroinflammation, and understanding the 
signaling mechanisms behind astrocytic inflammation and neuron-astrocyte cross-talk 
is important19. Here, we show that the negative fraction from the microglial separation 
contains GFAP-positive astrocytic cells (Figure 7A). Also, our Western blot analysis 
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for Fyn and p-Src-Y416 (Figure 7B) showed that both of these proteins can be 
detected in the negative fraction as well. These results together show that the negative 
fraction is an ideal preparation for astrocytic studies aimed at identifying proteins 
important for inflammatory signaling cascades.  
 
DISCUSSION 
 Older microglial isolation methods have limited recoveries that are not 
appropriate for various protein analyses by Western blot and RNA analyses by qRT-
PCR. The differential adherence and mild trypsinization methods are two common 
approaches with low microglial yields 13-15. The column-based CD11b approach also 
has low recovery, but achieves greater purity than differential adherence and mild 
trypsinization 13-15,17. Our original column-free CD11b approach greatly improved the 
isolated yields, making it suitable for protein and RNA analyses such as Western 
blotting and qRT-PCR, but at the cost of decreased purity 15. 
 Our newly modified method retains the yields of the original method and 
increases the purity slightly from ~95-97% to ~>99%, but in half the completion time, 
which is critical for cell survival. Crucial steps within the protocol can assure optimal 
microglial isolation. While decapitating the pups, care should be taken to keep the 
heads on ice and then dissected in a laminar airflow chamber within 5-10 mins. 
Prolonged brain excision times will make it difficult to obtain the full of brain because 
it begins to lose its solidity at ambient temperatures, compromising the microglial 
yields.  Notably, if steps 2.9 and 2.10 are repeated at least once, there is an 
observable increase in the purity and the viability. If the yield from the separation is 
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low, the separation can be repeated using fewer flasks per mL of recommended 
media, or by increasing the volume of separation (>1mL). Decreasing cell crowding 
generally will improve purity, viability, and yield. The magnetic incubation time may be 
extended in step 2.15 for the purposes of increasing purity. This can assure proper 
magnetic binding of the microspheres that are attached to the microglia. Furthermore, 
additional magnetic incubations may be performed in step 2.17 for the sake of 
increasing purity and yield. 
  The feasibility of the protocol is equivalent to or better than the original CD11b 
method, however, the new method is refined and shorter. Another significant 
advantage gained from this refined method is the option of utilizing the red channel 
for fluorescence microscopy, which is occupied by PE in the original method (Table 1) 
15. Though we get high yield and purity of microglia with the method, the astrocytic 
yield obtained from this separation is less pure since it retains some fibroblasts. As 
described in step 2.22, after plating the astrocytes and incubating for 6 h, the growth 
media should be replaced with fresh media. Astrocytes are the first to attach to the 
flask, while much of the fibroblasts remain in suspension. The replacement of the 
media generally will remove the majority of contaminating fibroblasts. Although this 
technique assures a high purity of astrocytes, a secondary purification method to 
achieve purer cultures of is warranted.  
 Overall, this modified CD11b isolation method generates highly pure primary 
microglial cells and astrocytes in a short amount of time. The shorter isolation time 
generally improves cell survival rates. It provides a useful model system for elucidating 
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Figure 2: Microglia isolated using CD11b positive selection kit II have high 
purity.  
a) Immunocytochemistry of isolated microglial culture probing for GFAP in red 
channel and IBA1 in green channel. b) Immunoblot of isolated microglial culture 
probing for GFAP  





Figure 3: The modified isolation procedure does not have any auto-fluorescence 
from magnetic beads.  
Immunocytochemistry of isolated microglial culture using the new isolation method 






Figure 4: LPS stimulation increased nitrite production in microglial culture.  
a) Isolated microglial cells treated with 1 μg/mL LPS for 24 h and treatment medium 
were collected to determine nitrite release by Griess assay. b) q-RT-PCR for Nos2 
from isolated microglia treated with LPS for 24 h. The figures represent mean ± SE 
from 2 or more independent experiments. Data analyzed using Student’s t test 





Figure 5: LPS induced pro-inflammatory cytokine release from microglial cells.  
a) Luminex multiplex assay was performed on treatment medium collected from 
isolated microglial cells treated with 1 μg/mL LPS for 24 h. b) q-RT-PCR for IL-1βand 
TNFα from isolated microglia treated with LPS for 24 h. The figures represent mean ± 
SE from 2 or more independent experiments. Data analyzed using Student’s t test 





Figure 6: Isolated microglia can be used for signaling studies.  
Western blot analysis showing that Fyn and p-Src-Y416 can be detected from 





Figure 7: The negative fraction from the microglial separation contains 
astrocytes that can be used for signaling studies.  
a) Western blotting shows that the negative fraction contains GFAP-positive cells. b) 









Table 1: Comparative analysis between the refined microglial isolation method and 
the original method of isolation. 
 
  
Parameters Current method Modified method 
Cost $620 $620 
Time 55 min 25 min 
Fluorescence Yes (red channel) No 
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Abstract   
Microglia are the first responders of the central nervous system, acting as the 
key modulators of neuroinflammation observed during neurotoxic insults as well as in 
the pathophysiology of several neurodegenerative disorders including Alzheimer’s, 
Parkinson’s, and Huntington’s diseases. The number of publications on microglia has 
increased steadily throughout the past decade because of immense interests in the 
neuroinflammation that precedes the neurodegenerative process. To study microglial 
biology and its role in modulating neuroinflammation, immortalized microglial cell lines 
representing mouse, rat, and human have been developed. Among these, the BV2 
mouse microglial cell line is the most well characterized and widely used cell culture 
model.  However, even unstimulated BV2 cells exhibit an amoeboid morphology, 
indicating a highly activated and inflammatory state compared to primary microglia, 
thus making them less than ideal for studying low-dose effects of toxicants on 
microglial activation. Therefore, we performed an in-depth characterization of a 
recently developed mouse microglial cell (MMC) line, which we compared with primary 
microglia (PMG) and BV2s to determine the ideal cell line for studying neurotoxicant 
effects on microglial function. Comparative analyses reveal that MMCs are strikingly 
similar to PMG in basal activity, morphology, and sensitivity, characteristics that BV2s 
lack. Basal nitrite and inflammatory cytokine levels are significantly higher in BV2s 
compared to MMCs. Furthermore, BV2 cells are less reactive to the inflammagen LPS 
compared to MMCs, due to their higher basal activation state. Collectively, we 
demonstrate, based on in-depth analyses of morphology, basal activity, and 
responsivity to three different stimuli (LPS, aggregated -synuclein, and neurotoxic 
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manganese), that MMCs mimic neonatal PMG, and are discernibly more suitable than 




Microglia are the first immune responders in the brain. Persistently active and 
unregulated microglia are key modulators of chronic neuroinflammation observed in 
several neurodegenerative disorders.  Activated microglia are distinct from resting 
microglia both morphologically as well as functionally with respect to the production 
and secretion of proinflammatory factors (Glass et al., 2010; Panicker et al., 2015). 
Several lines of evidence, from cell culture to animal models to postmortem tissue 
analyses to genetic linkage analyses, conclusively demonstrate that sustained 
neuroinflammation negatively affects neuron health, and in fact, contributes to 
neuronal death (Block et al., 2007; Gordon et al., 2016; Kirkley et al., 2017; Panicker 
et al., 2015; Sarkar et al., 2017b). Lipopolysaccharide (LPS)-activated microglia 
undergo morphological changes from ramified (surveillant) type to amoeboid type, 
releasing ROS, nitrite, and various other pro-inflammatory mediators and cytokines 
that can be toxic over time. Like macrophages, microglia can also undergo an 
alternative activation, which leads to production of anti-inflammatory factors. For 
example, IL-4 can induce this alternative anti-inflammatory phenotype in microglial 
cells (Nakagawa and Chiba, 2014). Walker and Lue (2015) suggested the probable 
existence of another microglial phenotype, known as M3. Thus, microglial activation 
is complex, and the molecular footprints underlying the various phenotypes are the 
focus of much research.  
Microglial activation leading to neurodegeneration has been well documented 
in AD, PD, and other neurodegenerative disease (Block et al., 2007; Glass et al., 2010; 
Solito and Sastre, 2012). Misfolded proteins, including aggregated α-synuclein 
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(αSynAgg) and amyloid-β, that are pathological hallmarks of PD and AD, can 
hyperactivate microglia, leading to chronic inflammation and loss of neurons (Halle et 
al., 2008; Heneka et al., 2013).  
Various xenobiotics, including manganese (Mn) (Aschner et al., 2009a; 
Aschner et al., 2009b; Filipov et al., 2005a; Guilarte, 2010; Moreno et al., 2009a; 
Moreno et al., 2008; Moreno et al., 2009b; Neal and Guilarte, 2012; Streifel et al., 
2012; Verina et al., 2011), copper (Cu) (Choo et al., 2013; Zhang et al., 2011), and 
zinc (Zn) (Kauppinen et al., 2008), are also known to activate microglial cells. 
Exposure to such environmental neurotoxicants has been linked to an increased risk 
of Parkinsonian syndrome. Importantly, Mn-induced microglial activation leads to the 
production of pro-inflammatory factors that have been shown to cause neuronal 
damage (Burton and Guilarte, 2009; Filipov et al., 2005b). Mn also enhances the LPS-
induced production of pro-inflammatory factors in microglial cells (Dodd and Filipov, 
2011). Mn-induced microglial activation can also subsequently activate astrocytes, 
leading to an exacerbation of the pro-inflammatory condition (Kirkley et al., 2017); 
however, many of the molecular signaling mechanisms of metal-induced microglial 
activation remain unknown. 
Microglia are not only involved in disease pathogenesis, but also play an 
important role in nervous system development. Microglia have been shown to play an 
important role in shaping the neuronal circuit during development (Wu et al., 2013) by 
modulating the axon processes via synaptic pruning. The number of publications on 
microglial cells in the last decade have increased steadily with every passing year 
(Fig. 1A), especially the importance of microglia in AD, PD, multiple sclerosis (MS), 
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and other neurodegenerative disorders. To study microglial biology and its role in 
modulating neuroinflammation, several immortalized microglial cell lines have been 
developed (Fig. 1B), including BV2, N9, and EOC (mouse microglial cell lines); HAPI 
(rat microglial cell line); and the HMC3 and HMO6 (human microglial cell lines). Among 
the six prevalent cell lines, BV2 cell lines have been used in ~75% of the publications 
(Fig. 1B). Since 2010, the number of publications on BV2 has substantially increased 
(Fig. 1C). Though BV2 microglial cell lines are not identical to primary microglia in 
morphology or activation state, the prevalent use of BV2 may be attributed to the 
following: i) lack of good, easily obtainable cell lines; ii) cost of primary culture; iii) low 
yield of primary microglial cells; and iv) difficulty in isolating primary cells.  
In this study, we performed a more in-depth characterization of a newly developed 
microglial cell line which was immortalized from primary mouse microglia. We 
compared this new mouse microglial cell line (MMC) with the predominantly used BV2 
microglia, demonstrating that the basal level of BV2 microglia is higher than that of 
MMCs.  We also demonstrate that the MMC responded to a variety of stimuli, including 
LPS, misfolded αSynAgg, and the environmental neurotoxicant Mn.  
Material and Methods 
Chemicals and Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), DMEM-F12, fetal bovine serum 
(FBS), L-glutamine (Q), penicillin/streptomycin (P/S), Sodium Pyruvate (SP), and Non-
Essential Amino Acids (NEAA) were obtained from Invitrogen (Carlsbad, CA). 
CellTiter Glo Luminescent Cell Viability Assay kit was obtained from Promega 
(Madison, WI). The CD11b magnetic separation kit was purchased from Stem Cell 
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Technologies (Vancouver, Canada). All standards used for the Luminex multiplex 
cytokine assay were purchased from PeproTech Inc (Rocky Hill, NJ). Streptavidin-
Biotin and biotinylated antibodies used for Luminex were purchased from 
eBioSciences (San Diego, CA). Phagocytosis assay kit was purchased from Cayman 
Chemicals (Ann Arbor, MI). 
Literature Review 
To assess the use of microglial cell lines in peer-reviewed studies, the following 
terms were searched in PubMed: microglia, BV2 microglia, HAPI microglia, N9 
microglia, HMO6 microglia, HMC3 microglia, EOC microglia.  
Cell culture and Treatments 
Primary Microglia: Primary microglia were obtained from 1- to 3-day postnatal 
mouse pups, as described in our published protocol (Sarkar et al., 2017c). The brains 
were excised, immersed in 0.25% trypsin-EDTA (TE), and incubated for 15 min in a 
37° C water bath with occasional mixing. The TE was neutralized with growth medium 
(10% FBS with 1% P/S, Q, SP, NEAA in DMEM-F12), and the brains were washed 4 
times by adding and removing fresh growth medium. The brains were then 
homogenized via trituration, filtered through a 70-μm filter, and then the cell 
suspension was plated in T75 flasks (2 T75 flasks per brain). After 6 days, the growth 
medium was decanted and replaced with fresh growth medium. On the 16th day, the 
cells were collected, subjected to an antibody CD11b positive selection, and isolated 
using a magnetic column that binds magnetic spheres complexed onto the CD11b 
surface marker. Once the cells are seeded appropriately, they are ready for treatments 
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after 48 h. All experiments were performed in treatment medium (2% FBS with 1% 
P/S, Q, SP, NEAA in DMEM-F12). 
BV2:  BV2 microglia were maintained in 10% FBS with 1% P/S and Q in 
DMEM. All experiments were performed in treatment medium (2% FBS with 1% P/S 
and Q in DMEM). 
Wild-type mouse microglial cell (MMC) line: MMCs were derived by viral-
transduced immortalization of primary microglia, which were a kind gift from Dr. D. 
Golenbock (University of Massachusetts). These cells have similar morphology and 
surface markers as primary microglial cells (Halle et al., 2008). MMCs were 
maintained in 10% FBS with 1% P/S, Q, and SP in DMEM-F12. All experiments were 
performed in treatment medium (2% FBS with 1% P/S, Q, and SP in DMEM-F12) 
(Sarkar et al., 2017b).  
Immunocytochemistry (ICC) 
For ICC, coverslips were placed in 24-well plates, immersed in poly-D-Lysine, 
and then washed with phosphate-buffered saline (PBS). Next, cells were seeded with 
their respective growth medium. After the experiment, the treatment medium was 
decanted and the cells on the coverslips were fixed by incubating at RT with 4% 
paraformaldehyde for 25 min. The cells were then washed with PBS 4 times. Next, 
the cells were blocked with blocking buffer (2% BSA with 0.05% Triton-X100 and 
0.005% Tween-20 in PBS) for 45 min to 1 h. Primary antibodies were made with 1% 
BSA in PBS, incubated overnight at 4° C, and then washed for 30 min with PBS. All 
secondary antibodies were made with 1% BSA in PBS, incubated at RT for 90 min, 
and then washed for 30 min with PBS. Finally, Hoechst nuclear stain was made in 
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PBS at 1:5000 and added for 5 min. After washing, the coverslips were mounted on 
pre-coated slides using Fluoromount (Sigma-Aldrich). The following antibodies were 
used: IBA1 (AB_2314667, 1:1000), iNos (AB_2152867, 1:500). Alexa dye-conjugated 
secondary antibodies were used for ICC experiments. 
Recombinant human α-synuclein purification and aggregation 
Recombinant human α-synuclein was purified following our previous 
publication (Sarkar et al., 2017a). Briefly, E. coli cells were transformed with human 
α-synuclein plasmid and grown on an agar plate with ampicillin (Amp). Pre-culture was 
prepared by inoculation of a single bacterial colony from the agar plate into a tube 
containing 10 mL of LB broth with Amp and incubated overnight at 37 °C. Next, the 
pre-culture was inoculated into 1 L of LB medium containing Amp, and every hour the 
OD600 was taken until the culture reached an OD of 0.5. The α-synuclein expression 
was induced by adding 1 mM isopropyl β-D-1-thiogalactopyranoside (Invitrogen), and 
the cells were further incubated at 37 °C for 8 h before harvesting. Cells were lysed 
and recombinant α-synuclein was purified and aggregated as previously described 
(Sarkar et al., 2017a).  
qRT-PCR 
RNA extraction and qRT-PCR were performed as described previously (Sarkar 
et al., 2017b; Seo et al., 2014). Briefly, cells were plated in 6-well plates and treated. 
Following treatment, TRIzol reagent was used to isolate total RNA from the cells and 
the concentration was measured using NanoDrop. Affinity Script qPCR cDNA 
synthesis system (Agilent Technologies) was used to convert RNA to cDNA. Real-
time PCR was performed with the RT2 SYBR Green master mix (Thermo Fisher 
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#K0172). The following genes from QuantiTect Primer Assay (Qiagen) were used for 
qRT-PCR: pro-IL-1β, pro-IL-18, IL-12b, TNF-α, IL-6, and NOS2. The housekeeping 
gene 18S rRNA (Qiagen #PPM57735E) was used as the reference for all qRT-PCR 
experiments. The results are reported as fold change in gene expression, which was 
determined via the ΔΔCt method using the threshold cycle (Ct) value for the 
housekeeping gene and for the respective gene of interest in each sample (Lawana 
et al., 2017). 
Western Blotting  
Western blot analysis was performed according to previous published protocols 
(Langley et al., 2017). Briefly, cell samples were lysed using modified RIPA buffer and 
sonicated using a refrigerated cup-sonicator. Bradford assay was performed for 
protein estimation. Next, 25 µg of protein was loaded in each well of 10% SDS-
acrylamide gel and ran for 2-2.5 h at 110 V. Proteins were transferred to a 
nitrocellulose membrane at 27 V for 18 h at 4° C. The nitrocellulose membranes were 
blocked using LI-COR blocking buffer for 1 h. The blocked nitrocellulose membranes 
were incubated in the primary antibody for gp91-phox (BD Biosciences) for 3 to 18 h, 
washed with PBS-Tween (0.01%), incubated in infrared LI-COR secondary antibodies 
for 1 h, washed again with PBS-Tween, and imaged using a LI-COR scanner. 
Secondary antibodies were used according to manufacturer’s instructions.  β-actin 
was used as the loading control. 
Phagocytic Assay 
Phagocytic assay was performed according to manufacturer’s protocol. Briefly, 
40,000 MMCs were plated on PDL-coated coverslips in 24-well cell culture plates. 
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Cells were treated with 1 µM αSynAgg for 24 h. FITC-labeled IgG beads were added 
along with the treatment at a dilution of 1:300. Following treatment, excess FITC-
labelled beads were washed away with Hanks' balanced salt solution (HBSS). Cells 
were fixed using 4% PFA and imaged using a fluorescent microscope.  
Luminex Multiplex Cytokine Assay 
Luminex cytokine assay was performed according to our previous publications 
(Panicker et al., 2015; Sarkar et al., 2017a). Briefly, PMG and MMCs (100,000 
cells/well) were treated in 96-well plates.  After treatment, 40 μL of the medium was 
collected and added to 40 µL of primary antibody conjugated to magnetic 
microspheres and incubated overnight at 4°C in a clear-bottomed, black 96-well plate. 
Following incubation in primary antibodies, each well was triple-washed using a 
magnetic washer, incubated for 1 h with biotin-conjugated secondary antibodies, 
triple-washed again, incubated with streptavidin/phycoerythrin for 30 min and washed 
two more times. A Bio-Plex reader was used to read the 96-well plates. 
MTS Assay 
MTS assay was performed according to our previous publication (Sarkar et al., 
2017a). Briefly, 100,000 cells/well were plated in a 96-well tissue culture plate and 
treated with 1–3000 ng/mL of LPS for 24 h. After treatment, 10 µL of MTS dye was 
added to each well and incubated for 60 min at 37° C. Absorbance readings were 





Griess assay was performed according to our previous publication (Langley et al., 
2017). Briefly, 100,000 cells/well were plated in 96-well plates. Cells were treated with 
1–3000 ng/mL of LPS. Following treatment, 50 µL of media was mixed with an equal 
volume of Griess reagent and incubated for 10 min. The plate was read using a plate 
reader at 540 nM. Sodium nitrite was used to make the standard curve.    
Data Analysis 
Prism 7.0 (GraphPad) was used for statistical analysis with p≤0.05 considered 
statistically significant. One-way ANOVA was used for comparison among multiple 
groups. In most cases, Tukey post-hoc analysis was applied. For comparing 2 groups, 
Student’s t-test was performed. 
 
Results 
LPS effects on the morphology of BV2s, MMCs, and PMG 
Classical activation of microglia leads to an amoeboid morphology with 
enlarged soma and fewer processes. In this experiment, we determined the 
morphological changes associated with LPS treatment in BV2s, MMCs, and PMG. 
Cell lines were treated with 1 µg/mL of LPS for 6 h, fixed and subjected to ICC.  
Microscopic analysis demonstrates a change in morphology of MMCs and PMG upon 
LPS exposure from a ramified to a more amoeboid shape that includes drastic 
hypertrophy. On the contrary, the widely used microglial cell line BV2 exhibits an 
amoeboid shape prior to treatment suggesting that they are already activated and LPS 
treatment does not induce further change in morphology (Figs. 1D-E). These results 
suggest that LPS-induced morphological changes in MMCs are more similar to the 
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morphological changes seen in PMG. Therefore, the hypertrophic morphological 
changes observed in MMCs and PMG could be used as a measure of microglial 
activation, which is lacking in BV2s. 
Comparison of LPS-induced iNOS expression and nitrite production in 
microglial cell lines 
Hallmarks of microglial inflammation include iNOS induction and subsequent 
nitrite production (Gordon et al., 2016; Panicker et al., 2015).  Nitrite released from 
activated glial cells is neurotoxic and contributes to the neurodegenerative process 
(Mander and Brown, 2005). Probing for basal iNOS expression revealed that BV2 
microglial cells exhibited higher iNOS levels when compared to both MMCs and PMG 
(Fig. 2A). Upon LPS treatment (1 µg/mL) for 6 h, iNOS expression was rapidly induced 
in MMCs and PMG relative to controls, whereas iNOS induction in BV2 cells was not 
strikingly different from controls.  
Since increased iNOS expression will result in increased nitrite production, we 
quantified basal, extracellularly released nitrite levels by Griess assay. BV2 cells 
released significantly higher nitrite than did MMCs or PMG (Fig. 2B). Extracellularly 
released nitrite levels did not differ significantly between PMG and MMCs (Fig. 2B). 
Together, these findings show that BV2 cells are already in an activated state under 
basal conditions compared to MMCs and PMG. 
LPS increases the expression and production of pro-inflammatory factors 
significantly more in MMCs than in BV2s 
Similar to nitrite production, the production and secretion of pro-inflammatory 
cytokines are also major hallmarks of microglial inflammation (Gordon et al., 2016; 
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Panicker et al., 2015).  Pro-inflammatory cytokines released from activated glial cells 
are neurotoxic and contribute to the neurodegenerative process.  We performed qRT-
PCR to compare the basal expression levels of pro-inflammatory cytokines and NOS2 
(Fig. 3). The qRT-PCR analysis revealed that BV2s have significantly higher basal 
gene expression of the pro-inflammatory factors pro-IL-1β (Fig. 3A), IL-6 (Fig. 3B), IL-
12b (Fig. 3C), TNF-α (Fig. 3D) and NOS2 (Fig. 3E), with one exception being pro-IL-
18 (Fig. 3F). These data suggest significantly higher mRNA expression levels of pro-
inflammatory factors in BV2s compared to MMCs. However, when these cell lines are 
exposed to LPS for 6 h, pro-inflammatory cytokines and iNOS mRNA levels were 
significantly higher only in MMCs, not BV2 cells, when compared to their respective 
untreated controls. When compared to LPS-stimulated BV2 cells, pro-IL-1β (Fig. 4A), 
IL-6 (Fig. 4B), IL-12b (Fig. 4C), pro-IL-18 (Fig. 4D), TNF-α (Fig. 4E) and NOS2 (Fig. 
4F) were rapidly upregulated in MMCs. These data collectively suggest that MMCs 
are a good model system for understanding the mechanism of microglial inflammation.  
LPS induces gp-91phox in the MMCs 
Gp91-phox is a key component of NADPH oxidase (Nox-2) complex and has 
been identified as one of the major downstream effectors of LPS-induced 
inflammation. LPS-induced free-radical formation is diminished in Nox2/gp91-phox 
deficient mice (Clement et al., 2010), and gp91-phox plays a role in neuroinflammation 
in PD (Langley et al., 2017). To further verify the downstream effector of LPS-induced 
inflammation in the MMCs, cells were treated with LPS for 1 h. Western blot analysis 
revealed that LPS induced gp91-phox in the MMCs (Fig. 5A), which was corroborated 
by ICC analysis (Fig. 5B). These data support previous findings in glial cells, further 
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showing that this cell line can be used for studying Nox-2 signaling mechanisms 
underlying microglial activation.    
 
LPS induces proinflammatory response in MMC cells in a dose-dependent 
manner 
To further characterize the response of the MMCs upon exposure to an 
inflammatory stimulus, we performed a dose-response analysis of various LPS-
induced inflammatory parameters. Given that LPS treatment can induce mitochondrial 
dysfunction (Kuwabara and Imajoh-Ohmi, 2004), we treated the MMCs with different 
doses of LPS (1-3000 ng/mL) for 24 h. An MTS assay revealed that LPS reduced 
metabolic activity in a dose-dependent manner (Fig. 6A). The 24 h IC50 concentration 
was calculated to be 8.6 ng/mL LPS. Moreover, a Griess assay revealed that LPS 
induced a dose-dependent increase in nitrite release (Fig. 6B). Our Luminex assay 
demonstrated that low-dose LPS exposure (1 ng/mL) produced pro-inflammatory 
factors including IL-6 (Fig. 6C), IL-12 (Fig. 6D), TNF-α (Fig. 6E), and IL-1β (Fig. 6F). 
Together, these data suggest that LPS stimulation can induce a broad dose-
dependent inflammatory response in MMCs. 
αSynAgg induces comparable pro-inflammatory responses in MMCs and PMG 
Misfolded αSyn and its aggregates are major pathological features of PD. We 
have previously shown that αSynAgg classically activates microglial cells, producing 
pro-inflammatory cytokines and nitrite in BV2 cells and primary microglia (Gordon et 
al., 2016).  To determine if MMCs can be activated by αSynAgg, we treated MMC cells 
with 1 µM αSynAgg for 24 h and compared them with PMG. The αSynAgg treatment 
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elicited an inflammatory response in MMCs that was comparable to the response in 
PMG, as revealed by Luminex analysis of IL-1β (Fig. 7A), TNF-α (Fig. 7B), and IL-6 
(Fig. 7C). Although IL-6 production was lower in the MMCs than in PMG, production 
of the other pro-inflammatory factors was consistent between the two cell lines. In 
addition, a phagocytic assay revealed that the MMCs were able to engulf FITC-labeled 
IgG beads (Fig. 7D), thus demonstrating phagocytic activity, which was increased by 
exposing these cells to αSynAgg. These data further demonstrate that the MMCs may 
be used as a microglial model for neuroinflammation in diseases associated with 
protein misfolding.  
Manganese activates the MMCs producing inflammatory factors 
We have recently demonstrated that the environmental toxicant Mn also 
induces microglial inflammation in primary microglia and in animal models of 
Parkinsonism (Dodd and Filipov, 2011; Sarkar et al., 2017b). To verify if MMCs can 
be used to model metal-induced inflammation, cells were treated with 100 µM Mn for 
24 h. Mn significantly induced NOS2 mRNA levels in the MMCs, as revealed by qRT-
PCR analysis (Fig. 8A). Furthermore, a Luminex assay revealed that Mn significantly 
upregulated release of the pro-inflammatory factors TNF-α (Fig. 8B) and IL-6 (Fig. 
8C). These data suggest that these cells can be used to study neurotoxic metal-
induced inflammation in microglia. 
Discussion 
Notably, in the past two decades, chronic neuroinflammation has been the 
subject of intense research (Fig. 1A). Elucidating the role of microglia in CNS 
pathophysiology is now regarded as fundamental in therapeutically targeting 
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neurodegenerative disorders such as Parkinson’s, Alzheimer’s,  and Huntington’s 
(Schapansky et al., 2015). Optimal in vitro models are thus indispensable for 
delineating cellular pathways and identifying molecular targets that could be exploited 
for such therapeutics. Herein, we provide an in-depth comparative analysis of the 
inflammatory states of the most widely used cell line, BV2 (Fig. 1C) and a novel, 
immortalized wild-type mouse microglial cell line (MMC). We argue that the MMCs are 
more advantageous for studies of neuroinflammation because of their inherent 
tendency to remain basally surveillant, yet more sensitive and comparable to neonatal 
mouse primary microglia than the widely used BV2 cell line.  
As evidenced in knockout animals, iNOS is a critical intracellular mediator of 
inflammation, conferring resistance against MPTP-induced loss of substantia nigral 
neurons (Liberatore et al., 1999). Furthermore, iNOS converts arginine to citrulline 
while also forming the byproduct nitric oxide (NO), a powerful signaling molecule 
(Hallemeesch et al., 2003; Moehle and West, 2015). However, in highly oxygenated 
conditions, NO can react with superoxide to form peroxynitrite, which can exert 
cytotoxic effects. Levels of its breakdown product, nitrite, correlate with the degree of 
inflammation (Hunter et al., 2013; Pacher et al., 2007). In this study, basal or 
unstimulated BV2s exhibited higher levels of iNOS compared to MMCs and PMG, 
which was corroborated by measuring nitrite levels in Griess assays (Fig. 2A-B). 
Significantly lower levels of basal iNOS and nitrite in MMCs make them far more 
suitable for signaling studies involving iNOS, NO, and potentially other unrelated 
oxidative stress mechanisms. Since oxidative stressors are prime factors that 
contribute to the neuroinflammatory and degenerative processes (Sarkar et al., 
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2017b), MMCs appear to be the more appropriate immortalized cell culture model for 
studying microglial activation.  
Both the BV2s and the MMCs were immortalized from C57BL/6 mice utilizing 
the J2 retrovirus carrying the v-myc/v-raf genes (Blasi et al., 1990; Halle et al., 2008). 
However, basal gene expression for various cytokines, as well as NOS2, were all 
significantly higher in BV2s except for pro-IL-18 (Fig. 3). Upon stimulation with LPS, 
MMCs demonstrated significantly greater sensitivity by exerting a more robust 
transcriptional burst of inflammatory genes (Fig. 4). This sensitivity and robustness 
may be crucial to more effectively defining signaling mechanisms of inflammation 
spurred by microglia, especially at earlier time points and in low-dose neurotoxicant 
exposure studies. 
Although MMCs were initially generated by Golenbock and colleagues, the cell 
model was not well characterized for neurotoxicity studies (Halle et al., 2008).  Here, 
we provide a more comprehensive analysis of their fundamental responsivity to 
stimulants such as LPS, Mn, and αSynAgg. LPS is known to dysregulate the 
mitochondrial membrane potential (Kuwabara and Imajoh-Ohmi, 2004) and to 
modulate mitochondrial bioenergetics at early time points (Sarkar et al., 2017b). As 
such, we employed the MTS assay to assess LPS’s effects on mitochondrially related 
metabolic activity of MMCs. At the traditional 24-h time point, an effective dose of 8.6 
ng/mL of LPS inhibited metabolic activity (Fig. 6A). This was further supported by the 
dose-dependent release of nitrite, in which 10 ng/mL LPS was sufficient to produce 
~15 μM of nitrite (Fig. 6B). Similarly, inflammatory cytokine analysis revealed that LPS 
treatment increased IL-1β levels in a dose-dependent manner. Although a dose 
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response for IL-6, IL-12, or TNFα was lacking, 10 ng/mL was sufficient to elicit a 
substantial quantity of cytokines. Interestingly, IL-6 appears to function as the primary 
cytokine effector since a major release was observed even at 1 ng/mL.  Based on this 
analysis, low-dose LPS for time points of 24 h or longer should be appropriate without 
significant cytotoxicity. On the other hand, higher doses should be effective at earlier 
time points. This is apparent from the significant increase in gp91-phox protein, a key 
generator of superoxide that reacts with NO to produce peroxynitrite (Fig. 5) (Pacher 
et al., 2007). 
Others have shown that αSynAgg induces microgliosis (Sanchez-Guajardo et 
al., 2013; Wang et al., 2015), which promotes inflammatory signaling through critical 
kinases such as protein kinase Cδ (Gordon et al., 2016). Comparatively the MMCs 
are not drastically different from PMG in releasing the major cytokines IL-1β, IL-6, and 
TNFα after being exposed to αSynAgg (Fig. 7). Similar results were obtained for IL-1β 
by stimulating the MMCs and PMG with fibrillar amyloid-β (Halle et al., 2008). These 
results further highlight the flexibility of MMCs, making them ideally suited for various 
in vitro paradigms. The metal Mn is known to be neurotoxic (Harischandra et al., 
2015), but it also can be a potent inducer and exacerbator of inflammation (Sarkar et 
al., 2017a; Tjalkens et al., 2017). Here, we corroborate the existing data by 
demonstrating elevated levels of NOS2 and the cytokines TNFα and IL-6 after Mn 
treatment (Fig. 8). Collectively, these results support adopting MMCs to supplant BV2s 
as the model system of choice.   
In conclusion, we demonstrate that the newly available MMC line is an excellent 
in vitro cell culture model that can appropriately supplant the widely used BV2 cell line 
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for the purposes of testing neurotoxic chemicals for inducing neuroinflammatory 
responses. MMCs mirror primary microglia exceptionally well when compared to 
BV2s. While unstimulated, they resemble a surveillant state of primary microglia, but 
under stimulation, their responsivity is remarkably similar to activated primary 
microglia. Their inherent sensitivity enables them to generate similar inflammatory 
mediators under various inflammatory stimuli that encompass classical, chronic, and 
environmental paradigms. Thus, MMCs are a better alternative to BV2s for studying 
the cellular and molecular mechanisms underlying microglial activation during 
neurotoxic insults.   
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Figure 1: Morphological comparison between the mouse microglial cell (MMC) 
line, the BV2 cell line, and primary microglia (PMG). A) Number of yearly 
338 
 
publications on microglia in PubMed. B) Distribution of the number of PubMed-indexed 
publications on various microglial cell lines. C) Number of yearly publications on BV2 
microglia in PubMed. D) Phase contrast microscopy of BV2 and MMC after LPS 





Figure 2: BV2s have higher basal nitrite levels compared to MMCs and PMG. A) 
ICC analysis showing BV2 cells have higher iNOS level compared to MMC and PMG. 
B) Griess assay showing BV2 cells produce higher nitrite compared to MMC and 
PMG. Data analyzed via ANOVA with Tukey post-hoc analysis, ***p<0.001. Data 





Figure 3: BV2s have higher basal pro-inflammatory factors compared to MMCs. 
A-F) qRT-PCR analyses of basal levels of A) pro-IL-1β, B) IL-6, C) IL-12b, D) TNF-α, 
E) NOS2, and F) pro-IL-18 in BV2 and MMC. Data analyzed via Student’s t-test, 







Figure 4: LPS-stimulated pro-inflammatory response is weaker in BV2s 
compared to MMCs. A-F) qRT-PCR analysis of levels of A) pro-IL-1β, B) IL-6, C) IL-
12b, D) pro-IL-18, E) TNF-α, and F) NOS2 in BV2s and MMCs 6 h after LPS treatment. 
Data analyzed via ANOVA with Tukey post-hoc analysis, ***p<0.001. Data 







Figure 5: LPS induces gp-91phox in MMC. A) Western blot and B) ICC analysis 






Figure 6: MMCs respond to LPS in a dose-dependent manner. A) MTS assay 
performed on MMCs after treatment with 1, 3, 10, 30, 100, 300, 1000 and 3000 ng/mL 
LPS for 24 h reveals dose-dependent decrease in metabolic activity. B) Griess assay 
performed on MMCs after treatment with 1, 3, 10, 30, 100, 300, 1000 and 3000 ng/mL 
LPS for 24 h demonstrating dose-dependent increase in nitrite release. C-F) Luminex 
assay performed on MMCs after treatment with 1, 3, 10, 30, 100, 300, 1000 and 3000 
ng/mL LPS for 24 h demonstrating increase in secreted C) IL-6, D) IL-12, E) TNF-α, 
and F) IL-1β. Data analyzed via ANOVA with Tukey post-hoc analysis. Data 







Figure 7: αSynAgg induces comparable pro-inflammatory response in MMCs and 
PMG. A-C) Luminex analysis of levels of secreted A) IL-1β, B) TNF-α and C) IL-6 in 
MMCs and PMG 24 h after αSynAgg treatment. D) Phagocytic activity assay 
demonstrating that 24-h αSynAgg treatment intensified phagocytic activity in MMCs. 
Data analyzed via ANOVA with Tukey post-hoc analysis, ***p<0.001. Data 







Figure 8: Mn activates MMCs producing inflammatory factors. A) qRT-PCR 
analysis of levels of NOS2 in MMCs 24 h after 100-µM Mn treatment. B-C) Luminex 
analysis of levels of secreted B) TNF-α and C) IL-6 in MMCs and PMG 24 h after Mn 
treatment. Data analyzed via Student’s t-test, **p<0.01, ***p<0.001. Data represented 
as mean±SEM with 3-5 biological replicates from 2 independent experiments. 
 
 
 
 
